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A new platform for the delivery of short interfering RNA (siRNA) was investigated. 
Polymer-coated AuNPs were functionalised with phosphorothioate modified (PS) 
nucleic acids. The PS-modification allows their conjugation onto AuNPs though the 
formation of Au-S bonds. The conjugation of PS-single strand oligonucleotide (PS-
ssODN) on polymer-coated AuNPs resulted in high loading efficiency. Particles 
prepared with PS-siRNA, which is a double-stranded molecule, did not show loading 
of siRNA. The addition of three PS-modifications on the siRNA (3PS-siRNA) did not 
improve the loading efficiency. These observations suggest that the conjugation of 
PS-ssODN onto AuNPs was not exclusively driven by the Au-S bond formation, but 
that the exposed bases within the single strand can also drive the conjugation onto 
Au, presumably through the formation of Au-N bonds. Work in this thesis also 
investigated the introduction of pH-sensitivity into a siRNA delivery platform. An 
important feature of any nanocarrier is its stimuli response towards an intracellular 
trigger. Polymers presenting pH-responsiveness are potentially useful in siRNA 
delivery as the endosomal acidic environment within the target cells can be harnessed 
to trigger siRNA release. The pH-sensitivity of model hydrazone and imine bonds was 
evaluated. The model hydrazones tested did not show the required pH-sensitivity, 
however, two imines were identified stable at pH 7 and hydrolyzed at pH 5, a suitable 
pH-sensitivity for siRNA applications. Time limits prevented the further development 
of the imine system, however, the model hydrazone was successfully appended onto 
polymer scaffolds and conjugated onto AuNPs. Their complexation with siRNA 
resulted in 60 % loading efficiency, however, the particles did not release siRNA after 
incubation in a buffer at pH 5.0. This observation confirms the poor pH-sensitivity of 
hydrazone bonds. Further studies must be developed to determine the pH-sensitivity 
of imines in polymer systems, and thus, evaluate its potential as candidates for the 
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Acute myeloid leukaemia (AML) is an uncontrolled clonal proliferation of the 
myeloid lineage progenitors in the bone marrow and in the blood.1 The disease 
classification and prognosis is based on several cytogenetic abnormalities, such as the 
translocation t(8;21) (q22;q22), also called RUNX1/ETO.2 The resulting RUNX1/ETO 
fusion protein is associated with cell proliferation and self-renewal capacity of the 
myeloid progenitor, leading to leukemic proliferation and AML maintenance.3,4 
Treatment of AML usually comprises intensive and genotoxic chemotherapy, causing 
undesired side effects which can severely decrease the quality of life of patients.5 
Therefore, depletion of RUNX1/ETO by short interfering RNAs (siRNA) presents as an 
interesting approach for the better prognosis and treatment of AML. The translation of 
synthetic siRNA from in vitro applications into therapeutic use still remains a major 
challenge for the therapy success.6 The poor pharmacokinetics properties of siRNA 
requests the development of a delivery platform to safely transport and protect siRNA 
molecules against enzymatic degradation and fast renal clearance in the blood 
circulation.7 In this work, the development of two different nanocarriers is discussed. 
The nanocarriers were designed to perform different functions at each stage of 
pharmacokinetics, promoting prolonged blood circulation, efficient cellular uptake and 
fast siRNA release.  
 
1.1 Acute myeloid leukaemia 
Acute myeloid leukaemia is a type of blood cancer that affect the myeloid cell 
lineage and is characterised by the uncontrolled proliferation of myeloid cells that fail 
to differentiate during the process of haematopoiesis.8 Haematopoiesis takes place in 
the bone marrow and it leads to the differentiation of haematopoietic stem cells (HSCs) 
to generate all blood cell types. In normal haematopoiesis process, HSCs are capable 
of self-renewing and generate multipotent progenitors, that will further differentiate into 
the precursors of the myeloid and lymphoid lineage.9  
At the onset of AML, the myeloid progenitors can undergo genetic mutations 
which leads to increased proliferation and self-renewing, and decreased differentiation 
into mature myeloid cells.10 These genetic mutations result in uncontrolled production 
of immature (poorly differentiate) myeloid cells, called blasts, which overrun the bone 
marrow niche. The accumulation of blasts leads to bone marrow failure, resulting in 
decreased production of mature cells from the myeloid lineage (erythrocytes, 
leukocytes and platelets).11 The clinical manifestations of AML reflects the 
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accumulation of malignant blasts in the bone marrow and peripheral blood, which 
includes anaemia, leucocytosis and thrombocytopenia. Patients usually show signs of 
fatigue, anorexia and weight loss.12 The diagnosis of AML is usually confirmed by the 
presence of > 20 % blast cells in the peripheral blood or bone marrow, and also when 
several well characterised cytogenetic abnormalities associated with the disease are 
detected.5,12  
AML is characterised as a clonal malignant disorder on account of the clonal 
expansion of a single malignant cell (Figure 1.1).1 After genetic alteration on a 
progenitor cell, differentiation will be inhibited whilst self-renewing and proliferation will 
increase, resulting in the expansion of the malignant cells. As leukaemia progresses, 
some cells will gain additional mutations, producing sub-clonal populations.13 Although 
all malignant cells will maintain the initial mutation, the genetic mutations accumulate 
and the subclones progress in parallel, increasing the heterogeneity of the tumour. 
Thus, the identification of the products from the genetic alterations of an original 
malignant cell is a very attractive approach for the treatment of AML.  
 
 
Figure 1.1: Clonal evolution in AML. The colours represent different sub-clonal populations. A single 
mutant cell can lead to clonal expansion with further genetic mutations creating sub-clonal 
populations in parallel, increasing the heterogeneity of the tumour.  
 
1.1.2 Incidence and classification of AML  
AML is the most common acute leukaemia in adults, and its estimated that 3,100 
new cases are diagnosed every year (more than 8 per day), representing ~ 1 % of all 
cancer cases in the UK. The number of new cases in 2016 in the UK was 1,283 cases 
in women and 1,673 case in men. The incidence in the UK of AML have increased 
more than 20 % over the last 25 years.14 Further studies by Dores et al.,15 showed 
higher AML incidence rate according to the patient age, presenting 0.8 %, 1.5 %, 4.3 
%, 23.1 % and 28.7 % for age groups 0-1, 1-4, 5-19, 40-59 and 60-74, respectively. 
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These observations largely reflect the higher incidence for AML in older people, a 
population that is related with poor prognosis of the disease. 
AML had been first divided into 8 subtypes categories by the French-American-
British cooperative group (FAB).16 They subdivided AML according to the cellular type, 
morphology and differentiation status into the categories: M0 (undifferentiated acute 
myeloblastic leukaemia), M1 (acute myeloblastic leukaemia with minimal maturation), 
M2 (acute myeloblastic leukaemia with maturation), M3 (acute promyelocytic 
leukaemia), M4 (acute myelomonocytic leukaemia), M5 (acute monocytic leukaemia), 
M6 (acute erythroid leukaemia) and M7 (acute megakaryoblastic leukaemia). 
However, since the advance of cytogenetics and the identification of unique 
biomarkers that can improve the diagnostic criteria and dictate the patient prognosis, 
the World Health Organization (WHO) combined the old FAB classification and the 
most recent cytogenetics abnormalities into a new and more complete classification 
(Table 1.1 and Table 1.2).17  
 
Table 1.1: World Health Organization (WHO) classification of AML. Adapted from Arber, et al.17 
Classification Description 
AML with recurrent genetic abnormalities  
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22);CBFB-MYH11 
APL with PML-RARA 
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
AML with t(6;9)(p23;q34.1);DEK-NUP214 
AML with inv(3)(q21.3q26.2) or 
t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with 
t(1;22)(p13.3;q13.3);RBM15-MKL1 
Provisional entity: AML with BCR-ABL1 
AML with mutated NPM1 
AML with biallelic mutations of CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes  
Cytogenetic abnormalities sufficient to 
diagnose AML with myelodysplasia-related 
changes when > 20% PB or BM blasts are 
present and prior therapy has been excluded 
 
Cytogenetic abnormalities Complex karyotype 















Table 1.2: Continuation of WHO classification for AML. 
Classification Description 







Therapy-related myeloid neoplasms  AML with genetic abnormalities associated with chemotherapy 
AML not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma  Myeloid sarcoma 
Myeloid proliferations related to Down 
syndrome  
Transient abnormal myelopoiesis (TAM) 
Myeloid leukaemia associated with Down 
syndrome 
 
1.1.3 Treatment of AML 
The standard treatment for AML patients consists of two stages: induction and 
post-remission (or consolidation) therapy.12 The induction therapy consists of a “7+3” 
regime scheme, which combines 7 days of continuous administration of cytarabine 
(interferes in the DNA synthesis by replacing cytosine) with 3 days of anthracycline 
(DNA damaging agent).18 The induction therapy aims to reduce the bulk of leukemic 
blasts and induce complete remission of the disease. The induction therapy should be 
followed by the consolidation therapy in order to completely eradicate any residual 
disease and achieve lasting remission. The consolidation therapy is tailored to each 
individual, depending on the individual’s age, health and leukaemia karyotype.19 It can 
include high doses of cytarabine (HiDAC) administered over five days for 
approximately four weeks (total of 3 or 4 cycles) and co-administration of mitoxantrone. 
Consolidation therapy can also consists of HiDAC followed by autologous or allogenic 
stem cell transplantation.20 Despite the advances of the current treatments, 10-40 % 
of AML patient do not achieve complete remission, which increase the risks of relapse, 
associated with poor prognosis.19,21 Moreover, the poor prognosis for the elderly, who 
account for the majority of new cases, remains a concern. Even with the existing 
treatment, up to 70 % of patients over the age of 65 will die of AML within one year of 
diagnosis.22 The current treatment for AML is extremely aggressive which can severely 
impair the quality of life of patients, leading to early and long-term undesired side-
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effects, such as the development of treatment-related secondary cancers.19 The 
cytogenetic abnormalities are the most critical factors in achieving complete remission 
and avoiding relapse in patients.23 Thus, the development of new treatments targeting 
the products of these abnormalities is a promising strategy for a better prognosis of 
AML, especially for elderly and relapsed patients.  
 
1.1.4 The translocation t(8;21)(q22;q22) and the leukemic fusion protein 
RUNX1/ETO 
The chromosomal translocation t(8;21) is one example of cytogenetic abnormality 
that is highly prevalent in AML and results in the expression of the fusion protein 
RUNX1/ETO.24 Chromosomal translocations occur when a segment of one 
chromosome is exchanged with a segment from a nonhomologous one, resulting in 
the expression of a chimeric fusion protein consisting of regions from both original 
chromosomes. The resulting fusion proteins are known to play an important role in the 
development of tumours and represent an important parameter for diagnosis and 
prognosis of several cancers, especially malignant haematological disorders.25  
In the t(8;21) leukaemia (Figure 1.2 A), RUNX1 gene from chromosome 21 fuses 
to ETO gene located on chromosome 8. The fusion usually occurs within breakpoints 
in intron 5 of RUNX1 and in intron 1a-1b of ETO.2 This chimeric gene generates the 
fusion protein RUNX1/ETO (Figure 1.2 B) consisted of the 177 N-terminal amino acids 
of RUNX1 and the most of amino acids that are located on the C-terminus of ETO, 
presenting in total 752 amino acids.26  
In normal cells, the RUNX1 gene encodes RUNX1 protein that contains Runt 
homology domain (RHD). RHD facilitates RUNX1 binding to DNA and is indispensable 
for the regulation of haematopoiesis and homeostasis of HSCs.27,28 The eight twenty-
one (ETO) gene encodes ETO proteins that comprises four Nervy homology regions 
named NHR-1, NHR-2, NHR-3 and NHR-4 . The ETO proteins bind to different co-
repressors, such as N-CoR and SMRT resulting in transcription repression.29 In the 
case of t(8;21), the repressor activity of ETO inhibits the DNA-binding activity of 
RUNX1, and thus, defines the suppressive roles of RUNX1/ETO fusion protein is this 
subtype of leukaemia.4,30 
The translocation t(8;21) is related with approximately 40 % of M2 subtype of 
AML (FAB classification) and 8 – 20 % of all AML cases. The translocation is also 





Figure 1.2: Schematic representation of the translocation t(8;21) (q22;q22). (A) Genomic structure of 
t(8;21). The breakpoint occurs in two possible locations in intron 1a-1b in ETO and one location in 
intron 5 in RUNX1. (B) Protein structure of RUNX1/ETO featuring 752 amino acids. The RHD domain 
of RUNX1 is fused to most of the ETO including the NHR regions.2,26  
  
The RUNX1/ETO fusion protein is a leukaemia initiator transcription factor that 
interferes with the RUNX1 function, inhibiting cell differentiation. The RUNX1/ETO 
protein is known to enhance leukemic cells proliferation and self-renewal of the myeloid 
progenitors, resulting on the development of AML.31 The fusion protein affects a wide 
range of cellular mechanisms and can also contribute for the development of additional 
genetic abnormalities.26 One of the main mutations associated with patients carrying 
the t(8;21) is the mutations in the c-KIT tyrosine kinase receptor. The oncogenic 
cooperativity between these oncoproteins leads to AML development and 
maintenance, and its usually associated with an aggressive leukemic phenotype and 
poor prognosis.32 Moreover, Martinez-Soria, et al.33 demonstrated that RUNX1/ETO 
cooperates with the activation protein 1 (AP-1) to drive cyclin D2 (CCND2) expression 
that is crucial to promote and maintain the progression of the cycling cells. Therefore, 
depletion of RUNX1/ETO reduces the expression of CCND2 and consequently, inhibits 
cell cycle and proliferation. The group also demonstrated that depletion on 
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RUNX1/ETO inhibited cell proliferation colony formation in vitro.4,34 The in vivo 
depletion of RUNX1/ETO resulted in decreased tumour formation and increased 
median survival in a xenotransplantation model. Taken together, the knockdown of 
RUNX1/ETO by RNA interference (RNAi) therapy is a promising strategy for the 
treatment of AML.3  
 
 1.2 RNA interference therapy and short interfering RNAs 
RNA interference (RNAi) therapy enables the control of protein expression by 
silencing the expression of an endogenous gene.35 The RNAi mechanism was first 
described by Andrew Fire and Craig Mello in 1998.36 Their work demonstrated the 
ability of exogenous double strand RNA (dsRNA) to sequence-specific silence gene 
expression in the nematode worm Caenorhabditis elegans, rendering them the Nobel 
Prize in Medicine of 2006. However, was only after the work of Hammond, et al.37 that 
the RNAi mechanism was fully elucidated with the discovery of the RNA-Induced 
Silencing Complex (RISC). 
The mechanism of RNAi (Figure 1.3) is triggered by the presence of long pieces 
of dsRNA in the cell cytoplasm (Figure 1.3 A). The dsRNA is then cleaved by the 
enzyme Dicer into smaller fragments known as short interfering RNA (siRNA).35 The 
produced siRNA is incorporated into a protein complex called the RNA-Induced 
Silencing Complex (RISC).38 A multifunctional protein contained within RISC, known 
as Argonaute 2 (AGO2), unwinds the siRNA. The guide strand (antisense strand) 
forms and activates RISC, whereas the passenger strand (sense strand) of the siRNA 
is cleaved.39 The activated RISC selectively seeks out and degrades the 
complementary sequence of messenger RNA (mRNA) to the guide strand.40 The 
activated RISC complex will continuously seek for additional mRNA targets, which 
further propagates gene silencing41. 
Another small RNA that produces RNAi effect includes the microRNAs (miRNA) 
(Figure 1.3 B), a stem-loop like structure featuring 21-25 nucleotides.42 The miRNA 
pathway begins with endogenously encoded primary miRNA transcripts (pri-miRNAs) 
that are transcribed by RNA polymerase II and are processed by the Drosha enzyme 
complex to yield the precursor miRNAs (pre-miRNAs). These precursors are then 
exported to the cytoplasm by Exportin 5 and subsequently bind to the Dicer enzyme 




Figure 1.3: Mechanism of RNA interference. (A) Long dsRNA is cleaved into siRNA by the Dicer 
enzyme and its incorporated into the RISC complex containing the AGO2 enzyme. AGO2 cleaves 
the passenger (sense) strand of siRNA so that active RISC containing the guide (antisense) siRNA 
strand recognises the target sites of the complimentary mRNA. AGO2 then promotes the cleavage 
of the mRNA and the activated RISC is recycled. (B) The pre-miRNAs are formed by the 
endogenously encoded pri-miRNAs and are then exported to the cytoplasm by Exportin 5. The pre-
miRNA binds to the Dicer enzyme complex, where it is processed for loading onto the AGO2–RISC 
complex and promote the mRNA cleavage. 
 
Elbashir, et al.44 showed the RNAi effect in mammalian cells by introducing 
synthetic siRNA sequences and proved that exogenous siRNAs could indeed achieve 
sequence-specific gene silencing.44 Synthetic siRNA molecules are well-defined 
structures of double strand RNA of 19-22 nucleotides with 2 nucleotide overhangs at 
either 3’ ends.35,45 The antisense sequence (guide strand) of the siRNA is designated 
to be complementary to the sequence of the targeted mRNA. Once siRNAs are 
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internalised in the cell cytoplasm, it is directly loaded into the AGO2-RISC complex, 
activating the RNAi mechanism (Figure 1.3) to seek out and promote degradation of 
the targeted mRNA. As siRNAs enter the RNAi pathway later (skipping the DICER 
step), it is less likely to interfere in the endogenous miRNA pathway,46 and therefore it 
is an attractive candidate for RNAi therapeutics.  
 
1.3 Application and challenges of siRNA delivery in vivo 
 The first successful application of siRNA in vivo was reported by McCaffrey, et 
al.47 only one year after the application of synthetic siRNA in mammalian cells 
demonstrated by Elbashir and co-workers.44 The group co-injected high doses of 
luciferase-expression plasmid with naked siRNA targeting the firefly luciferase into the 
tail vein of the mice. The mice treated with the targeted siRNA showed a decrease in 
the luminescence signal of 70 %. Moreover, the group also evaluated the co-injection 
of the luciferase plasmid with an unrelated siRNA sequence. The mice treated with the 
siRNA unrelated sequence did not show decrease in luciferase expression, showing 
the specific gene silencing of siRNA molecules in vivo. The delivery method used by 
the group is based on the injection of large volumes of the solution and its called the 
hydrodynamic delivery method. Although the group showed promising results, this 
method results in hemodynamic changes in the blood flow and lack of tissue specificity 
(molecules mainly accumulate in the liver), limiting its use for clinical applications. Thus 
the delivery of nucleic acids to the target cells remains a major obstacle to translate 
the siRNA therapeutics into clinical applications.  
 In order to activate the RNAi pathway, siRNA molecules must travel through the 
bloodstream and cross the cellular membrane of the target cell. However, siRNAs are 
hydrophilic and polyanionic molecules with high molecular weight ~ 13 kDa and, 
therefore, are too large and negatively charged to successfully enter the cell 
cytoplasm.48 Localised siRNA delivery, when siRNA molecules are directly injected 
into the target tissue, results in high bioavailability and consequently, effective RNAi 
silencing.49 However, localised administration is only available for a few tissues (e.g. 
eye, skin) and superficial tumours, being the systemic administration ideal as a non-
invasive method for the treatment of a large number of diseases. Naked siRNA 
presents poor pharmacokinetics when administered systemically, once it is subjected 
to fast renal clearance and degradation by nucleases in the blood.50 Hence, for the 
systemic delivery of siRNA the use of nanocarriers is essential to achieve efficient 
transfection into the target cell or tissue.  
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 The success of the nanocarriers will be dependent on the capacity of the 
delivery platform to overcome the biological barriers associated with in vivo siRNA 
delivery (Figure 1.4). To overcome these challenges, the nanocarrier must be able to 
protect the siRNA from the fast renal clearance and from degradation by nucleases, 
accumulate on the desired cell or tissue, facilitate the cellular uptake usually by 
endocytosis, promote the siRNA release in the cytosol of the target cell and present 
negligible toxicity.  
 
 
Figure 1.4: Biological barriers associated with the in vivo delivery of siRNA. 
 
The particle size of the nanocarriers is an important factor in order to overcome 
the biological barriers for in vivo applications. Nanoparticles smaller than < 10 nm (or 
< 50 kDa) are rapidly excreted through the renal clearance,45 reducing the particle half-
life and consequently, the accumulation into the target tissue. Particles presenting 
large particle size (> 200 nm) are easily recognised by the reticuloendothelial system 
(RES), a phenomenon known as opsonisation that results in the phagocytosis of the 
particles and decreased blood circulation time.51 Moreover, due to the high proliferation 
rate and unbalanced growth of solid tumours, the angiogenesis (formation of new blood 
vessels) results in new blood vessels structurally abnormal with wide fenestrations 
(large spaces), allowing the extravasation of molecules presenting < 200 nm size from 
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the blood stream to the tumour tissue. This phenomenon is known as Enhanced 
Permeability and Retention effect (EPR effect)52 and is a specific feature of tumour 
vessels, not occurring in healthy tissue (such as bone marrow sinusoids). The EPR 
effect facilitates the passive accumulation of prolonged-circulation nanocarriers (size 
< 200 nm) in the tumour site. Thus, particles between 10 nm and 200 nm are ideal for 
delivery applications.  
The particle surface charge is also an important factor for the development of 
nanocarriers. Positively charged nanoparticles are usually exploited for siRNA delivery 
purposes. The positive charges are effective for loading siRNA due to electrostatic 
interactions with the polyanionic molecule.53 In addition, the negative charges of the 
cellular membrane enhances the cellular uptake of positively charged nanoparticles, 
resulting in high transfection efficiencies of these particles in vitro. However, in vivo 
applications result in non-specific binding with negatively charged proteins in the 
bloodstream, leading to recognition by the RES system and removal of the 
nanoparticles from the blood vessels.45 Hence the minimum surface charge should be 
maintained for in vivo applications of nanocarriers. Neutrally charged nanoparticles 
present low colloidal stability due to particle aggregation, therefore, a sterical 
stabilisation is needed. Polyethylene glycol (PEG) is a hydrophilic polymer that when 
added to nanoparticles can substantially decrease RES recognition. Because of its 
inherent hydrophilicity and steric repulsion effects, PEG reduces phagocyte 
interactions and complement activation,54 providing at the same time colloidal stability 
to the formulations. In addition, PEG has proved to be safe and effective in prolonging 
the half-life of many nanocarriers.55–58 It also allows the attachment of targeting 
moieties that enable accumulation of the nanoparticles only in the target tissue. 
Targeting nanoparticles to specific tissues results in enhanced accumulation and 
specific cellular internalisation of siRNA, decreasing off-target RNAi effects.  
After cellular uptake and internalisation of the nanocarriers by endocytosis, the 
particles often become entrapped in an endocytic vesicle, called endosome.59 The 
escape from the endosome membrane and release of the siRNA cargo into the cytosol 
is vital for the perpetuation of the RNAi machinery. The intracellular trafficking (Figure 
1.5) of siRNA begins in the early endosome, where the pH environment is ~ 6.0 – 5.5 
and is rapidly carried to the late endosome, where the pH decreases rapidly (~ 5.0). 
Subsequently, the nanoparticles trafficking continues until it reach the lysosomes 
vesicles, in which the pH decreases further (~ 4.5) and contains a variety of enzymes 




Figure 1.5: Cellular uptake of the nanocarriers by endocytosis and endosomal escape for the 
perpetuation of the RNAi mechanism . 
 
Strategies that could stimulate the siRNA release and endosomal escape have 
been extensively studied. Cationic polymers, such as polyethyleneimine (PEI) can 
escape from the endosomes by a phenomenon known as the “proton-sponge effect” 
(Figure 1.6). In this approach, the positive charges of the polymer promote a buffering 
effect inside the endosome vesicle, which leads to an increase of the influx of protons 
and counter-ions. This phenomenon results in an osmotic swelling followed by 




Figure 1.6: Endosomal escape by "Proton-sponge Effect". Cationic polymer is internalised in the 
endocytic vesicles called endosomes. The positive charges of the polymer cause influx of protons 
and counter-ions resulting in the increase of the osmotic pressure. The endosome swells causing 
membrane rupture and release of the contents. 
 
The development of a new nanocarrier for efficient delivery of siRNA demands a 
deep understanding of the interaction mechanisms between nanoparticles, cells and 
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tissues and blood circulation. The nanocarriers must be thoroughly designed to 
overcome the challenges regarding the clinical applications of siRNA. The 
development of nanocarriers that present features that can be triggered in specific 
conditions, such as the endosome compartment, are crucial for siRNA delivery 
strategies.  
 
1.4 Nanocarriers for siRNA delivery 
The main classes of delivery platforms are categorised in viral and non-viral 
vectors. Due to the natural ability of viruses to transfect cells with genetic material, viral 
vectors have been studied for the delivery of therapeutic nucleic acids.62 Viruses such 
as lentivirus, adenovirus, retrovirus and adeno-associated virus can be transformed 
into delivery systems by changing part of the virus genome with a therapeutic nucleic 
acid.54,63 However, viral vectors presented high cytotoxicity and immunogenic 
problems during clinical trials,63,64 limiting the use of these vectors for clinical 
applications. Thus, synthetic approaches have been presented as exciting alternatives 
for the delivery of nucleic acids in clinical applications, showing improved safety and 
more facile manufacture in large scales. 
The non-viral vectors comprise nanoparticle like lipid-based platforms, polymeric 
nanoparticles and inorganic nanoparticles (such as iron oxide nanoparticles and gold 
nanoparticles). 
 
1.4.1 Lipid-based nanoparticles 
Lipid-based delivery systems have been extensively reported for siRNA delivery 
as liposomes or lipid nanoparticles. They are usually formed from the disposition of a 
lipid bilayer in aqueous environment, forming an unilamellar or multilamellar sphere 
with an aqueous core that can load siRNA.65 Cholesterol is commonly used as a 
component of a delivery platform due to its lipophilic properties and cellular transport 
mechanisms. The addition of cholesterol to the formulation increases the stability of 
the lipid bilayer66 and it can also facilitate the cellular uptake of the nanocarriers 
mediated by endocytosis.67,68 Cationic lipids such as 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) are usually included into liposome formulations to 
facilitate endocytosis and siRNA loading.69 However, these lipids can have cytotoxic 
effects and fast clearance of the body on account of their positive charges.70 To 
overcome the cytotoxicity challenges of cationic liposomes, PEG can be added to the 
formulations. However, pegylated liposomes can show decreased transfection 
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efficiencies.71 Although liposomes are popular siRNA delivery platforms, concerns 
regarding the toxicity of cationic lipids still remains. Despite these problems, lipid-
based delivery platforms have been successfully applied into clinics. Onpattroâ by 
Alnylam Pharmaceuticals has been recently approved for the treatment of a 
neurodegenerative disease. The formulation is the first RNAi drug into clinics and it will 
be further discussed.  
 
1.4.2 Polymeric nanoparticles 
An alternative to lipid-based nanocarriers is the use of synthetic polymers as 
components of siRNA delivery platforms. Polymeric micelles are formed by self-
assembly of block copolymers where one or more of the blocks convey an amphiphilic 
nature to the polymer system, resulting in spherical particles when placed in aqueous 
solvents.72 The concept of polymeric micelles for drug delivery was introduced by 
Kataoka’s group in 1992 (Figure 1.7).73 The group developed the block copolymer 
PEG-PAsp, where the hydrophobic drug doxorubicin was conjugated onto the PAsp 
block through a covalent bond. The final copolymer PEG-PAsp-DOX formed spherical 




Figure 1.7: Micelle formation in aqueous solutions by self-assembly of PEG-PAsp-DOX 
copolymers.73 
 
Cationic polymers are often included in polymeric micelles for complexation with 
siRNA through the electrostatic interactions with the negative charges of the nucleic 
acid sequence.74 Pujol et al.75 developed a polymeric nanoparticle consisted of two 
amphiphilic diblock copolymers, PEG-b-PCL and PDMAEMA-b-PCL (Figure 1.8). The 
self-assembly of the diblock copolymers resulted in monodisperse micelles with varied 
hydrodynamic diameters (ranging from 30 – 100 nm) depending on the copolymer 
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ratio. They further evaluated the gene knockdown efficiency and toxicity of particles 
carrying siRNA targeting the luciferase gene. The particles were prepared in different 
ratios of PEG-b-PCL and PDMAEMA-b-PCL to evaluate the cytotoxic effect of 
positively charged particles. The group demonstrated that cytotoxicity increased when 
higher ratios of the cationic polymer were used. From the comparison between gene 
knockdown efficiency and cytotoxicity, the group could determine the optimal 
formulation (formulation that presented the highest gene knockdown and the lowest 
cytotoxicity) to efficiently promote gene silencing without associated toxicity.  
 
 
Figure 1.8: Polymeric nanoparticle for siRNA delivery. The nanoparticles were formed by the self-
assembly of the amphiphilic copolymer PEG-b-PCL and the cationic copolymer PDMAEMA-b-PCL.75 
 
Cationic polymers can also be easily complexed with siRNA on its own, forming 
stable particles called polyplexes.76 A good example is poly-lysine (PLL), a small 
polypeptide of the essential amino acid L-lysine45 which was one of the first cationic 
polymers to be used as a nucleic acid delivery platform.77 However, the high 
cytotoxicity of PLL and lack of buffering capacity results in poor endosomal escape, 
limiting its application into clinics.78 Besides the natural capability of cationic polymers 
to load nucleic acids on account of the charge ionic interactions, cationic polymers 
have also showed to facilitate the endosomal escape through the “proton-sponge” 
effect.49 PEI is considered the gold standard for nucleic acid transfection on account 
of its high buffering capacity.79 Yin, et al.80 demonstrate the transfection efficiency in 
vivo of polyplexes formed by a thiol modified PEI-deoxycholic acid (TP-DA-PEI) 
(Figure 1.9). The polymer TP-DA-PEI was crosslinked with a thiolated siRNA to form 
more compact and stable polyplexes on account of the formation of disulfides bonds. 
The particles presenting hydrodynamic diameters of ~ 200 nm showed great stability 
in serum for 48 h and high transfection efficiency in A549 cells (adenocarcinoma). The 
group also demonstrated the in vivo antitumor effect of polyplexes carrying siRNA 
targeting the VEGF gene. After systemic administration on tumour-bearing mice, the 
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cross-linked polyplexes showed successful transfection of siRNA and significant 
tumour growth inhibition.  
 
 
Figure 1.9: Cross-linked polyplexes for efficient siRNA transfection. TP-DA-PEI copolymer was 
cross-linked with a thiol-modified siRNA to form more compact and stable polyplexes.80  
 
Another example of polymeric nanoparticles presenting multiple function was 
demonstrated by Pittella, et al. (Figure 1.10).81 The group developed a hybrid 
nanocarrier composed of a charge conversional copolymer (PEG-b-CPP) and calcium 
phosphate (CaP). The CaP forms a stable core incorporating the polyanions siRNA 
and PEG-b-CPP. The conversional charge copolymer induces the proton-sponge 
effect and consequently, endosomal escape on account of the polycation formed in 
acidic pH. The hybrid nanocarrier presented as spherical nanoparticles of ~ 40 nm 
size. Moreover, the group showed the successfully delivery of siRNA targeting the 
VEGF gene in pancreatic cell lines, resulting in ~ 80 % of VEGF gene knockdown.  
Polymeric nanoparticles have been widely studied for nucleic acid delivery and 
show a great potential as siRNA delivery platforms. Furthermore, polymers can be 
combined with inorganic nanoparticles to form hybrid systems. In an example, through 
electrostatic interactions or through covalent binding, cationic copolymers can be 




Figure 1.10: Hybrid nanoparticles featuring a charge conversional polymer (PEG-b-CPP) and calcium 
phosphate (CaP) for the delivery of siRNA.81 
 
1.4.3 Gold nanoparticles 
Gold nanoparticles (AuNPs) have been widely employed for biomedical 
applications on account of their unique properties and multiple surface functionalities.82 
AuNPs can be easily synthesised in a wide range of size and shapes and their surface 
can be easily functionalised with biomolecules through sulfur-gold chemistry. 
Moreover, AuNPs presents different physicochemical properties associated to their 
size and shape.83 The Surface Plasmon Resonance (SPR) phenomenon is one of the 
most important physicochemical properties of AuNPs.84 When a metal particle is 
exposed to light, the oscillating electromagnetic field of the light induces a collective 
coherent oscillation of the free electrons on the metal surface (Figure 1.11).85 The 
amplitude of the electron’s oscillation reaches a maximum at a specific frequency, and 
therefore, the optical properties (absorption and scattering of light) of AuNPs can be 
monitored by UV-Vis spectroscopy. The SPR can be modulated by changing the size, 
morphology, surface charge and ligands on the surface of the AuNPs.86 The versatility 
of AuNPs provides a range of materials for biomedical applications such as 




Figure 1.11: Surface Plasmon Resonance (SPR) phenomenon. Schematic representation of the 
oscillation of the free electrons on the AuNP surface on account of the electromagnetic field of the 
incident light.85 
 
Mirkin, et al.94 was one of the pioneers in conjugating nucleic acids onto AuNPs. 
Since then, the group have developed AuNPs coated with nucleic acids mainly 
focusing on biosensing applications95 and gene regulation.93 The group functionalised 
13 nm AuNPs with a thiol-modified ethylene glycol (SH-EG) and a thiol-modified siRNA 
(Figure 1.12).93 The siRNA sequence included the SH-EG on the 3’ end of the sense 
strand. Conjugation onto the AuNP surface occurred though sulfur-gold chemistry, 
resulting in ~ 30 siRNA duplexes per AuNP. The particles successfully promoted the 
gene silencing of the luciferase protein in vitro, showing the promising use of this 
particle for gene knockdown. 
 
 
Figure 1.12: Conjugation of thiol-modified siRNA onto AuNPs surface through the sulfur-gold 
chemistry.93 
 
Yi and co-workers96 developed a multifunctional delivery platform based on 
functionalised 20 nm AuNPs (Figure 1.13). The group synthesised a diblock copolymer 
modified with a lipoic acid at the w-end. The lipoic acid facilitated the conjugation onto 
AuNPs via the sulfur-gold bond. Moreover, they also modified the PEG terminus at the 
block copolymer by adding the cyclic Arg-Gly-Asp (cRGD) peptide to construct the 
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target moiety of the delivery platform. cRGD specifically binds to avb3/avb5 integrins 
which are overexpressed in a range of tumour cells, therefore facilitating the active 
accumulation of the nanocarriers. The resulting polymer (cRGD-PEG-PLL-LA) was 
first complexed with siRNA (uPIC) thorough ionic interactions between the cationic 
block PLL and the siRNA sequences. AuNPs were then functionalised with uPICs to 
obtain the multifunctional nanocarrier cRGD-uPIC-AuNP. The group confirmed the 
efficacy of the targeting moiety cRGD by in vivo tumour accumulation in a 
subcutaneous HeLa model. After systemic administration, the cRGD-uPIC-AuNP 
enhanced gene silencing efficacy in the subcutaneous tumour when compared with a 
non-target control nanocarrier. Moreover, systemic administration of nanocarriers 
loaded with siRNA targeting the papilloma virus-derived E6 oncogene significantly 
inhibited the growth of subcutaneous HeLa tumours. 
 
 
Figure 1.13: Schematic illustration of cRGD-uPIC-AuNP. First, uPIC was formed by the 
complexation of cRGD-PEG-PLL-LA with siRNA. cRGD was used as a targeting moiety for cancer 
cell lines. Second, uPICs were conjugated onto AuNPs through the double Au-S bonds from the lipoic 
acid moieties. Additional thiolated PEG (PEG-SH) was conjugated onto AuNPs to constructed cRGD-
uPIC-AuNP particle of 40 nm size.96  
 
These examples highlight the versatility of AuNPs in biomedical applications. By 
combining AuNPs with diblock copolymers it is possible to create a multifunctional 
delivery platform able to perform according to each stage of the siRNA delivery in 
clinical use. The development of a delivery platform that features physicochemical 
stability, prolonged blood circulation and is able to release siRNA according to the 
acidic stimulus of the endosome enhances the application of siRNA into therapeutics.  
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1.5 Current status in clinical trials of siRNA therapies 
Since the discovery of RNAi therapy and its utilisation on silencing genes that 
encode proteins that are hard to target with conventional drugs, remarkable progress 
has been achieved in the development of siRNA therapeutics. The first clinical trial 
(clinical trial registration number NCT00689065, CALAA-01) was published in 2010 by 
Davis, et al.97 The group showed the first systemic delivery of synthetic siRNA for the 
treatment of solid tumours. They reported the reduction of mRNA levels of the subunit 
M2 of the ribonucleotide reductase (RRM2) followed by a reduction in the expression 
of the RRM2 protein after systemic administration of nanoparticles containing RRM2 
siRNA. The nanoparticles were composed of a cyclodextrin-based polymer and a PEG 
polymer decorated with a transferrin protein (TF) ligand. The TF ligand facilitates the 
binding to TF receptors that are upregulated in malignant cells. The clinical trial was 
terminated in 2013 due to nonspecific toxicity and a low rate of efficacy.  
In 2012, Alnylam Pharmaceuticals started the Phase I clinical trial for the drug 
Patisiran (ALN-TTR02) for the treatment of hereditary transthyretin amyloidosis 
(hATTR) with polyneuropathy98 (clinical trial registration number NCT01559077). 
Almost six years later, the US Food and Drug Administration (FDA) approved patisiran 
as the first RNAi drug for the treatment of hATTR, named Onpattro by Alnylam 
Pharmaceuticals (clinical trial phase II registrations numbers NCT01961921, 
NCT01611706799 and phase III registration number NCT01960348100,101). hATTR is 
an autosomal dominant, progressive and life-threatening neurodegenerative disease 
caused by a mutation in the gene encoding the transthyretin protein (TTR), which is 
mainly produced in the liver. This mutation results in the misfolding of the TTR protein 
and formation of amyloid fibrils that accumulate in the heart, nerves and other organs, 
causing polyneuropathy and cardiomyopathy.102 Patients affected by this disease 
suffer progressive impaired ambulation and other debilitating symptoms, with a median 
survival after diagnosis of 5 to 15 years.103 Patisiran is a lipid nanoparticle (LNP) 
carrying siRNA for silencing of both wild-type and mutant TTR proteins. The drug is a 
target for the liver and by targeting the TTR mRNA reduces the TTR protein serum 
levels, improving the patient’s symptoms and treatment. The LNP (Figure 1.14) 
comprises of cholesterol, a polar lipid (DSPC), a pegylated lipid (PEG2000-C-DMG) 
and an ionizable amino lipid (Dlin-MC3-DMA). The ionizable lipid is neutral at pH 7.0 
but becomes protonated under acidic pH (pH < 6.5), and therefore, is an advantageous 
feature for endosomal escape. The particles are formed in acidic pH by self-assembly 
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of the components with siRNA. Because of the ionizable nature of DLin-MC3-DMA, 
the protonation in acidic pH promotes electrostatic interactions with the negative 
charges of the siRNA and, therefore, successful siRNA loading. Once the 
nanoparticles are assembled, the hydrophilic outer layer of PEG promotes colloidal 
stability during storage.104 After cellular uptake and once internalised in the endosome 
compartment, the acidic pH protonates the ionizable lipid DLin-MC3-DMA promoting 
disassembly of the particles. The positive charges increase the influx of protons 
together with the interaction of the lipids to the endosome membrane, contributing to 
the membrane rupture and release of siRNA into the cytosol.105 
 
 
Figure 1.14: First RNAi drug approved by the FDA for treatment of hATTR. Patisiran (Onpattro, 
Alnylam Pharmaceuticals) is composed of lipid nanoparticle (LNP) carrying siRNA targeting the 3’ 
untranslated region of the mutant and wild-type TTR mRNAs. LNP schematic representation adapted 
from Setten, et al.103 
 
Much effort has been made to translate RNAi biology into RNAi therapeutics. 
According to the US National Library of Medicine (NIH clinical trials), the number of 
clinical trials in RNAi therapy has significantly increased in the past years.67,103 Alnylam 
Pharmaceuticals holds the majority of clinical trials involving the delivery of siRNA that 
are in latter stages (Phase II and III) (Table 1.3). At the moment, only one clinical trial 
is active for the treatment of haematological malignancies by siRNA silencing 
(NCT02528682) (Table 1.3). The clinical trial consists of lipid nanoparticles for 
systemic administration of siRNA. The siRNA targets the PD-L1/PD-L2 ligand that is 
involved in the reduction of the graft-versus-tumour response after allogenic stem cell 
transplantation. The trial is still at an early stage (Phase I and II) and no studies have 
been published so far.106  
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Table 1.3: Selected siRNA therapies currently in clinical trials. 
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The FDA approval of Patisiran marks a new era for RNAi therapy. Over the next 
five years, it is expected that many new breakthrough treatments will be published or 
will be in latter stages for clinical approval. Despite the current success, siRNA 
therapeutics targeting non-liver tissues still need further development. In this regard, 
this study proposes a novel nanocarrier for siRNA delivery targeting the RUNX1/ETO 
fusion protein. The delivery platform was designed to present multifunctional properties 
to enhance siRNA silencing efficacy. Two nanocarriers are developed in this study 
based on the combination of gold nanoparticles and polymers. The nanoparticles were 
designed to present redox and pH stimuli-responses for siRNA release. The 
experimental research includes the design, chemical synthesis of the polymers, 




1.6 Aims of the project 
 The main goal of the project was the development of a new delivery platform for 
the safe and successful delivery of siRNA into AML cells. The detailed goals are as 
follow: 
1) Conjugation of phosphorothioate-modified siRNA and polymer onto AuNPs to 
obtain a redox-responsive delivery platform; 
2) Synthesis of model hydrazones and imines for evaluation of the pH-sensitivity 
of the C=N bonds; 
3) Synthesis of diblock copolymers featuring hydrazone/imine moieties to obtain 
pH-responsive copolymers; 
4) Functionalisation of AuNPs with pH-responsive copolymers and complexation 




1.7 References  
1 C. S. Grove and G. S. Vassiliou, Dis. Model. Mech., 2014, 7, 941–951. 
2 L. F. Peterson, A. Boyapati, E. Y. Ahn, J. R. Biggs, J. O. Akiko, M. C. Lo, M. Yan 
and D. E. Zhang, Blood, 2007, 110, 799–805. 
3 N. Martinez Soria, R. Tussiwand, P. Ziegler, M. G. Manz and O. Heidenreich, 
Leuk.  Off. J. Leuk. Soc. Am. Leuk. Res. Fund, U.K, 2009, 23, 188–190. 
4 O. Heidenreich, J. Krauter, H. Riehle, P. Hadwiger, M. John, G. Heil, H. P. 
Vornlocher and A. Nordheim, Blood, 2003, 101, 3157–3163. 
5 U. Creutzig, M. M. van den Heuvel-Eibrink, B. Gibson, M. N. Dworzak, S. Adachi, 
E. de Bont, J. Harbott, H. Hasle, D. Johnston, A. Kinoshita, T. Lehrnbecher, G. 
Leverger, E. Mejstrikova, S. Meshinchi, A. Pession, S. C. Raimondi, L. Sung, J. 
Stary, C. M. Zwaan, G. J. L. Kaspers and D. Reinhardt, Blood, 2012, 120, 3187–
3205. 
6 F. Pittella, H. Cabral, Y. Maeda, P. Mi, S. Watanabe, H. Takemoto, H. J. Kim, N. 
Nishiyama, K. Miyata and K. Kataoka, J. Control. Release, 2014, 178, 18–24. 
7 M. Dalmina, F. Pittella, J. A. Sierra, G. R. R. Souza, A. H. Silva, A. A. Pasa and 
T. B. Creczynski-Pasa, Mater. Sci. Eng. C, 2019, 99, 1182–1190. 
8 V. Hoffbrand and P. Moss, Essential Haematology, Wiley-Blackwell, Sussex, 6th 
edn., 2011. 
9 S. Haas, A. Trumpp and M. D. Milsom, Cell Stem Cell, 2018, 22, 627–638. 
10 K. J. Hope, L. Jin and J. E. Dick, Nat. Immunol., 2004, 5, 738–743. 
11 A. Redaelli, J. M. Stephens, B. L. Laskin, C. L. Pashos and M. F. Botteman, 
Expert Rev. Anticancer Ther., 2003, 3, 311–329. 
12 I. De Kouchkovsky and M. Abdul-Hay, Blood Cancer J., 2016, 6, 441. 
13 A. Kreso and J. E. Dick, Cell Stem Cell, 2014, 14, 275–291. 
14 Cancer Research UK, Acute myeloid leukaemia (AML) | Cancer Research UK, 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/leukaemia-aml#heading-Zero, (accessed 21 
July 2019). 
15 G. M. Dores, S. S. Devesa, R. E. Curtis, M. S. Linet and L. M. Morton, Blood, 
2012, 119, 34–43. 
16 J. M. Bennett, D. Catovsky, M. -T Daniel, G. Flandrin, D. A. G. Galton, H. R. 
Gralnick and C. Sultan, Br. J. Haematol., 1976, 33, 451–458. 
17 D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz, M. M. Le Beau, C. 
D. Bloomfield, M. Cazzola and J. W. Vardiman, Blood, 2016, 127, 2391–2405. 
 27 
18 X. Yang and J. Wang, J. Hematol. Oncol., 2018, 11, 3. 
19 H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Büchner, A. K. Burnett, 
H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. 
Niederwieser, G. J. Ossenkoppele, M. A. Sanz, J. Sierra, M. S. Tallman, B. 
Löwenberg and C. D. Bloomfield, Blood, 2010, 115, 453 LP – 474. 
20 H. Dombret and C. Gardin, Blood, 2015, 127, 1–10. 
21 F. Thol, R. F. Schlenk, M. Heuser and A. Ganser, Blood, 2015, 126, 319–327. 
22 J. Meyers, Y. Yu, J. A. Kaye and K. L. Davis, Appl. Health Econ. Health Policy, 
2013, 11, 275–286. 
23 E. H. Estey, Am. J. Hematol., 2018, 93, 1267–1291. 
24 J. D. Rowley, Ann. Genet., 1973, 16, 109–12. 
25 F. Mitelman, B. Johansson and F. Mertens, Nat. Rev. Cancer, 2007, 7, 233–245. 
26 H. Reikvam, K. J. Hatfield, A. O. Kittang, R. Hovland and O. Bruserud, J. Biomed. 
Biotechnol., 2011, 2011, 1–23. 
27 R. Sood, Y. Kamikubo and P. Liu, Blood, 2017, 129, 2070–2082. 
28 M. Ichikawa, A. Yoshimi, M. Nakagawa, N. Nishimoto, N. Watanabe-Okochi and 
M. Kurokawa, Int. J. Hematol., 2013, 97, 726–734. 
29 K. Lam and D.-E. Zhang, Front. Biosci., 2012, 17, 1120. 
30 J. Wildonger, Development, 2005, 132, 2263–2272. 
31 A. Ptasinska, S. A. Assi, D. Mannari, S. R. James, D. Williamson, J. Dunne, M. 
Hoogenkamp, M. Wu, M. Care, H. McNeill, P. Cauchy, M. Cullen, R. M. Tooze, 
D. G. Tenen, B. D. Young, P. N. Cockerill, D. R. Westhead, O. Heidenreich and 
C. Bonifer, Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide 
changes in chromatin structure and transcription factor binding, Nature 
Publishing Group, 2012, vol. 26. 
32 C. Wichmann, I. Quagliano-Lo Coco, Yildiz, L. Chen-Wichmann, H. Weber, T. 
Syzonenko, C. Döring, C. Brendel, K. Ponnusamy, A. Kinner, C. Brandts, R. 
Henschler and M. Grez, Leukemia, 2015, 29, 279–289. 
33 N. Martinez-Soria, L. McKenzie, J. Draper, A. Ptasinska, H. Issa, S. Potluri, H. 
J. Blair, A. Pickin, A. Isa, P. S. Chin, R. Tirtakusuma, D. Coleman, S. Nakjang, 
S. Assi, V. Forster, M. Reza, E. Law, P. Berry, D. Mueller, A. Elder, S. N. 
Bomken, D. Pal, J. M. Allan, G. J. Veal, P. N. Cockerill, C. Wichmann, J. 
Vormoor, G. Lacaud, C. Bonifer and O. Heidenreich, Cancer Cell, 2018, 34, 626-
642.e8. 
34 N. Martinez, B. Drescher, H. Riehle, C. Cullmann, H.-P. Vornlocher, A. Ganser, 
 28 
G. Heil, A. Nordheim, J. Krauter and O. Heidenreich, BMC Cancer, 2004, 4, 44. 
35 G. J. Hannon, Nature, 2002, 418, 244–251. 
36 A. Fire, A. Fire, S. Xu, S. Xu, M. K. Montgomery, M. K. Montgomery, S. A. 
Kostas, S. A. Kostas, S. E. Driver, S. E. Driver, C. C. Mello and C. C. Mello, 
Nature, 1998, 391, 806–811. 
37 M. H. Scott, B. Emily, B. David and J. H. Gregory, Nature, 2000, 404, 293. 
38 A. de Fougerolles, H. P. Vornlocher, J. Maraganore and J. Lieberman, Nat. Rev. 
Drug Discov., 2007, 6, 443–453. 
39 C. Matranga, Y. Tomari, C. Shin, D. P. Bartel and P. D. Zamore, Cell, 2005, 123, 
607–620. 
40 S. L. Ameres, J. Martinez and R. Schroeder, Cell, 2007, 130, 101–112. 
41 G. Hutvágner and P. D. Zamore, Science, 2002, 297, 2056–2060. 
42 G. Meister and T. Tuschl, Nature, 2004, 431, 343–349. 
43 Y. Lee, M. Kim, J. Han, K. H. Yeom, S. Lee, S. H. Baek and V. N. Kim, EMBO 
J., 2004, 23, 4051–4060. 
44 S. M. Elbashir, J. Harborth and W. Lendeckel, Nature, 2001, 411, 1–5. 
45 J. Guo, L. Bourre, D. M. Soden, G. C. O’Sullivan and C. O’Driscoll, Biotechnol. 
Adv., 2011, 29, 402–417. 
46 D. Grimm, K. L. Streetz, C. L. Jopling, T. A. Storm, K. Pandey, C. R. Davis, P. 
Marion, F. Salazar and M. A. Kay, Nature, 2006, 441, 537–41. 
47 A. P. McCaffrey, L. Meuse, T.-T. T. Pham, D. S. Conklin, G. J. Hannon and M. 
A. Kay, Nature, 2002, 418, 38–39. 
48 J. Zhang, X. Li and L. Huang, J. Control. Release, 2014, 190, 440–50. 
49 K. A. Whitehead, R. Langer and D. G. Anderson, Nat. Rev. Drug Discov., 2009, 
8, 129–138. 
50 D. W. Bartlett and M. E. Davis, Nucleic Acids Res., 2006, 34, 322–333. 
51 H. H. Gustafson, D. Holt-Casper, D. W. Grainger and H. Ghandehari, Nano 
Today, 2015, 10, 487–510. 
52 Y. Matsumura and H. Maeda, Cancer Res., 1986, 46, 6387–92. 
53 J. Valencia-Serna, H. M. Aliabadi, A. Manfrin, M. Mohseni, X. Jiang and H. 
Uludag, Eur. J. Pharm. Biopharm., 2018, 130, 66–70. 
54 D. W. Pack, A. S. Hoffman, S. Pun and P. S. Stayton, Nat. Rev. Drug Discov., 
2005, 4, 581–593. 
55 C. Monfardini and F. M. Veronese, Bioconjug. Chem., 1998, 9, 418–450. 
56 L. Huang and S. Guo, J. Nanomater., , DOI:10.1155/2011/742895. 
 29 
57 S. Santos, J. Mol. Pharm. Org. Process Res., 2015, 03, 1–2. 
58 J. Suh, K.-L. Choy, S. K. Lai, J. S. Suk, B. C. Tang, S. Prabhu and J. Hanes, Int. 
J. Nanomedicine, 2007, 2, 735–41. 
59 H. J. Kim, A. Kim, K. Miyata and K. Kataoka, Adv. Drug Deliv. Rev., 2016, 104, 
61–77. 
60 M. Dominska and D. M. Dykxhoorn, J. Cell Sci., 2010, 123, 1183–1189. 
61 N. D. Sonawane, F. C. Szoka and A. S. Verkman, J. Biol. Chem., 2003, 278, 
44826–44831. 
62 C. E. Thomas, A. Ehrhardt and M. A. Kay, Nat. Rev. Genet., 2003, 4, 346–358. 
63 A. R. Marquez, C. O. Madu and Y. Lu, Oncomedicine, 2018, 3, 48–58. 
64 R. Tomanin and M. Scarpa, Curr. Gene Ther., 2012, 4, 357–372. 
65 V. P. Torchilin, Nat. Rev. Drug Discov., 2005, 4, 145–160. 
66 M. L. Briuglia, C. Rotella, A. McFarlane and D. A. Lamprou, Drug Deliv. Transl. 
Res., 2015, 5, 231–242. 
67 I. V Chernikov, V. V Vlassov and E. L. Chernolovskaya, Front. Pharmacol., 2019, 
10, 444. 
68 A. Alshehri, A. Grabowska and S. Stolnik, Sci. Rep., 2018, 8, 3748. 
69 M. J. Wagner, R. Mitra, M. J. McArthur, W. Baze, K. Barnhart, S. Y. Wu, C. 
Rodriguez-Aguayo, X. Zhang, R. L. Coleman, G. Lopez-Berestein and A. K. 
Sood, Mol. Cancer Ther., 2017, 16, 1114–1123. 
70 Z. Lin, M. Bao, Z. Yu, L. Xue, C. Ju and C. Zhang, Biomater. Sci., 2019, 7, 2777–
2792. 
71 J. Lee and H. J. Ahn, Biochem. Biophys. Res. Commun., 2018, 503, 1716–1722. 
72 U. Kedar, P. Phutane, S. Shidhaye and V. Kadam, Nanomedicine 
Nanotechnology, Biol. Med., 2010, 6, 714–729. 
73 M. Yokoyama, G. S. Kwon, T. Okano, Y. Sakurai, T. Seto and K. Kataoka, 
Bioconjugate Chem, 1992, 3, 295–301. 
74 S. K. Samal, M. Dash, S. Van Vlierberghe, D. L. Kaplan, E. Chiellini, C. Van 
Blitterswijk, L. Moroni and P. Dubruel, Chem. Soc. Rev., 2012, 41, 7147–7194. 
75 M. Omedes Pujol, D. J. L. Coleman, C. D. Allen, O. Heidenreich and D. A. Fulton, 
J. Control. Release, 2013, 172, 939–945. 
76 D. J. Gary, N. Puri and Y. Y. Won, J. Control. Release, 2007, 121, 64–73. 
77 W. Zauner, M. Ogris and E. Wagner, Adv. Drug Deliv. Rev., 1998, 30, 97–113. 
78 M. A. Mintzer and E. E. Simanek, Chem. Rev., 2009, 109, 259–302. 
79 R. V Benjaminsen, M. A. Mattebjerg, J. R. Henriksen, S. M. Moghimi and T. L. 
 30 
Andresen, Mol. Ther., 2013, 21, 149–157. 
80 Y. Yin, J. H. J. E. Lee, N. W. Kim, J. H. J. E. Lee, S. Y. Lim, E. S. Kim, J. W. 
Park, M. S. Lee, J. H. Jeong, E. J. Lee, W. N. Kim, H. J. Lee, Y. S. Lim, S. E. 
Kim, W. J. Park, S. M. Lee and H. J. Jeong, Polymers (Basel)., , 
DOI:10.3390/polym10090953. 
81 F. Pittella, M. Zhang, Y. Lee, H. J. Kim, T. Tockary, K. Osada, T. Ishii, K. Miyata, 
N. Nishiyama and K. Kataoka, Biomaterials, 2011, 32, 3106–3114. 
82 M. Sengani, A. M. Grumezescu and V. D. Rajeswari, OpenNano, 2017, 2, 37–
46. 
83 Y. C. Yeh, B. Creran and V. M. Rotello, Nanoscale, 2012, 4, 1871–1880. 
84 X. Huang and M. A. El-Sayed, J. Adv. Res., 2010, 1, 13–28. 
85 V. Amendola, R. Pilot, M. Frasconi, O. M. Maragò and M. A. Iatì, J. Phys. 
Condens. Matter, , DOI:10.1088/1361-648X/aa60f3. 
86 S. Srivastava, B. L. Frankamp and V. M. Rotello, Chem. Mater., 2005, 17, 487–
490. 
87 C. S. Thaxton, R. Elghanian, A. D. Thomas, S. I. Stoeva, J.-S. Lee, N. D. Smith, 
A. J. Schaeffer, H. Klocker, W. Horninger, G. Bartsch and C. A. Mirkin, Proc. 
Natl. Acad. Sci., 2009, 106, 18437–18442. 
88 C. D. Medley, J. E. Smith, Z. Tang, Y. Wu, S. Bamrungsap and W. Tan, Anal. 
Chem., 2008, 80, 1067–1072. 
89 X. Huang, B. Kang, W. Qian, M. A. Mackey, P. C. Chen, A. K. Oyelere, I. H. El-
Sayed and M. A. El-Sayed, J. Biomed. Opt., 2010, 15, 058002. 
90 C. Leduc, J. M. Jung, R. R. Carney, F. Stellacci and B. Lounis, ACS Nano, 2011, 
5, 2587–2592. 
91 S. Lu, X. Li, J. Zhang, C. Peng, M. Shen and X. Shi, Adv. Sci., 2018, 5, 1801612. 
92 N. L. Rosi, D. A. Giljohann, C. S. Thaxton, A. K. R. Lytton-Jean, M. S. Han and 
C. A. Mirkin, Science (80-. )., 2006, 312, 1027–1030. 
93 D. A. Giljohann, D. S. Seferos, A. E. Prigodich, P. C. Patel and C. A. Mirkin, J. 
Am. Chem. Soc., 2009, 131, 2072–2073. 
94 C. A. Mirkin, R. L. Letsinger, R. C. Mucic and J. J. Storhoff, Nature, 1996, 382, 
607. 
95 L. Li, Z. Jin, R. Mirkin C, A. Letsinger R, Nucleic Acids Res., 2002, 30, 1558–
1562. 
96 Y. Yi, H. J. Kim, P. Mi, M. Zheng, H. Takemoto, K. Toh, B. S. Kim, K. Hayashi, 
M. Naito, Y. Matsumoto, K. Miyata and K. Kataoka, J. Control. Release, 2016, 
 31 
244, 247–256. 
97 M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, 
Y. Yen, J. D. Heidel and A. Ribas, Nature, 2010, 464, 1067–1070. 
98 T. Coelho, D. Adams, A. Silva, P. Lozeron, P. N. Hawkins, T. Mant, J. Perez, J. 
Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. 
Cehelsky, B. R. Bettencourt, M. Geissler, J. S. Butler, A. Sehgal, R. E. Meyers, 
Q. Chen, T. Borland, R. M. Hutabarat, V. A. Clausen, R. Alvarez, K. Fitzgerald, 
C. Gamba-Vitalo, S. V. Nochur, A. K. Vaishnaw, D. W. Y. Sah, J. A. Gollob and 
O. B. Suhr, N. Engl. J. Med., 2013, 369, 819–829. 
99 O. B. Suhr, T. Coelho, J. Buades, J. Pouget, I. Conceicao, J. Berk, H. Schmidt, 
M. Waddington-Cruz, J. M. Campistol, B. R. Bettencourt, A. Vaishnaw, J. Gollob 
and D. Adams, Orphanet J. Rare Dis., 2015, 10, 109. 
100 M. Minamisawa, B. Claggett, D. Adams, A. V. Kristen, G. Merlini, M. S. Slama, 
A. Dispenzieri, A. M. Shah, R. H. Falk, V. Karsten, M. T. Sweetser, J. Chen, R. 
Riese, J. Vest and S. D. Solomon, JAMA Cardiol., 2019, 4, 466–472. 
101 S. D. Solomon, D. Adams, A. Kristen, M. Grogan, A. González-Duarte, M. S. 
Maurer, G. Merlini, T. Damy, M. S. Slama, T. H. Brannagan, A. Dispenzieri, J. L. 
Berk, A. M. Shah, P. Garg, A. Vaishnaw, V. Karsten, J. Chen, J. Gollob, J. Vest 
and O. Suhr, Circulation, 2019, 139, 431–443. 
102 D. Adams, A. Gonzalez-Duarte, W. D. O’Riordan, C.-C. Yang, M. Ueda, A. V. 
Kristen, I. Tournev, H. H. Schmidt, T. Coelho, J. L. Berk, K.-P. Lin, G. Vita, S. 
Attarian, V. Planté-Bordeneuve, M. M. Mezei, J. M. Campistol, J. Buades, T. H. 
Brannagan, B. J. Kim, J. Oh, Y. Parman, Y. Sekijima, P. N. Hawkins, S. D. 
Solomon, M. Polydefkis, P. J. Dyck, P. J. Gandhi, S. Goyal, J. Chen, A. L. Strahs, 
S. V. Nochur, M. T. Sweetser, P. P. Garg, A. K. Vaishnaw, J. A. Gollob and O. 
B. Suhr, N. Engl. J. Med., 2018, 379, 11–21. 
103 R. L. Setten, J. J. Rossi and S. ping Han, Nat. Rev. Drug Discov., 2019, 18, 421–
446. 
104 J. A. Kulkarni, M. M. Darjuan, J. E. Mercer, S. Chen, R. Van Der Meel, J. L. 
Thewalt, Y. Y. C. Tam and P. R. Cullis, ACS Nano, 2018, 12, 4787–4795. 
105 S. M. Hoy, Drugs, 2018, 78, 1625–1631. 
106 R. University, Clinical Trial MiHA-loaded PD-L-silenced DC Vaccination After 
Allogeneic SCT, 
https://clinicaltrials.gov/ct2/show/NCT02528682?term=NCT02528682&recrs=a






















2.1.1 Instruments and Software 
Table 2.1: Instruments and their respective softwares and manufacturers 
Instrument Manufacturer Software 
Allegra X-12R centrifuge Beckman Coulter  
5415R microfuge Eppendorf  
RF6000 Spectro   
FLUOstar Omega Microplate 
Reader 
BMG labtech Omega Software v3.1 
MARS software v2.1 
GraphPad Prism GraphPad Software Inc v8.00 
GeneAmp PCR System 9700 Applied Biosystems  
Bruker Avance III 
spectrometer 
 MestreNova v12.0.3 
ND-1000 spectrophotometer Nanodrop 
Technologies 
 
QuantStudio Real Time PCR Applied Biosystems  
QubitTM 4 Fluorometer ThermoFisher  
Zetasizer Nano ZS Malvern Panalytical Zetasizer Software 
v7.03 
Varian ProStar instrument Varian Inc. Galaxie Software 
Cirrus offiline 
Astra 
Viia7 PCR System Applied Biosystems QuantStudio Real Time 
PCR 
 
2.1.2 Chemicals and reagents 
Table 2.2: Reagents and their respective suppliers 
Reagents Supplier 
(2-Aminoethyl)trimethylammonium chloride 
hydrochloride 99% Sigma-Aldrich 
(Carboxymethyl)trimethylammonium chloride 
hydrazide 98% Sigma-Aldrich 
1-(Carboxymethyl)pyridinium chloride hydrazide 99% Sigma-Aldrich 
1,3,5-Trioxane ≥ 99% Sigma-Aldrich 
1,4-Dioxane anhydrous, 99.8% Sigma-Aldrich 
2-Aminoethyl methacrylate hydrochloride 90% Sigma-Aldrich 
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Table 2.3: Cont. reagents and their respective suppliers 
Reagents Supplier 
2-Fluoro-4-formylbenzoic acid 97% Apollo Scientific 
2-Hydroxyethyl methacrylate 97% Sigma-Aldrich 
2,2′-Azobis(2-methylpropionitrile) 98% Sigma-Aldrich 
3-Morpholinopropylamine 95% Sigma-Aldrich 
4-(2-Aminoethyl)morpholine 99% Sigma-Aldrich 
4-[3-(Dimethylamino)propoxy]benzaldehyde 96% Sigma-Aldrich 
4-Carboxybenzaldehyde 98% Alfa Aesar 
4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid  
> 97% 
Sigma-Aldrich 
6X DNA loading buffer Fermentas 
Agmatine sulfate salt ≥ 97% Sigma-Aldrich 
Amberlite IRA-410 Sigma-Aldrich 
Chloroform-d 100%, 99.96 atom % D Sigma-Aldrich 
Deuterium oxide, 99.9 atom % D Sigma-Aldrich 
Dimethylformamide distilled grade Rathburn Chemicals 
Ethylenediamine, 99.5%  Sigma-Aldrich 
Fetal calf serum Gibco 
GelRed staining (Biotium) Biotium 
Glutathione Sigma-Aldrich 
Gold nanoparticles 20 nm BBi Solutions 
HEPES, 99.5% Sigma-Aldrich 
Iodomethane, > 99% Sigma-Aldrich 
Lithium bromide, > 99% Sigma-Aldrich 
Luciferin Roche 
N,N-Dimethylethylenediamine, 95% Sigma-Aldrich 
Poly(ethylene glycol) methyl ether methacrylate  
Mn: 300 g mol-1 
Sigma-Aldrich 
Poly(ethylene glycol) methyl ether methacrylate  
Mn: 500 g mol-1 
Sigma-Aldrich 
Poly(methyl methacrylate) standards Agilent Technologies 




Table 2.4: Cont. reagents and their respective suppliers 
Reagents Supplier 
SyBR Green Life Tech 
Tetramethylsilane Sigma-Aldrich 
Thionyl chloride Sigma-Aldrich 
Triethylamine Sigma-Aldrich 
Trimethyl orthoformate Alfa Aesar 
Trypan blue Sigma-Aldrich 
 
2.1.3 Experimental kits 
Table 2.5: Experimental kits and their respective suppliers 
Kit Manufacturer 
Qiashredder Qiagen 
Qubit miRNA assay kit ThermoFisher 
Qubit ssDNA assay kit ThermoFisher 
RNeasy Mini Kit Qiagen 
RevertAidTM H Minus cDNA Synthesis Kit ThermoFisher 
 
2.1.4 Oligonucleotides and short interfering RNAs (siRNAs) 
Table 2.6: Sequences of oligonucleotides and siRNAs. * = Phosphorothioate modification. 
Oligonucleotides Manufacturer Sequence 
Primers 
RUNX1/ETO forward Sigma-Aldrich 5¢-AATCACAGTGGATGGGCCC -3¢  
RUNX1/ETO reverse Sigma-Aldrich 5¢-TGCGTCTTCACATCCACAGG-3¢  
GPDH forward Sigma-Aldrich 5¢-TGGCATGGCCTTCCGT-3¢ 
GAPDH reverse Sigma-Aldrich 5¢-TCTCCAGGCGGCACGTT-3¢ 
ssODN 
ssODN Sigma-Aldrich 5¢-Cy5-CAGTACGATTTCGAGGTT-3¢ 
PS-ssODN Sigma-Aldrich 5¢-Cy5-CAGTACGATTTCGAGGT*T-3¢ 
siRNAs 
PS-siRE sense AxoLabs 5¢-CUCGAAAUCGUACUGAGAAdT*dT-3¢ 
siRE antisense AxoLabs 5¢-UCUCAGUACGAUUUCGAGGdTdT-3¢ 
PS-siMM sense AxoLabs 5¢-CCUCGAAUUCGUUCUGAGAdT*dT-3¢ 
siMM antisense AxoLabs 5¢-UCUCAGAACGAAUUCGAGGdTdT-3¢ 
3PS-siLUC sense Sigma-Aldrich 5¢-CUUACGCUGAGUACUUCG*A*dT*dT -3¢ 
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siLUC antisense Sigma-Aldrich 5¢-UCGAAGUACUCAGCGUAAGdTdT-3¢ 
 
Short interfering RNAs (siRNAs) were provided as separate sense and antisense 
strands in lyophilised form. In order to prepare double-stranded siRNA, hybridisation 
buffer (Hepes buffer 25 mM, NaCl 100 mM, pH 7.4) was added to each strand at a 
final concentration of 100 µM. An equal molar ratio of each strand was transferred to 
a RNase-free Eppendorf tube and heated for 5 min at 95 °C. The reaction was allowed 
to cool to room temperature and siRNAs were stored at -20 °C. 
 
2.2 Tissue culture and cell lines 
2.2.1 Cell lines  
Table 2.7: Cell lines, tissue culture conditions and their cytogenetics 
Cell line Origin Tissue Culture Cytogenetics 

















Cells were split every 48-72 h in fresh media to keep cell concentration at 0.5 x 
106 cells mL-1. The cell lines were cultured in upright culture flasks in an incubator set 
to 37 °C, 5% CO2, fully humidified. 
 
2.2.2 Cell counting 
All cell lines were counted using Trypan Blue which selectively stains the dead 
cells a dark blue colour. The negatively charged Trypan Blue molecules pass only 
through the membrane of damaged dead cells while live viable cells do not absorb the 
dye. Equal volumes from the cell suspension and the dye were mixed giving a dilution 
factor of 2 that was loaded into a haemocytometer. The live/dead cells were counted 
under 10 ́  microscope magnification and the cell concentration (mL-1) was determined 
by the following equation:  
! = # × % × &	
Equation 1 
 
Where, C is the cell concentration in mL-1, n is the number of live cells, D is the dilution 
factor used and f is the chamber depth factor (= 10,000). 
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2.3 General methods 
2.3.1 Nuclear Magnetic Resonance spectroscopy (NMR) 
1H NMR Analysis was performed using a Bruker Avance III spectrometer at 300 
and 700 MHz. 13C NMR analysis was performed on a Bruker Avance III spectrometer 
at 75 MHz. Samples were dissolved in deuterated solvent (CDCl3 or D2O) and the 
residual solvent signal was used as an internal standard. MestreNova v12.0.3 was 
used to process the spectra.  
 
2.3.2 Gel Permeation Chromatography (GPC) 
The polymers were analysed by gel permeation chromatography (GPC) using a 
Varian ProStar instrument (Varian Inc.) equipped with a Varian 325 UV-Vis dual 
wavelength detector with a 254 nm laser, a Dawn Heleos II multi-angle laser light 
scattering detector (Wyatt Technology Corp.), a Viscotek 3580 differential refractive 
index detector and two PL gel 5 µm Mixed D 300 × 7.5 mm columns with a guard 
column (Polymer Laboratories Inc.) in series. Chromatogram analysis was performed 
on Galaxie software (Varian Inc.) and analysed with the Cirrus software (Varian Inc.) 
and Astra software (Wyatt Technology Corp.). Near monodisperse poly(methyl 
methacrylate) standards (Agilent Technologies) were used for calibration. Samples 
were prepared at 8 mg/mL and filtered through a 0.22 µm membrane. LiBr (1 g/l) in 
DMF at 50 °C was used as the mobile phase (flow rate: 0.6mL/min). 
 
2.3.3 Dynamic Light Scattering 
For the determination of the size distribution of the nanoparticles, DLS 
measurements were carried out at 25 ⁰C using a Zetasizer Nano ZS (Malvern 
Instruments) at a detection angle of 173⁰ with an incident He-Ne laser beam (633 nm). 
Data obtained from the rate of decay in the photon correlation function were analysed 
using the cumulant method to obtain the corresponding hydrodynamic diameters and 
polydispersity index (PdI) of the nanoparticles. The particles size is calculated from 
the translational frictional coefficient that is determined by the Stokes-Einsten1,2 
equation as described below: 
d(H) = kT / 3πηD 
 
Equation 2 
Where d(H) is the hydrodynamic diameter, k is the Boltzmann’s constant, T is the 
absolute temperature and η is the viscosity. 
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2.3.4 Determination of lSPR in 20 nm gold nanoparticles 
On account of the specific optical properties of spherical AuNPs, UV-Vis 
spectroscopy was used to characterise AuNPs and determine their stability in different 
media. UV-Vis Spectra were acquired on a FLUOstar Omega Microplate reader (BMG 
Labtech) between 350-700 nm and a wavelength interval of 2 nm and the absorbances 
were normalised. The lSPR was calculated between 470-600 nm according to the 
equation3 below: 
 
lSPR = S(Abs470-600 ´ l470-600) / SAbs470-600 
Equation 3 
 
Where Abs is the normalised absorbance values from 470 nm to 600 nm and l 
is the wavelength from 470 to 600 nm.3 
 
2.3.5 Loading efficiency of the nanocarriers 
The loading efficiencies of the nanocarriers were determined by an indirect 
quantification method and a direct quantification method. The indirect method 
determines the amount of unloaded cargo, which gives an indirect quantification of the 
amount of cargo that was therefore loaded onto the nanoparticles. The direct method 
quantifies the amount of loaded cargo and is determined after cleavage of the cargo 
from the surface of the particles. For particles prepared with Cy5-labelled PS-ssODN 
and Cy5-labelled ssODN, the quantification was determined by fluorescence 
spectroscopy. The quantification of particles prepared with siRNA was determined 
using the QuBit miRNA assay kit (Thermofisher) following the manufacture’s protocol. 
Briefly, the QuBit working solution is prepared by diluting the QuBit miRNA reagent 
(fluorescent dye) in the QuBit miRNA buffer at 1:200. The two QuBit miRNA standards 
and the samples were diluted with the QuBit working solution at 1:20. The 
fluorescence reading were acquired using the QuBit 3.0 fluorimeter at the blue 
excitation (420 – 495 nm) and green emission (500 – 550 nm). 
 
2.3.5.1 Indirect Quantification 
In a typical example, the amount of unloaded PS-ssODN was determined using 
the RF6000 spectrofluorometer (Shimadzu). Particles were centrifuged at 15,000 ´ g 
for 10 min. The supernatants were carefully collected and the amount of unloaded 
ssODN was determined by fluorescence spectroscopy. Fluorescence was recorded at 
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excitation/emission wavelengths of 650/670 nm. A calibration curve of PS-ssODN in 
Hepes buffer pH 7.4 was prepared at 0, 0.5, 3.0, 5.0 and 9.0 µM (Appendix A). The 
fluorescence measurements of the supernatants were interpolated from the calibration 
curve to determine the amount of unloaded PS-ssODN. The loading efficiency was 
calculated according to the equation bellow:  
 
()*+,#-	.&&,/,.#/0	% = 100	 −	 5#6)*+.+	778%9,#,:,*6	/)#/.#:;*:,)# × 	100 
Equation 4 
 
2.3.5.2 Direct Quantification 
In a typical example, particles were purified by centrifugation 15,000 ´ g for 10 
min and then washed with Hepes buffer pH 7.4 (900 µL) three times. The particles 
were then treated with dithiothreitol (DDT) 100 mM for 4 h to release the amount of 
loaded PS-ssODN. The centrifugation procedure was repeated and the supernatants 
collected for quantification by fluorescence spectroscopy. Fluorescence was recorded 
at excitation/emission wavelengths of 650/670 nm. The concentration of PS-ssODN 
in the supernatants was interpolated from calibration curves (Appendix A) to determine 
the amount of loaded PS-ssODN onto AuNPs. The loading efficiency was calculated 
according to the equation:  
 
()*+,#-	.&&,/,.#/0	% = 100	 ×	 6)*+.+	778%9,#,:,*6	/)#/.#:;*:,)# 
Equation 5 
 
2.4 Experimental Chapter 3 
2.4.1 Synthesis of pPEGMA polymers (P1 and P2) 
 
 

















RAFT Polymerisation was used to prepare pPEGMA polymers for conjugation 
onto AuNPs (Scheme 2.1). Poly(ethylene glycol) methyl ether methacrylate monomer 
M1 (PEGMA300 Mn: 300 g mol-1) was passed through a column of activated basic 
alumina to remove the inhibitor and stored at -20 °C before use. 4-Cyano-4-
(thiobenzoylthio)pentanoic acid (CTPA) and 2,2’-azobis(2-methylpropionitrile) (AIBN) 
was used as chain transfer agent (CTA) and initiator, respectively. In a typical 
example, PEGMA300 (7.00 g, 23.33 mmol, 50.0 eq.) and CTPA (130.2 mg, 0.466 mmol, 
1.0 eq.) were added to a Schlenk tube. AIBN (15.3 mg, 0.093 mmol, 0.2 eq.) and 1,3,5-
trioxane (50.0 mg, 0.555 mmol, 1.2 eq) were then added followed by DMF (10.5 mL). 
The reaction mixture was degassed through five freeze-pump-thaw cycles and purged 
with N2 and allowed to warm to room temperature. The reaction mixture was then 
placed in an oil bath at 70 °C. After 2 h, the reaction was quenched by freezing in liquid 
nitrogen. The reaction mixture was dialysed in distilled water and freeze-dried to obtain 
P1 as a pink oil. 1H NMR (300 MHz, CDCl3): d = 0.64 – 1.14 (br, -CHCH3, polymer 
backbone), 1.62 – 2.06 (br, -CHCH2, polymer backbone), 3.30 – 3.43 (br, -OCH3), 3.47 
– 3.56 (br, -OCH2CH2), 3.57 – 3.77 (br, -OCH2CH2, ethylene glycol chain), 3.96 – 4.22 
(br, -OCH2), 7.30 – 7.40 (br, Ar, polymer endgroup), 7.45 – 7.54 (br, Ar, polymer 
endgroup), 7.81 – 7.89 (br, Ar, polymer endgroup). The composition of P1 was 
determined by comparing the integration of the aromatic CTA protons with the 
integration of the methoxy methyl (-OCH3) of the monomer side chains. P2 was 
synthesised in the same conditions, however the polymerisation time was increased 
to 5 h to obtain a polymer of larger molecular weight. The same analysis was used to 
determine the composition of P2. 1H NMR (300 MHz, CDCl3): d = 0.63 – 1.13 (br, 
CHCH3, polymer backbone), 1.53 – 2.07 (br, CHCH2, polymer backbone), 3.34 – 3.40 
(br, -OCH3), 3.45 – 3.50 (br, -OCH2CH2), 3.59 – 3.69 (br, -OCH2CH2, ethylene glycol 
chain), 3.94 – 4.20 (br, -OCH2), 7.30 – 7.39 (br, Ar, polymer endgroup), 7.46 – 7.54 
(br, Ar, polymer endgroup), 7.81 – 7.89 (br, Ar, polymer endgroup). 
The monomer conversion was monitored by 1H NMR spectroscopy using the 
integrals of PEGMA300 vinyl group signals at 5.45 ppm and 6.01 ppm. 1,3,5-Trioxane 
was used as internal standard (5.10 ppm). The table below shows the RAFT 




Table 2.8: RAFT polymerisations of P1 and P2. a Determined by 1H NMR spectroscopy. 
Polymer Ratios [M]/[CTA]/[I] Solvent Time Monomer conversion 
P1 100/1.0/0.2 DMF 2 h 46% 
P2 100/1.0/0.2 DMF 5 h 72% 
 
2.4.2 Conjugation of pPEGMA to gold nanoparticles (AuNPs) 
For the conjugation of pPEGMA onto AuNPs, particles (1.16 nM, 100 µL) were 
incubated overnight with different molar ratios of P1 or P2 in a 96 well-plate. After 24h, 
10 µL of NaCl(aq) (1 M) was added and the UV-Vis spectrum was acquired using a 
FLUOstar Omega Microplate Reader between 350-700 nm and a wavelength interval 
of 2 nm. The induced aggregation factor was determined by calculating the ratio 
l615/l524. High aggregation factor indicates salt-induced aggregation and therefore, by 
evaluating the induced aggregation factor it is possible to determine the appropriate 
polymer concentration to successfully coat AuNPs. Uncoated AuNPs were used as a 
control.  
 
2.4.3 Conjugation of ssODN and siRNA onto AuNPs 
In a typical example, AuNPs (11.6 nM, 100 µL) were incubated with 4 µL of PS-
ssODN at 100 µM (final concentration 2.2 µM). After 10 min sonication, the suspension 
was left at room temperature overnight. The polymer was added (10 µL, final conc. 
0.7 µM) to the suspension and the particles were sonicated for 10 min. After 6 hours, 
60 µL of a solution containing 0.3% SDS(aq) and 0.3 M of NaCl(aq) was added (final 
concentration 0.1% and 0.1M). After 1 hour, 3.75 µL of NaCl(aq) (1.4 M) was added 
and the particles were incubated for 1 h. This step was repeated twice until the final 
concentration of NaCl reached 0.16 M and the suspension was allowed to react 
overnight. Nanoparticles were purified by centrifugation at 15,000 x g for 10 min and 
washed 3 times with Hepes buffer (10 mM) pH 7.4. Figure 2.1 and Table 2.9 describe 
the conjugation procedure. The same procedure was used to conjugate non-modified 
ssODN (Table 2.10) and PS-siRNA and 3PS-siRNA (Table 2.11). To optimize the 
loading of siRNA onto AuNPs, the protocol was adjusted by changing the final salt 
concentration during the salt aging process, the final SDS concentration, the titration 
time and also the temperature during loading (Table 2.11). 
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Figure 2.1: Preparation of gold nanoparticles coated with ssODN and polymer. 
 
Table 2.9:Conditions for preparation of AuNPs coated with PS-ssODN. 
PSssNPs 
Molar ratios 
AuNP:PS-ssODN:pPEGMA [NaCl(aq)] [SDS(aq)] NaCl titration time 
1:350:110 160 mM 0.1 % 3 h 
 




[NaCl(aq)] [SDS(aq)] NaCl titration time 
1:350:110 160 mM 0.1 % 3 h 
 





[NaCl(aq)] [SDS(aq)] NaCl  
titration time 
Heat 
PSsiNP.P1 1:350:110 160 mM 0.1% 3 h - 
PSsiNP.P2-T1 1:350:110 160 mM 0.1% 12 h - 
PSsiNP.P2-T2 1:350:870 160 mM - - - 





[NaCl(aq)] [SDS(aq)] NaCl  
titration time 
Heat 
3PSsiNP-T1 1:344:110 160 mM 0.1% 3 h - 
3PSsiNP-T2 1:850:110 260 mM 0.1 % 3 h - 
3PSsiNP-T3 1:350 160 mM 0.1 % 3 h - 
3PSsiNP-T4 1:350 - - 3 h 95 °C, 5 min 
3PSsiNP-T5 1:350 160 mM 0.1% 3 h 95 °C, 5 min 
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2.4.4 Stability of PSssNP.P2 
The stability of nanoparticles loaded with PS-ssODN was assessed by incubating 
50 µl of PSssNP.P2 in 50 µl of tissue culture medium RPMI containing 10% FCS. The 
final concentration of PS-ssODN in the samples was 0.5 µM. At different time points, 
the particles were isolated by centrifugation and the supernatant collected for 
quantification by fluorescence. The fluorescence measurements were interpolated 
from a calibration curve (Appendix A) and the concentration of PS-ssODN released 
from PSssNP.P2 determined.  
 
2.4.5 Glutathione mediated release of PSssNP.P2 
Samples at time points 0 h and 1 h from the stability assay were collected and 
GSH was added at a final concentration of 10 mM. After 1 h incubation, the samples 
were centrifuged at 15,000 ´ g for 10 min to precipitate the particles. The supernatants 
were carefully collected for quantification of PS-ssODN by fluorescence spectroscopy. 
The values were interpolated from a standard curve (Appendix A) and the amount of 
PS-ssODN released was determined. 
 
2.4.6 In vitro gene silencing 
To evaluate the gene silencing efficiency of siRNA contained in PSsiNPs, 0.5 mL 
of Kasumi-1 cells were seeded at 0.5 x 106 cells.mL-1 in a 24 well plate. PSsiNPs were 
added at a final siRNA (siRE and siMM) concentration of 200 nM. After 24 and 48 h, 
cells were collected and centrifuged at 300 x g for 5 min. The supernatant was 
discarded and the pellet resuspended in 500 μL of PBS 10 mM before further 
centrifugation at 300 x G for 5 min after which the supernatant was discarded and the 
pellet resuspended in RLT buffer (RNeasy kit). Samples were frozen at -20 °C for 
storage.  
 
2.4.6.1 RNA extraction  
Cell samples in RLT buffer were thawed and vortexed. mRNA was extracted 
using RNeasy Kit according to the manufacture’s protocol. Briefly, cell lysates were 
loaded into a QIAshredder column and centrifuged at 8,000 ´ g for 2 min. Ethanol (350 
μL) was added to each lysate and the sample was loaded into a RNeasy column and 
centrifuged at 8,000 ´ g for 30 s. The RNeasy spin column was then washed with 
700μL of RW1 buffer and twice with 500 μL of RPE, with centrifugation at 8,000 ´ g 
for 30 s between each step. In order to remove the excess of RPE buffer, samples 
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were centrifuged for a further 2 min at 8,000 ´ g before 50 μL RNase-free water was 
added to each column. After 1 min incubation the samples were centrifuged for 1 min 
at 8,000 ´ g and the concentration of RNA in the flow through was determined using 
the Nanodrop 2000. Samples were stored at -20 °C.  
 
2.4.6.2 cDNA synthesis 
cDNA was synthesised from the mRNA samples by reverse transcription using 
Revert Aid H minus 1st strand cDNA Kit (Thermo Fisher). RNA (1,000 ng) was added 
to 1 μL random hexamers and deionised water to a final total volume of 12 μL. The 
reaction was incubated at 70 °C for 5 min to disrupt mRNA secondary structures. The 
mixture was cooled to 4 °C and 8 μL of master mix (Table 2.12) was added to each 
reaction and the reverse transcription occurred under the following conditions: 25 °C, 
10 min; 42 °C, 60 min; 70 °C, 10 min; held at 4 °C. After cDNA synthesis, 30-80 μL of 
RNA-free water was added to samples and stored at -20 °C.  
 
Table 2.12: cDNA Master Mix formulation 
Reagent Amount 
5X Reaction buffer 4 
dNTP mix (10mM) 2 
Riboblock RNase inhibitor 1 
RevertAid H minus reverse transptase 1 
 
2.4.6.3 Real-time quantitative reverse transcriptional PCR (RT-qPCR) 
Real-time RT-qPCR was performed on an ABI Prism 7000 sequence detection 
system using SYBRGreen PCR Master Mix (Table 2.13). GAPDH was used as the 
house-keeper gene to normalise data before statistical analysis. The master mix 
(Table 2.13) was prepared according to manufacturer’s protocol. In a 384 well plate 8 
µL of master mix was added to each well. cDNA from each sample (2 µL) was pipetted 
into wells in triplicate and a water control was included. The plate was sealed and 
centrifuged at 1000 ´ g for 1 min before being loaded into the sequence detection 
system. The reaction was performed as follows: 50 °C, 2 min; 95 °C, 10 min; 60 °C, 
15 seconds; followed by 40 cycles of 95 °C, 15 seconds; 60 °C, 1 min; followed by a 
single cycle of 95 °C, 15 seconds; 60 °C 15 seconds; 95 °C 15 seconds. Analysis was 
performed using the QuantStudio Real-Time PCR software and relative RUNX1/ETO 
expression was calculated according to the formula bellow:  
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-DCtRUNX1/ETOt = CtRUNX1/ETOt - CtGAPDH                           Equation6 
-DDCtRUNX1/ETO = -DCtRUNX1/ETOt - DCtRUNX1/ETOc                   Equation 7 
Rel. RNA expression = 2- (-DDCtRUNX1/ETO)                        Equation 8 
Where, Ct is the mean cycle threshold of each replicate. 
 
Table 2.13: RT-qPCR Master Mix 
Reagent Amount 
SyBr Green 5 µl 
Primer Mix (10 µM) 0.3 µl 
RNA-free water 2.7 µl 
 
2.4.7 Luciferase gene knockdown 
Luciferase assay was used to fast determine the gene knockdown efficiency of 
3PS-siLUC. Kasumi-1 pSLIEW cells (90 μL) were seeded at 0.5 x 106 cells mL-1 in a 
96 well plate. To determine the sequence efficiency to promote gene knockdown, 3PS-
siLUC was eletroporated to the cells at 50, 100 and 200 nM. After 24 and 48 h 
incubation time, luciferin (10 µL at 4.5 mg.mL-1 in RPMI) was added to samples. The 
luminescence of samples was read using the Omega plate reader after 3, 5 and 10 
min. Results were averaged to determine the luminescence of each well. 
 
2.5 Experimental Chapter 4 
2.5.1 Synthesis of A1 
 
Scheme 2.2: Synthesis of aldehyde A1. (i) CH(OCH3)3 MeOH, H2SO4, 24 h. (ii) Ethylenediamine, 




























Aldehyde A1 was prepared in a four-step synthesis(Scheme 2.2). Synthetic 
intermediates are labelled with lower case letters. 
 
2.5.1.1 Synthesis of methyl-4-(dimethoxymethyl)-benzoate (a) 
4-Carboxybenzaldehyde (20.0 g, 0.133 mol) was dissolved in MeOH (120 mL) 
and acidified with concentrated H2SO4 (20 drops). Trimethyl orthoformate (44 mL, 
0.400 mol) was added in one portion and the mixture was refluxed for 24 h with stirring. 
The mixture was transferred to a separating funnel with saturated NaHCO3 (100 mL) 
and the aqueous layer was extracted with CH2Cl2 (3 x 150 mL). The organic extracts 
were combined and dried over MgSO4, filtered and evaporated to dryness to afford a 
yellow oil (23.83 g, 0.11 mol, 85 %) which was used without further purification. 1H 
NMR (CDCl3, 300 MHz): d = 3.30 (s, 6H), 3.89 (s, 3H), 5.41 (s, 1H), 7.52 (d, 2H, J = 9 
Hz) and 8.00 ppm (d, 2H, J = 9 Hz). 13C NMR (CDCl3, 75 MHz) d = 52.2, 52.7, 102.4, 
126.9, 129.6, 130.3, 143.0 and 166.9 ppm.  
 
2.5.1.2 Synthesis of N-(2-aminoethyl)-4-(dimethoxymethyl)benzamide (b) 
Purified a (16.40 g, 78.0 mmol) was refluxed in ethylenediamine (200 mL) for 18 
h. Ethylenediamine was removed under pressure to afford a deep brown solid which 
was purified by column chromatography (SiO2, CH2Cl2:EtOH:Et3N, 80:15:5 v/v). The 
fractions were collected and evaporate to dryness to afford a pale white solid (7.2 g, 
30.2 mmol, 44 % yield). 1H NMR (CDCl3, 300 MHz): d = 2.29 (s, 2H), 2.90 (t, 2H, J = 
6.0 Hz), 3.28 (s, 6H), 3.45 (q, 2H, J = 6.0 Hz), 5.37 (s, 1H), 7.22 (br t, 1H), 7.47 (d, 2H, 
J = 9.0 Hz) and 7.81 ppm (d, 2H, J = 9.0 Hz). 13C NMR (CDCl3, 75 MHz): d = 42.2, 
52.7, 58.0, 102.5, 126.9, 127.1, 134.6, 141.4 and 167.6 ppm. 
 
2.5.1.3 Synthesis of 2-(4-Formylbenzamido)-N,N,N-trimethylethan-1-aminium 
N-(2-Aminoethyl)-4-(dimethoxymethyl)benzamide (b) (4.0 g, 16.8 mmol) was 
dissolved in MeOH (100 mL). K2CO3 (4.6 g, 33.6 mmol was added followed by addition 
of iodomethane (48.0 g, 336 mmol) in one portion, and this mixture was stirred for 8 h 
at 55 °C. Residual iodomethane was removed under reduced pressure and Et2O (30 
mL) was added and the suspension was agitated in a sonic bath for 30 min and filtered 
to afford a pale brown solid. This solid was dissolved in 1:1 acetone:water (50 mL) and 
acidified with 2 mL of concentrated HCl. After stirring at room temperature for 2 h the 
mixture was filtered and the filtrate evaporated to dryness. The resulting pale brown 
solid was purified by precipitation in a saturated aqueous solution of KPF6  and isolated 
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by filtration. The hexafluorophosphate is an anion that exhibits low solubility in water 
and therefore, can be isolated by filtration. Then, the filtrate was dissolved in MeOH in 
the presence of trimethylammonium-functionalised Amberlite (chloride form) (IRA-
410) to exchange the counter ion and obtain the water-soluble aldehyde A1 as a white 
solid (3.6 g, 13.4 mmol, 80 %) 1H NMR (D2O, 300 MHz): d = 3.07 (s, 9H), 3.46 (t, 2H, 
J = 6.0 Hz), 3.73 (t, 2H, J = 6.0 Hz), 7.73 (d, 2H, J = 9.0 Hz), 7.83 (d, 2H, J = 9.0 Hz), 
9.80 (s, 1H). 13C NMR (CDCl3, 75MHz): d = 34.1, 53.2, 64.0, 127.8, 130.1, 138.0, 
138.3, 169.7 and 195.5 ppm (Appendix B). High-resolution mass spectrometry was 
performed using a Waters LCT Premier mass spectrometer (water Inc.). HRMS+ 
C13H19N2O2: Theoretical: 235.14. Actual: 235.15. 
 
2.5.2 Synthesis of 4-formylbenzoyl chloride (1) and 2-fluoro-4-formylbenzoyl 
chloride (2). 
4-Carboxybenzaldehyde (3.0 g, 20 mmol) was dissolved in PhCH3 (300 mL) 
followed by the addition of SOCl2 (11 mL, 160 mmol). The mixture was refluxed for 18 
h and residual SOCl2 was removed under reduced pressure to obtain 1. 1H NMR 
(CDCl3, 300 MHz): d = 8.04 (d, 2H, J = 9.0 Hz, 8.27 (d, 2H, J = 9.0 Hz), 10.15 (s, 1H). 
13C NMR (CDCl3, 75MHz): d = 129.9, 131.9, 140.5, 166.8, 167.7, 169.7 and 191.1 
ppm. The same procedure was repeated using 2-fluoro-4-formylbenzoic acid to obtain 
2-fluoro-4-formylbenzoyl chloride 2 as pale-yellow oil. 1H NMR (CDCl3, 300 MHz): d = 
7.66 (dd, 1H, J = 12.0 Hz), 7.75 (dd, 1H, J = 6.0 Hz), 8.19 (t, 1H, J = 6), 10.1 (s, 1H). 
13C NMR (CDCl3, 75MHz): d = 117.2, 117.5, 119.9, 125.2, 134.6, 163.2, 165.3 and 
189.5 ppm. 
 
2.5.3 Hydrazone and imine hydrolysis 
All pH measurements were made using a Hanna HI 90103 instrument which was 
calibrated regularly using commercial buffer solutions (Sigma-Aldrich). Aliquots of 1 M 
or 0.1 M NaOH and HCl were used to increase and lower the pH in all reactions. In a 
typical experiment, aldehyde A1 (3 mL, 20 mM) and 
(carboxymethyl)trimethylammonium chloride hydrazide HZ1 (3 mL, 20 mM) were 
dissolved in D2O at room temperature. The solutions were mixed and the pH adjusted 
to pH 12.0 with aliquots of NaOH(aq) (1 M). The mixture was analysed by 1H NMR 
spectroscopy and the complete conversion of the reaction was confirmed by 
appearance of the CH signal of the hydrazone bond (d ~ 8 ppm). The pH of the mixture 
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was slowly titrated with H3PO4(aq) (1 M) and the hydrolysis monitored by 1H NMR 
spectroscopy. After titration with H3PO4(aq) (1 M), the sample was left to equilibrate for 
30 min and the pH was measured again to confirm the pH value. The sample was then 
analysed by 1H NMR spectroscopy to determine the yield of hydrazone by integration 
of aldehyde and hydrazone signals, using tetramethylsilane (TMS) as an internal 
standard. The same procedure was repeated for all aldehydes, hydrazides and 
amines, and the polymer system described in Chapter 4. The formation of imines was 
also performed in 1:10 molar ratios. The yields of hydrazones or imines were 
calculated according to equation 9 and 10, respectively: 
 
Yield of hydrazone (%) = 100 ´ ((ƒHydrazone)/ (ƒHydrazone+ƒaldehyde))       Equation 9 
     Yield of imine (%) = 100 ´ ((ƒImine)/ (ƒImine+ƒaldehyde))               Equation 10 
 
Where ƒ is the integral value of each signal. 
 
2.5.4 Synthesis of pHEMA-b-pPEGMA by RAFT polymerisation 
2.5.4.1 Synthesis of macroCTA pPEGMA (P5) 
 
 
Scheme 2.3: Synthesis of macroCTA P5 by RAFT polymerisation. 
 
CTPA (22.4 mg, 0.08 mmol, 1 eq) and AIBN (2.63 mg, 0.016 mmol, 0.2 eq) were 
added to a small Schlenk tube (Scheme 2.3). Poly(ethylene glycol) methyl ether 
methacrylate (PEGMA, Mn: 500 g mol-1) (M2) (4 g, 8.0 mmol, 100 eq) was passed 
through a column of activated basic alumina to remove the inhibitor and then added 
to the mixture. After addition of 1,4-dioxane (5 mL), the reaction mixture was degassed 
through five freeze-pump-thaw cycles before the vessel was backfilled with N2 and 
allowed to warm to room temperature. The reaction mixture was then placed in an oil 
bath at 70 °C and the polymerisation was quenched after 3 h (Scheme 2.3). The 

















to obtain P5 as a pink oil. 1H NMR (300 MHz, CDCl3): d = 0.65 – 1.13 (br, CHCH3, 
polymer backbone), 1.54 – 2.06 (br, CHCH2, polymer backbone), 3.31 – 3.40 (br, -
OCH3), 3.42 – 3.48 (br, -CH2O), 3.50 – 3.77 (br, -CH2CH2, ethylene glycol chain), 3.95 
– 4.25 (br, -OCH2), 7.30 – 7.43 (br, Ar, polymer endgroup), 7.45 – 7.56 (br, Ar, polymer 
endgroup), 7.73 – 7.90 (br, Ar, polymer endgroup). The composition of P5 was 
determined by comparing the integrals of the characteristic aromatic protons of the 
polymer endgroup with the integral of the methoxy methyl (-OCH3) protons of the side 
chain of the monomer.  
 
2.5.4.2 Copolymerisation of HEMA monomer M3 (P6) 
 
Scheme 2.4: Synthesis of diblock copolymer P6 by RAFT polymerisation. 
 
In a typical example, the macroCTA P5 ( 463.0 mg, 0.01 mmol, 1 eq) and AIBN 
(0.82 mg, 0.005 mmol, 0.3 eq) were added to a small Schlenk tube (Scheme 2.4). 2-
hydroxyethyl methacrylate M3 (HEMA, Mw: 130.14 g mol-1,130.14 mg, 1.0 mmol, 100 
eq) was added to the mixture followed by the addition of 1,4-dioxane (3 mL). The 
reaction mixture was degassed through five freeze-pump-thaw cycles and then was 
backfilled with N2 and placed in an oil bath at 70 °C. After 6 h the polymerisation was 
quenched in liquid nitrogen and the reaction mixture was dialysed in CH2Cl2:MeOH 
(50:50 v/v) and evaporated to dryness to obtain P6 as a pink oil. 1H NMR (300 MHz, 
D2O): d = 0.64 – 1.30 (br, CHCH3, polymer backbone), 1.70 – 2.35 (br, CHCH2, 
polymer backbone), 3.37 – 3.45 (br, -OCH3, pPEGMA block), 3.58 – 4.00 (br, -
OCH2CH2, ethylene glycol chain), 4.04 – 4.34 (br, -OCH2, pHEMA and pPEGMA 
block). The composition of P6 was determined by comparing the integration of the 
methoxy methyl (-OCH3) protons from the pPEGMA block with the integration of the 
overlapped signals of the ethylene glycol chain (-OCH2) of the pHEMA and pPEGMA 
blocks. The same procedure was repeated for poly(ethylene glycol) methacrylate 
monomer M4 (PHEMA, Mn: 500 g mol-1) varying the equivalence of AIBN and the 































Table 2.14: Conditions for the RAFT polymerisation of diblock copolymers. 
Polymer Molar Ratios 
[M]/[CTA]/[I] 
Solvent Time Monomer conversion 
P6 100/1.0/0.3 1,4-dioxane 6 hours 47 % 
P8 100/1.0/0.3 1,4-dioxane 3 h 32 % 
P9 100/1.0/0.5 1,4-dioxane 3 h 50 % 
P10 100/1.0/0.5 Toluene Overnight 34 % 
P11 100/1.0/0.5 DMF 3 h 54 % 
 
2.5.5 Synthesis of aldehyde-functionalised di-blocks 
 
Scheme 2.5: Synthesis of aldehyde functionalised polymers. 
 
Diblock copolymer pHEMA-b-pPEGMA (P6, Mn: 28,200 g mol-1, 126 mg, 0.196 
mmol -OH, 1.0 eq) was dissolved in CH2Cl2 (8 mL) and added to a round bottom flask 
in an ice-bath followed by addition of triethylamine (39.5 mg, 0.40 mmol, 2.0 eq). 4-
Formylbenzoyl chloride 1 (165 .0mg, 0.975 mmol, 5.0 eq) was dissolved in CH2Cl2 (8 
mL) and added dropwise to the reaction mixture (Scheme 2.5 A). After 18 h, the 
reaction mixture was evaporated to dryness and dialysed in MeOH. The polymer was 
evaporated to dryness to obtain P7 as a pale pink oil. The same procedure was 
repeated with P11 to obtain the aldehyde-functionalised polymer P14 (Scheme 2.5 C). 
For the fluoro-monosubstituted aldehyde polymer, P11 was reacted with 2-fluoro-4-










































































































formylbenzoyl chloride 2 to obtain P12 (Scheme 2.5 B) as a pale yellow solid. 1H NMR 
(300 MHz, CDCl3) P7: The polymer showed the characteristics signals of the polymer 
backbone and the ethylene glycol chain of the pPEGMA block. The signal of the 
ethylene glycol chain from the pPHEMA block appeared shifted to downfield at d = 
4.19 – 4.36 (br, -OCH2) and 4.40 – 4.66 (br, -CH2O). The aldehyde signals appeared 
at d = 7.83 – 8.36 (br, aromatic protons) and 9.84 and 10.30 br, -CH, aldehyde 
protons). The yield of the aldehyde functionalisation of P7 was determined by 
comparing the integration of the methoxy methyl (-OCH3) protons from the pPEGMA 
block with the integration of the aldehyde signals (-CH and Ar protons) of the pPHEMA 
block. The same procedure was repeated for polymer P12 and P13. 
 
2.5.6 Synthesis of hydrazone-functionalised polymers 
In a typical example, P12 (Scheme 2.6 A) (Mn: 76,400 g mol-1,146 mg, 0.115 
mmol aldehyde, 1.0 eq) was dissolved in MeOH followed by the addition of (77 mg, 
0.46 mmol, 4.0 eq) HZ1. After 24 h, the reaction mixture was purified by dialysis in 
ultra-pure water and freeze-dried to obtain P13 as a pale-yellow solid. The yield of 
hydrazone functionalisation was determined by the disappearance of the aldehyde 
signals (d ~ 10.0 ppm) in the 1H NMR spectrum. The same procedure was repeated 
to obtain P15 (Scheme 2.6 B).  
 














P12: m = 93

















P13: m = 93








































P14: m = 93











P15: m = 93












2.5.7 Polyplex formation between hydrazone-polymers and siRNA 
The polyplexes (P13siPP and P15siPP) were obtained by self-assembly of the 
polymer solutions with siRNA. A solution of siRNA in RNAse-free water (50 µL, 4 µM) 
was mixed with the polymer solutions (50 µL) in different molar ratios. The N/P ratios 
were calculated by the ratio of the positive charges (ammonium groups within the 
polymer) to the negative charges (phosphate groups within siRNA, final conc. 80 µM). 
After complexation at different N/P ratios, the samples were incubated for 1 h at room 
temperature.  
 
2.5.8 Gel retardation assay 
An agarose gel electrophoresis assay or gel retardation assay was performed to 
evaluate the loading capacity of the polyplexes. A 3 % agarose gel was prepared in 
0.5 X TBE buffer. 5 µL of 10,000X GelRed staining (Biotium) was added to the gel 
before casting. 2 µL of 6X DNA loading buffer (Fermentas) was mixed with 8 µL of 
sample, and samples were loaded into wells. The gel was allowed to run for 1 h at 80 
V in 0.5 X TBE buffer and visualised with a BioRad transluminator (UV). 
 
2.5.9 Conjugation of hydrazone-polymers to AuNPs 
AuNPs (1.16 nM, 100 µL) were incubated overnight with different molar ratios of 
P13 or P15 in a 96 well-plate. After 24 h, 10 µL of NaCl(aq) (1 M) (final conc. 100 mM) 
was added and the UV-Vis spectrum was acquired using a FLUOstar Omega 
Microplate Reader between 350-700 nm and wavelength interval of 2 nm. To 
determine the ideal polymer concentration to be used on the coating of 20 nm AuNPs, 
the induced aggregation factor was determined by calculating the ratio l615/l524. 
Uncoated AuNPs were used as a control.  
 
2.5.10 Preparation of AuNPs coated with hydrazone-polymers and siRNA 
AuNPs (11.6 nM, 100 µL) were first incubated overnight with P13 (10 µL) at 
different molar ratios (1:100, 1:500 and 1:1,000). Particles were then purified by 
centrifugation at 15,000 ´ g for 10 min and washed three times with Hepes buffer pH 
7.4. 2 µL of siRNA (final concentration 0.4 µM) was added and the suspension was 
allowed to equilibrate for 1 h. The loading efficiency was determined by the indirect 
quantification method using the Qubit miRNA kit as previously described in section 
2.3.5.1. Table 2.15 shows the composition for the particles formed. 
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P13100si2NP 1:100 2 
P13500si10NP 1:500 10 
P131,000si20NP 1:1,000 20 
P15100si1.2NP 1:100 1.2 
P15500si6NP 1:500 6 
P151,000si12NP 1:1,000 12 
 
2.5.11 Stability of P131,000si20NP in different pHs 
Particles P131,000si20NP (25 µL) were incubated with phosphate buffer 10 mM 
(75 µL) at pH 7.2 and 5.0. After 24 h, the particles were isolated by centrifugation at 
15,000 ´ g for 15 min and the supernatants collected for quantification of released 
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Phosphorothioate modified siRNA for 











Since the discovery of RNA interference by Fire & Mello,1 siRNA provides a new 
perspective for treatment of intractable and genetic related diseases. However, the 
safe and efficient delivery of siRNA to the target cytoplasm is still a major challenge in 
RNAi therapy.2 This challenge arises as naked siRNA molecules are susceptible to 
enzymatic degradation in the body and also possess anionic charges that supress the 
penetration into cellular membrane.3 Hence, the design and development of new 
nanocarriers is essential to overcome these delivery challenges.  
Gold nanoparticles (AuNPs) have been a promising tool for bioapplications such 
as biosensing, bioimaging and drug delivery on account of their unique chemical and 
physical properties. In addition to the specific optical properties depending on their 
size and morphology, AuNPs can be surface modified with biomolecules and polymers 
through thiol chemistry to optimise colloidal stability and biocompatibility.4 Thiol 
modification of nucleic acids is the main approach successfully used for the 
functionalisation of gold surfaces, a process driven by the formation of the strong gold-
thiol interactions.5,6 Mirkin et al.7 were one of the first groups to report the 
chemisorption of thiolated oligonucleotides to AuNPs. The group prepared 13 nm 
AuNPs coated with two different single strands of thiolated DNA oligonucleotides. After 
addition of a complementary sequence that binds to a portion of both strands (linker), 
AuNP aggregation was observed. The findings demonstrated the successful coating 
of AuNPs with thiolated oligonucleotides and post-hybridisation of the grafted 
sequences. They further reported8 the synthesis of DNA oligonucleotide-AuNPs 
conjugates by evaluating the surface coverage and stability of oligonucleotide probes 
featuring one thiol modification, a disulfide or three thiol modifications. They reported 
that the conjugates prepared with the trithiol oligonucleotide showed significantly 
higher stability against DDT than the conjugates prepared with monothiol or disulfide 
terminated oligonucleotides. Moreover, the conjugates prepared with the trithiol 
oligonucleotide showed the highest surface coverage, and thus, indicated that the 
oligonucleotides bearing three thiol modifications exhibit higher loading on the AuNPs 
surface.8 
Although thiolated nucleic acids have been widely used to achieve successful 
functionalisation of gold nanoparticles, thiol-modified siRNAs are expensive to 
synthesize and can be difficult to work with as thiol groups can easily be oxidised to 
disulfides. An interesting alternative approach is the utilisation of nucleic acids whose 
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non-bridging phosphate oxygen atoms have been substitute by sulfurs, so-called 
phosphorothioate modification (PS) (Figure 3.1).  
 
 
Figure 3.1: Chemical structure of (A) non-modified and (B) phosphorothioate (PS) modified nucleic 
acids. 
 
Phosphorothioate-modified nucleic acids can be synthesised by conventional 
solid phase synthesis and cost only 3% of the price of thiol-modified oligo.9 Moreover, 
phosphorothioates can also be adsorbed to gold surfaces,10 possess increased 
stability towards degradation by nucleases,11 and thus are promising candidates for 
conjugation of modified siRNAs to AuNPs.  
For the success of RNAi therapy, the safe release of siRNA into the cell 
cytoplasm is essential. The ideal delivery platform must be stable at physiological pH 
and promote the fast release of siRNA into the cytosol, allowing the RNAi mechanism 
to operate. Nanoparticles that possess a bioresponsive behaviour are essential for 
siRNA delivery platforms. The sulfur-Au bond is relatively stable in physiological fluids 
and in the extracellular space, however, it is labile in the cytosol due to a redox 
imbalance of glutathione (GSH), a thiol reducing agent that can bind to Au.12 The 
difference in the extracellular concentrations (~ 2–10 ´ 10−6 M) versus intracellular 
concentrations (~ 2–10 ´ 10−3 M) of GSH13 offers an intracellular specifc response to 
AuNPs coated with PS-modified siRNA. In extracellular conditions, the delivery 
platform would remain stable, however, once in the cytosol, the higher concentrations 
of GSH would bind to the AuNPs, triggering the displacement and release of PS-siRNA 


































































A main concern in siRNA delivery is the colloidal stability and biocompatibility of 
in vivo nanocarriers. To be able to deliver therapeutic concentrations of siRNA to the 
target cell, a nanocarrier must be sufficiently stable in the blood circulation and present 
prolonged half-life circulation. Surface modification of nanoparticles with polyethylene 
glycol, termed PEGylation, has shown to be safe and effective in providing stability 
and increased blood circulation in vivo.14 The hydrophilicity of PEG provides steric 
shielding of the AuNP in aqueous solutions, resulting in colloidal stability and 
preventing unwanted recognition of particles by the immune system.15 
In this chapter, AuNPs functionalised with hydrophilic PEG chains and modified 
PS-siRNA were prepared (Figure 3.3). The polymer poly(ethylene glycol methyl ether 
methacrylate) (pPEGMA) was synthesised by reversible addition fragmentation chain 
transfer (RAFT) polymerisation. The polymers were conjugated onto AuNPs through 
chemisorption of their dithioester end groups. The loading efficiency of PS-siRNA was 
evaluated and gene silencing of RUNX1/ETO gene assessed. 
 
 
Figure 3.2: Mechanism for intracellular siRNA release mediated by glutathione (GSH). High 
intracellular concentrations of GSH competitively bind to AuNPs, displacing the PS-siRNA and 
polymer into the cytosol of target cell. 
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Figure 3.3: Scheme of AuNPs coated with PS-siRNA and pPEGMA. pPEGMA is conjugated 
through anchoring the dithioester of the polymer end groups into gold. Modified siRNA is 




3.2 Results and Discussion 
Herein the design, preparation and characterisation of AuNPs coated with PS-
modified nucleic acids and pPEGMA are described. The nomenclature of the 
nanoparticles is summarised (Figure 3.4) and describes the type of modified nucleic 
acid and the polymer formulation conjugated onto the AuNP. When different protocols 
were tested, or by changing the formulation conditions or the components added, the 




Figure 3.4: Nanoparticle nomenclature. AuNPs were coated with single strand oligonucleotide 
(ssODN) or short interfering RNA (siRNA) and pPEGMA polymer of different molecular weight (P1 
or P2). 
 
Two generations of functionalised AuNPs were investigated. The first generation 
of nanoparticles (PSssNP) investigated were prepared by coating AuNPs of 20 nm 
size with PS-modified single strand oligonucleotide (PS-ssODN) and pPEGMA. The 
PS-ssODN was first conjugated to AuNPs because is cheaper to purchase than 
modified siRNAs, and thus was used to prove the hypothesis of functionalisation onto 
gold surfaces through the PS modification. The second generation of nanoparticles 
were developed to load siRNA (PSsiNP). PSsiNPs were prepared by functionalizing 
AuNPs with pPEGMA and PS-modified siRNA that features either one (PS-siRNA) or 
three (3PS-siRNA) PS modifications on their siRNA sequences. The resulting particles 
were characterised and the loading efficiency and gene silencing were evaluated. 




Figure 3.5: Nanoparticles prepared by coating AuNPs with pPEGMA (P1 or P2) and (A) PS-ssODN, 
(B) PS-siRNA, (C) 3PS-siRNA and (D) non-modified ssODN. The salt aging is the method used to 




3.2.1 Synthesis and characterisation of pPEGMA polymer prepared by RAFT 
polymerisation  
RAFT polymerisation is a versatile technique that allows the controlled synthesis 
of homopolymers and block copolymers with very low polydispersity.16 Thus, polymers 
produced by RAFT polymerisation are attractive building blocks for the 
functionalisation of AuNPs via the “grafting to” approach.17 Polymer grafted gold 
nanoparticles can be obtained by the conjugation of AuNPs with thiol-functionalised 
polymers. This technique usually comprises the reduction of the terminal RAFT 
functionality to a thiol moiety by its reduction with nucleophiles such as primary 
amines.18,19 
The polymers (P1 and P2) were synthesised (Scheme 3.1) by RAFT 
polymerisation of poly(ethylene glycol) methyl ether methacrylate monomer M1 
(PEGMA300 Mn: 300 g mol-1) using 4-cyano-4-(thiobenzoylthio) pentanoic acid (CTPA) 
as chain transfer agent (CTA) and 2’-azobis(2-methylpropionitrile) (AIBN) as initiator. 
The polymerisation time was increased to obtain two pPEGMA polymers presenting 
different molecular weight. The use of CTPA as RAFT chain transfer agent produces 
polymers bearing a dithioester end group that can be chemisorbed onto gold without 
transformation to thiols.20 Thus, the polymers obtained by RAFT polymerisation can 
be used for the functionalisation of gold nanoparticles via the “grafting to” approach 
without a subsequent synthetic step to reduce their end groups to thiols.  
 
 
Scheme 3.1: RAFT polymerisation of PEGMA300 monomer M1. P1 and P2 polymers were obtained 
after 2 and 5 h of polymerisation, featuring 30 and 83 units of PEGMA, respectively. 
 
The polymers were dialysed in water to remove unreacted monomers, freeze-
dried to obtain pink oils and then characterised by 1H NMR spectroscopy and gel 















P1: m = 30
P2: m = 83M1
AIBN, CTPA
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Table 3.1: Characterisation of P1 and P2. a As determined by 1H NMR spectroscopy (700 Hz, CDCl3). 
b As determined by GPC in DMF (0.6 mL min-1 with 1g/L LiBr) calibrated against methyl methacrylate 
standards of very low polydispersity (PDI <1.08). 
Polymer Mn (g/mol)a Mn (g/mol)b Mw (g/mol)b PDIb 
P1 9,300 6,500 8,100 1.24 
P2 25,200 19,200 23,200 1.21 
 
The 1H NMR spectra of P1 and P2 (Fig. 3.6 A and B, respectively) showed 
broadened signals, confirming the successful polymerisation of M1. The 1H NMR 
spectrum of P1 (Figure 3.6 A) showed well-defined signal at d = 3.30 – 3.43, assigned 
to the terminal methoxyl groups (-OCH3) of PEGMA side chains. The signal at d = 3.57 
– 3.77 corresponds to the protons of the ethylene glycol chains (-OCH2CH2) and the 
signals at d = 0.64 – 1.14 and d = 1.62 – 2.06 to the polymer backbone. The signals 
at d = 7.30 – 7.40, d = 7.45 – 7.54 and d = 7.81 – 7. 89 ppm correspond to the aromatic 
protons of the polymer end group. These signals were used to determine the degree 
of polymerisation (DP) by comparing their integrals to those of the signal of the 
terminal methoxyl groups. For P1, the DP = 30 correspond to an average molecular 
weight (Mn) = 9 kDa. The 1H NMR spectrum of P2 (Figure 3.6 B) showed the 
characteristics signals for PEGMA as previously described for P1. End group analysis 
of P2 indicated DP = 83 and Mn = 25 kDa. These results showed that by using RAFT 
polymerisation it is possible to obtain polymers of controlled chain lengths by merely 
changing the polymerisation times.  
GPC analysis of P1 and P2 (Fig. 3.7 A and B) showed monomodal molecular 
weight distributions (PDI = 1.24 for P1 and 1.21 for P2), indicating the polymerisations 
have proceeded with a good level of control. The shorter retention time for P2 (23.91 
min) (Fig. 3.7 B) when compared to P1 (25.38 min) (Fig. 3.7 A), confirmed the 
difference in molecular weight determined by 1H NMR spectroscopy. In addition, the 
Mn determined by GPC correlates reasonably well with Mn determined by 1H NMR 
spectroscopy. The small differences observed could be attributed to the fact that the 
standards used for calibration (nearly monodisperse PMMA) are not pPEGMA 
standard polymers. Taken together, these results indicate the successful and 
controlled RAFT polymerisation of PEGMA to synthesise pPEGMA of distinctive sizes 
(P1 and P2). 
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Figure 3.6: Characterisation of P1 and P2. 1H NMR spectrum (700 Hz, CDCl3) of (A) P1 and (C) P2. 




Figure 3.7: Normalised refractive index traces of (A) P1 and (B) P2 obtained by GPC analysis in 
DMF containing 1g/L of LiBr at 0.6 mL/min. Near monodisperse poly(methyl methacrylate) standards 
were used for calibration and the average molecular weight (Mn) determined as 6,500 Da for P1 and 
19,200 Da for P2.  
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3.2.2 Conjugation of pPEGMA to AuNPs 
 
Figure 3.8:Preparation of AuNPs coated with pPEGMA. AuNPs were incubated with different ratios 
of aqueous solutions of P1 or P2 to obtained polymer grafted gold nanoparticles. 
 
Citrate-stabilised gold nanoparticles of 20 nm size were functionalised with P1 
and P2 by incubation of AuNPs with different molar ratios of polymer (Figure 3.8). To 
evaluate the amount of polymer needed to shield the gold core, 10 µL of NaCl(aq) (1.0 
M) (final conc. 100 mM) was then added, and the UV-Vis spectrum recorded at 350-
700 nm. In the presence of high concentration of salt, citrate-stabilised AuNPs tend to 
form permanent aggregates that may sediment out of solution as a precipitate. This 
process is known as salt-induced aggregation21 and occurs on account of the 
electrostatic stabilisation of the negative charges of AuNPs by the salt ions. The 
surface plasmon band (lSPR) is a distinct absorption peak in the UV-Vis region due to 
the surface plasmon resonance (SPR) of gold nanoparticles.22 The SPR of AuNPs is 
dependent upon their size and morphology, thus 20 nm citrate stabilised AuNPs 
present a SPR band at lSPR = 520 – 525 nm.23 Large aggregates, as those formed by 
salt-induced aggregation, present a red-shift and broadening of the SPR band, 
resulting in a colour change of the solution from red to blue. Thus, the induced 
aggregation of polymer functionalised AuNPs after NaCl addition was evaluated by 
determining the aggregation factor calculated by the ratio l615/l524. The band at l = 
524 nm characterised the 20 nm AuNPs, while the absorbance increase at 615 nm is 
consistent with the red-shift of particle aggregation (Figure 3.9 A – inset c). Therefore, 
high values of aggregation factor imply gold nanoparticles aggregation. Figure 3.8 
shows the salt-induced aggregation of nanoparticles coated with P1 (Figure 3.9 A) and 
P2 (Figure 3.9 B). Uncoated AuNPs were tested as a control, showing high 
aggregation factor values consistent with the expected salt-induced aggregation of 
citrate-stabilised AuNPs. For AuNPs coated with P1, 1,000 and 5,000-fold excess 
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molar ratios showed the lower values of aggregation factors after addition of NaCl(aq) 
(1M) (Figure 3.9 A).  
 
 
Figure 3.9: Stability of AuNPs coated with (A) P1 and (B) P2 at different polymer molar ratios in 
NaCl(aq) (1 M). Dark red bars show the aggregation factors obtained from UV-Vis experiments of 
polymer-functionalised AuNPs. Green (A) and blue (B) bars represent the aggregation factors after 
addition of NaCl(aq) (1 M). The inset (c) shows typical UV-Vis spectra of uncoated AuNPs after 
addition of 10 µL of NaCl(aq) (1 M), resulting in an absorbance increase at 615 nm.  
 
Results with P2 functionalised AuNPs indicated that only a 500-fold excess was 
necessary to maintain the low values of aggregation factor (Figure 3.9 B). The lower 
molar ratio of P2 required to stabilize AuNPs can be attributed to the fact that P2 has 
larger polymer chains than P1, and thus fewer polymer chains are required to shield 
the gold surface from NaCl. These results showed that the successful coating of 
AuNPs with polymers can be achieved by using RAFT polymers via the sulfur-Au 
chemistry, confirming that the dithioester end group chemisorbed onto Au. 
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3.2.3 Conjugation of Phosphorothioate-modified single strand oligonucleotide 
to AuNPs. 
 
Figure 3.10: Preparation of AuNPs coated with pPEGMA and Cy5 labelled PS-ssODN. (A) 
Nanoparticles were prepared using the salt aging method SDS to obtain PSssNPs. (B) 
Phosphorothioate modified sequence of PS-ssODN.  
 
PSssNPs were prepared using the “salt aging” approach.5 This method is based 
on adding small concentrations of NaCl(aq) over a period of time. NaCl decreases the 
electrostatic repulsion between the negative charges of nucleic acids and citrate 
stabilised AuNPs and thus, promotes a better conjugation of nucleic acids to gold. 
However, the presence of salt can lead to unwanted aggregation that can be avoided 
by adding surfactant molecules to the salt aging process.24 Herein, Cy5-labelled PS-
modified single strand oligonucleotide (PS-ssODN) that features a single terminal PS-
moiety was incubated with polymer (P1 or P2) and 20 nm AuNPs in the presence of 
sodium dodecyl sulfate (SDS) to help optimize the conjugation of PS-ssODN (Figure 
3.10). The particles were purified by centrifugation at 15,000 rpm for 10 min and 




Table 3.2: Preparation and characterisation of PSssNPs. AuNPs were coated with PS-ssODN and 
polymer (P1 or P2) by salt aging method in the presence of SDS. aDetermined by DLS measuments. 













PSssNP.P1 1:350:110 160 mM 0.1 % 3 h 35 0.2 527 
PSssNP.P2 1:350:110 160 mM 0.1 % 3 h 31 0.2 526 
 
DLS Measurements (Figure 3.11 A) of PSssNPs obtained showed a significant 
increase in size for particles prepared with P1 (PSssNP.P1 - green line) and P2 
(PSssNP.P2 - blue line) and narrow unimodal distributions presenting polydispesity 
indices (PdI) of 0.2. The SPR band of 20 nm AuNPs determined by UV-Vis was lSP = 
524 nm and is in accordance23 with the expected value for spherical 20 nm citrate-
stabilised AuNPs. In addition, PSssNP.P1/P2 showed a small red-shift in the SPR 
band determined by UV-Vis (526 and 527 for PSssNP.P1 and PSssNP.P2, 
respectively) (Figure 3.11 B). The red-shift of PSssNPs can be correlated with the 
increase in size by DLS, indicating the successful coating of AuNPs with PS-ssODN 
and pPEGMA (P1 or P2).  
 
 
Figure 3.11: Characterisation by (A) DLS and (B) UV-Vis of AuNPs coated with PS-ssODN and 
pPEGMA. The green line shows the characterisation of particles prepared with P1 (PSssNP.P1) and 
the blue line shows the characterisation of particles prepared with P2 (PSssNP.P2). 
  
The loading efficiency of PS-ssODN to AuNPs was evaluated by fluorescence 
spectroscopy using the indirect and the direct quantification methods (Chapter 2 – 
section 2.3.5). Indirect quantification is determined by the quantification of the amount 
of unloaded PS-ssODN (Figure 3.12 – black bars), from which the quantification of the 
loaded PS-ssODN can be inferred. To determine the amount of unloaded PS-ssODN, 
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the nanoparticles were isolated by centrifugation and the supernatant collected for 
quantification by fluorescence spectroscopy.  
The direct quantification method, in which nucleic acids are cleaved from the 
AuNPs and then quantified, was used after the particles were purified by centrifugation 
in Hepes buffer (10 mM). The particles were then treated with DDT 100 mM to release 
the components from the AuNP surfaces. After particles were isolated by 
centrifugation, loaded PS-ssODN was quantified (Figure 3.12 – grey bars). When the 
indirect quantification is added to the direct quantification, the sum of the values should 
be very close to the initial concentration added, giving confidence in the 
measurements and indicating that the method is reliable to determine nucleic acid 
concentration in solution. 
 
 
Figure 3.12: Quantification of loaded (grey bars) and unloaded (black bars) PS-ssODN by 
fluorescence spectroscopy. The indirect quantification was determined by measuring unloaded PS-
ssODN in the supernatant of PSssNPs. The direct quantification was determined by measuring 
loaded PS-ssODN. The initial concentration (red line) was set to 100 % and the loading efficiency 
(%) calculated. The percentages above the quantification bars represent the calculated loading 
efficiency. 
 
In both direct and indirect methods, the fluorescence values from samples were 
interpolated from previously prepared standard curves (Appendix A) to determine the 
concentration of PS-ssODN. Then, the loading efficiency was calculated by assuming 
the initial concentration added to the particles to be 100 % (Figure 3.12). Both 
PSssNP.P1 and PSssNP.P2 prepared showed similar loading efficiencies (» 50%). It 
is important to note that if the quantified concentration of unloaded PS-ssODN (Figure 
3.12 – black bars) is added to the concentration of loaded PS-ssODN (Figure 3.12 – 
grey bars), their sums are close to the initial amounts added to the formulation. 
Furthermore, the loading efficiency (Figure 3.12) and the narrow unimodal size 
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distribution (Figure 3.11 A) presented by PSssNPs indicate that the salt aging process 
in the presence of a surfactant is effective in promoting the conjugation of PS-ssODN 
and polymer to AuNPs, and also prevents uncontrolled aggregation of nanoparticles. 
For the safe delivery of nucleic acids into the cytosol of the target cell, 
nanocarriers must be stable for prolonged time in extracellular environment. The 
stability of PSssNP.P2 was thus evaluated in tissue culture conditions, which are a 
reasonable mimic of extracellular conditions. PSssNP.P2 were prepared and purified 
by centrifugation at 15,000 x g for 10 min. Then, PSssNP.P2 were incubated at 37 °C 
in RPMI 1640 supplemented with 10% of fetal calf serum (FCS) at final concentration 
of 0.5 µM of PS-ssODN. At different time points, the samples were centrifuged and 
the supernatant collected to determine the concentration of PS-ssODN released from 
PSssNP.P2. As a control, naked PS-ssODN (in the absence of any AuNPs) at 0.5 µM 
was incubated with tissue culture medium in the same conditions. The concentration 
of PS-ssODN was determined by fluorescence spectroscopy and the values 
interpolated from a standard curve (Appendix A). Figure 3.13 A shows the 
quantification of PS-ssODN over time after incubation in tissue culture medium 
supplemented with FCS. The concentration of naked PS-ssODN decreased after 30 
min of incubation with tissue cultured medium (Figure 3.13 A – blue bars) that can be 
attributed to unwanted degradation of naked PS-ssODN by nucleases in the FCS. 
Naked nucleic acids are known to present low stability due to fast degradation by 
DNAses and RNAses found in animal or human serum. Thus, the use of nanocarriers 
to protect nucleic acids against fast enzymatic degradation is essential to safely deliver 
the cargo to the cell cytosol. The stability of PSssNP.P2 is shown in Figure 3.13 A 
(pink bars). The concentration of PS-ssODN was only detected after 4 h of incubation 
in tissue culture medium supplemented with FCS, and only 11% of PS-ssODN was 
released from PSssNP.P2 (time point 24 h), indicating that PSssNP.P2 possess good 
stability in extracellular in vitro conditions.  
The ability of PSssNP.P2 to release PS-ssODN upon exposure to GSH was also 
evaluated. GSH is a thiol reducing agent that is present in the cell cytoplasm in 
millimolar concentrations, whereas the extracellular concentrations values decrease 
by 1 – 3 orders of magnitude25,26. Thus, GSH is able to covalently bind onto AuNPs 




Figure 3.13: Stability of PSssNP.P2 in different media. (A) Quantification over 24 h of Cy5 – labelled 
PS-ssODN in RPMI 1640 supplemented with 10% FCS. (B) Quantification of PS-ssODN released 
after addition of glutathione (20 mM). 
  
To demonstrate the glutathione mediated response of PSssNP.P2, the samples 
at 0 h and 1 h from the stability assay showed in Figure 3.13 A were collected. These 
samples contain PSssNP.P2 loaded with 0.5 µM of PS-ssODN in tissue culture 
medium supplemented with FCS. GSH at a final concentration of 20 mM was added 
and the samples were incubated for 1 h at 37 °C. After centrifugation, the supernatants 
were collected for quantification of PS-ssODN released from nanoparticles. Figure 
3.13 B shows the GSH-response of PSssNP.P2. After 1 h treatment with GSH, PS-
ssODN was recovered in the supernatant of both samples, indicating that the thiol 
reducing agent displaced PS-ssODN. The results shown in Figure 3.13 demonstrate 
the specific intracellular GSH-response of PSssNP.P2. In extracellular conditions the 
particles displayed good stability and did not release PS-ssODN (Figure 3.13 A). 
However, when in conditions that simulate the reducing environment of the cell 
cytosol, the nanoparticles were able to release the total concentration of PS-ssODN 
(Figure 3.13 B). 
 
3.2.4 Conjugation of PS-siRNA to gold nanoparticles 
The same salting aging procedure was used for the conjugation of 
phosphorothioate modified siRNA (PS-siRNA) to AuNPs to prepare PSsiNPs. The 
sequence of PS-siRNA used targets the RUNX1/ETO gene (PS-siRE). A second PS-
siRNA sequence was used as a mismatch control (PS-siMM). Figure 3.14 shows the 
schematic representation of particles formed (A) and the PS-siRNA sequences (B and 





Figure 3.14: Preparation of AuNPs coated with PS-siRNA and pPEGMA. (A) Schematic 
representation of PSsiNPs. (B) Phosphorothioate modified siRNA sequence targeting RUNX1/ETO 
gene (PS-siRE). (C) Phosphorothioate modified siRNA sequence of mismatch control (PS-siMM). 
 
Table 3.3: Preparation and characterisation of PSsiNPs. AuNPs were coated with PS-siRNA and 
polymer (P1 or P2) by titration of NaCl over 3 h. The siRNA sequences used to prepare PSsiNPs were 
PS-siRE or PS-siMM. aDetermined by DLS measuments. bDetermined by UV-Vis spectrum analysis. 
PSsiNPs Molar ratios 








PSsiNP.P1 1:350:110 160 mM 0.1 % 3 h 45 0.3 530 
PSsiNP.P2 1:350:110 160 mM 0.1 % 3 h 48 0.34 530 
 
The nanoparticles were purified and characterised by DLS and UV-Vis 
spectroscopy (Figure 3.15). The nanoparticles PSsiNP.P1 (green line) and 
PSsiNP.P2 (blue line) (Figure 3.15 A) showed a significant increase in size after 
coating. Their average hydrodynamic diameters were 45 nm and 48 nm, respectively. 
The size histograms showed unimodal distributions with a PdI ~ 0.3 (Figure 3.15 A). 
The UV-Vis spectra (Figure 3.15 B) showed a red-shift of the SPR band for PSsiNP.P1 
and PSsiNP.P2, supporting the increase in particle sizes and suggesting effective 




Figure 3.15. Characterisation of AuNPs coated with PS-siRNA and P1 (green line) or P2 (blue line). 
Size distribution histogram by intensity obtained by DLS measurements (A) and UV-Vis spectra of 
PSsiNPs (B).  
 
The concentration of unloaded PS-siRNA was determined using the QubiT 
miRNA Assay Kit (Thermofisher). The Qubit microRNA Assay Kit allows easy and 
accurate quantification of microRNA (miRNA) using the Qubit 3.0 Fluorometer, even 
in the presence of common contaminants such as salts, free nucleotides, solvents, 
detergents, and protein. The kit uses a  nucleic acid intercalator dye that exhibits green 
emission when bound to double stranded siRNAs and miRNAs. The nanoparticles 
were removed from the solution by centrifugation and the supernatants were collected. 
The concentration of unloaded PS-siRNA was measured, allowing an indirect 
quantification of the siRNA loading onto AuNPs. The total concentration of siRNA 
recovered in the supernatants was very similar to the concentration of siRNA used in 
the loading, indicating that PS-siRNA was not loaded to AuNPs (Figure 3.16).  
 
 
Figure 3.16: Quantification of unloaded PS-siRNA in the supernatants of PSsiNP.P1 (green bar) 
and PSsiNP.P2 (blue bar). Unloaded PS-siRNA was determined using a Qubit miRNA assay kit. 
The red line represents the initial concentration of PS-siRNA added to PSsiNPs. 
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To further confirm the low loading of PS-siRNA presented by PSsiNPs, gene 
silencing of RUNX1/ETO PS-siRNA (PS-siRE) was evaluated by real-time qPCR. 
PSsiNP.P1 and PSsiNP.P2 containing PS-siRE or PS-siMM were prepared as 
described in Table 3.3. The nanoparticles were characterised and purified by 
centrifugation at 15,000 x g for 10 min. PS-siMM was used as a mismatch control 
sequence for Kasumi-1 cell lines. These cells are a well-studied model for 
RUNX1/ETO translocation in AML,27 and thus can be used to study the gene 
knockdown of nanocarriers containing PS-siRE. Kasumi-1 cells were transfected with 
PSsiNPs containing 100 nM of PS-siRE or PS-siMM and after 48 h gene knockdown 
was assessed. RUNX1/ETO transcript expression was normalised to GAPDH house-
keeping gene and the gene silencing compared to non-treated cells (Fig 3.17). There 
was no significant difference in the gene knockdown of the cells treated with 
nanoparticles containing PS-siRE and the non-targeting control PS-siMM, indicating 
that the minor gene silencing observed (~ 10 %) was not related to the delivery of 
siRE. Moreover, to a nanocarrier be considered successful for the delivery of siRNA 
the gene knockdown efficiency is expected to be ~ 50 %.28–30  
 
 
Figure 3.17: RUNX1/ETO knockdown in Kasumi-1 cells. Cells were treated with Mock (nanoparticles 
without siRNA), PSsiNPs containing PS-siRE (100 nM) and PSsiNPs containing PS-siMM as a 
mismatch control (100 nM). The graphs show the RUNX1/ETO mRNA expression levels after 
treatment with nanoparticles prepared with P1 (A) and P2 (B). 
 
The absence of gene silencing suggests that there was no significant attachment 
of PS-siRNA to AuNPs, which is in agreement with the loading assay showed in Figure 
3.15. The increase in size of AuNPs (Fig. 3.15) suggests the successful coating of 
AuNPs, however, the quantification of unloaded PS-siRNA and the lack gene silencing 
(Figure 3.16 and 3.17) indicate that the increase in size is associated only to the 
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adsorption of pPEGMA onto the AuNP surfaces. These results indicate that the 
conjugation of double stranded nucleic acids to AuNPs, such as siRNA, does not occur 
in a similar manner as single strand nucleic acids. The significant loading efficiency 
observed for PS-ssODN onto AuNPs suggests that the phosphorothioate modification 
is not the only factor to contribute to the conjugation of AuNPs with nucleic acids.  
To attempt to nimprove the loading efficiency of particles prepared with PS-
siRNA, the preparation method for PSsiNP.P2 was modified and the concentration of 
unloaded PS-siRNA was determined. Table 3.4 shows the modifications on the 
preparation method regarding molar ratios of components, concentration of surfactant, 
salt aging concentration and titration time of NaCl. The particles formed are labelled 
as PSsiNP.P2 and the letter (T) was added to the label followed by the protocol 
number. 
 
Table 3.4: Modifications in the method for preparation of PSsiNPs. AuNPs were coated with PS-siRNA 
and P2 varying the molar ratios of components, NaCl and SDS total concentration and time of salt aging 
method. 
PSsiNPs Molar ratios [NaCl(aq)] [SDS(aq)] NaCl titration time 
PSsiNP.P2-T1  
AuNP:PS-siRNA:P2 
1:350:110 160 mM 0.1% 12 h 
PSsiNP.P2-T2 
AuNP:PS-siRNA:P2 
1:350:870 160 mM - 3 h 
PSsiNP.P2-T3 
AuNP:PS-siRNA:P2 
1:350:870 - - - 
 
PSsiNP.P2-T1 was prepared using the same molar ratios of components used 
for the preparation of PSssNPs (particles prepared with PS-ssODN). However, the 
salt aging process was extended to 12 h. NaCl helps to decrease the charge repulsion 
between AuNPs and siRNA, nevertheless, it needs to be slowly titrated to prevent 
particle aggregation. After preparation of PSsiNP.P2-T1, particles were centrifuged 
and the supernatant collect for quantification of unloaded PS-siRNA. Figure 3.17 
shows that the total concentration of PS-siRNA added to the formulation was 
recovered in the supernatant, indicating that the loading of PS-siRNA to AuNPs did 
not occur. Therefore, the prolonged salt aging process did not improve the loading of 
PS-siRNA. 
During the salt aging process, SDS prevents AuNPs aggregation by forming a 
protective interdigitated bilayer around the gold core.24,31 The PS-siRNA can penetrate 
the layer and be adsorbed onto Au, however, the reaction is quite slow.31 To evaluate 
the influence of SDS in the loading efficiency of PS-siRNA, PSsiNP.P2-T2 were 
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prepared in absence of SDS. In addition, the molar ratio of P2 to AuNPs was increased 
to assist in displacing the citrated molecules from AuNPs, decreasing the charge 
repulsion and providing colloidal stability to the system. A different preparation 
protocol was also tested without NaCl and SDS (PSsiNP.P2-T3). For PSsiNP.P2-T3, 
the only factor contributing to the loading of PS-siRNA to gold is the presence of the 
polymer that helps displacing the citrate molecules from the AuNPs surface, 
decreasing the charge repulsion between siRNA and particle. All particles were 
isolated by centrifugation and the supernatant collected for quantification of unloaded 
PS-siRNA. Figure 3.18 demonstrate that the total concentration of PS-siRNA added 
(red bars) to the formulations were recovered in the supernatants (blue bars). These 
results provide an indirect measurement of the loading efficiency (percentages – 
Figure 3.18) and indicate that PS-siRNA was not loaded to AuNPs, confirming that the 
changes to the preparation protocols presented in Table 3.4 did not amend the loading 
efficiency of PSsiNPs. 
 
 
Figure 3.18: Quantification of unloaded PS-siRNA. PSsiNP.P2 prepared according to the modified 
protocols presented in Table 3.4. Particles were centrifuged and the quantification of unloaded PS-
siRNA (blue bars) was measured in the particles supernatant using the Qubit miRNA kit. Considering 
the initial concentration added (red bars) the loading efficiency (percentages displaced above the 
blue bars) was calculated. 
 
Results so far indicated that phosphorothioate modification of the siRNA 
sequence does not result in their conjugation to AuNPs. The phosphorothioate 
modification, although able to conjugate to gold, presents a lower affinity towards gold. 
Zhou et al.9 showed the adsorption of thiol, phosphorothioate and non-modified DNA 
oligonucleotides to 13 nm AuNPs. The DNA sequences used featured a polyA tale on 
the 5’-end. The PS-modified sequence contained 8 PS-modifications on the polyA 
block, and thiolated and non-modified sequences were used for comparison. The 
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conjugates prepared with the thiolated sequence showed higher DNA density on the 
AuNPs surface, followed by the PS-modified and non-modified sequences. Therefore, 
it might be possible to improve the loading of phosphorothioate into AuNPs by simply 
increasing the number of phosphorothioate modifications in the siRNA, which would 
result in a strong polyvalent interaction with Au. Thus, siRNA modified with 3 
phosphorothioates (3PS-siRNA) on the 3’ end of the sense strand (Figure 3.19) was 
conjugated to AuNPs and the loading efficiency was evaluated. The 3PS-siRNA 
sequence targets the luciferase reporter gene (3PS-siLUC) and is designated in 
Figure 3.19 B. 
 
 
Figure 3.19: Schematic representation of 3PSsiNP.P2. (A) AuNPs were coated with P2 and 3PS-
siRNA. (B) The 3PS-siRNA sequence used targets the Luciferase gene (3PS-siLUC) and features 3 
phosphorothioate modifications on the 3’ end of the sense strand.  
 
The firefly luciferase reporter gene assay is commonly used as a tool to study 
gene expression at the transcriptional level. The assay is based on the enzymatic 
reaction of luciferin (substrate) by the firefly luciferase enzyme to yield oxyluciferin, 
generated in an electronically excited state which emits light upon transition to the 
ground state. Once the luciferase gene is silenced through RNAi therapy, it is possible 
to determine the gene silencing efficiency by quantifying the luminescence intensity. 
Consequently, the luciferase reporter assay is an ideal low-cost assay to test a variety 
of nanomaterials in a short period of time, remaining highly sensitive.32 
Before conjugation onto AuNPs, it was important to confirm that the multiple 
phosphorothioate modifications on the siRNA did not lead to unwanted effects on the 
RNAi mechanism. Therefore, the gene silencing efficacy of 3PS-siLUC was evaluated. 
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Kasumi-1 cell lines were transduced with pSLIEW resulting in the expression of the 
firefly luciferase in an AML cell line. The cells were eletroporated with different 
concentration of 3PS-siLUC and luciferin (Britelite Plus™) was added as a substrate 
after 24 and 48 h treatment. Cell luminescence was measured to determine the gene 
knockdown mediated by 3PS-siLUC. As shown in Figure 3.20, modified siRNA 
promoted around 70 % of gene knockdown after 24 and 48 h for cells treated with 50 
nM of 3PS-siLUC. A dose-response efficiency was observed, especially after 48 h 
treatment, when increasing the dose of 3PS-siLUC resulted in greater gene silencing. 
The luciferase reporter assay demonstrates that the modification of siLUC by adding 
three phosphorothioate moieties to the 3’ end of the sense strand did not adversely 
affect the RNAi mechanism, as the modified siRNA was able to promote gene 
knockdown of luciferase reporter gene.  
 
 
Figure 3.20: Luciferase reporter assay of Kasumi-1 pSLIEW cell line for evaluation of the effect of 
phosphorothioate sequence modifications in the RNAi mechanism. Cells were eletroporated with 
3PS-siLUC at 50, 100 and 200 nM. Luminescence was measured after addition of luciferin and 
controls were set as 100 %. Results are expressed as mean and SEM (n = 3). ****p < 0.0001 when 
compared to controls. 
 
To conjugate 3PS-siLUC to AuNPs, different protocols were explored (Table 
3.5). 3PSsiNP.P2-T1 was prepared using the same conditions as nanoparticles 
prepared with PS-ssODN (PSssNPs). It is important to have an excess concentration 
of siRNA in order to promote maximum functionalisation of particles.9 Thus, 
3PSsiNP.P2-T2 was prepared with a larger excess (850 fold) of 3PS-siLUC. In 
addition, the salt aging final concentration was also increased to try to optimize the 
loading efficiency of 3PS-siLUC. Particles 3PSsiNP-T3, 3PSsiNP-T4 and 3PSsiNP-

































polymer can shield the AuNPs, preventing the siRNA to anchor to the gold surface. 
3PSsiNP-T3 was prepared using the salt aging method as previously described. 
Briefly, the particles were formulated in the presence of SDS (final concentration 0.1 
%) and NaCl(aq) (1.4 M) was slowly titrated over a period of 3 h, reaching a final 
concentration of 0.16 M. 3PSsiNP-T4 and 3PSsiNP-T5 were prepared by adding an 
excess amount of 3PS-siLUC to AuNPs and heating at 95 °C for 5 min to allow the 
dehybridisation of siRNA. The particles were allowed to cool to room temperature and 
the loading efficiency was then evaluated. For 3PSsiNP-T5, NaCl(aq) (1.4 M) was 
slowly titrated during cooling. The dehybridisation of siRNA could improve the loading 
efficiency due to the decrease in the surface charge repulsion. Hybridised siRNA 
present negative charges due to the phosphate backbone, while dehybridised strands 
bares the ring nitrogens of the bases. These nitrogens can be protonated at neutral 
pH, resulting in a less negatively charged molecule. In addition, the exposed bases on 
the sequence can also conjugate to gold surfaces,9,33 improving the loading of 3PS-
siLUC.  
 
Table 3.5: Methods for preparation of 3PSsiNPs. AuNPs were coated with 3PS-siLUC and P2 varying 
the molar ratios of components, the total salt concentration and surfactant, and the temperature. 
3PSsiNPs Molar ratios 
AuNP:3PS-siLUC:P2 
[NaCl(aq)] [SDS(aq)] Heat 
3PSsiNP.P2-T1 
AuNP:3PS-siLUC:P2 1:350:110 160 mM 0.1 %  
3PSsiNP.P2-T2 
AuNP:3PS-siLUC:P2 1:850:110 260 mM 0.1 %  
3PSsiNP-T3 
AuNP:3PS-siLUC 
1:350 160 mM 0.1 %  
3PSsiNP-T4 
AuNP:3PS-siLUC 
1:350   95 °C for 5 min 
3PSsiNP-T5 
AuNP:3PS-siLUC 
1:350 160 mM 0.1% 95 °C for 5 min 
 
Figure 3.21 shows the concentration of unloaded (indirect quantification) and 
loaded (direct quantification) 3PS-siLUC for the nanoparticles prepared. The loading 
efficiency was calculated considering the initial concentration of 3PS-siLUC as 100 % 
(Chapter 2 – section 2.3.5). For particles prepared with P2 (3PSsiNP.P2-T1 and -T2) 
and particles which features only AuNPs and 3PS-siRNA (3PSsiNP-T3 and -T4), the 
loading of 3PS-siLUC was not observed. The total amount of 3PS-siLUC added to the 
particles formulation was recovered in the particles supernatants (3PSsiNP.P2-T1 and 
-T2, 3PSsiNP-T3 and -T4) (dark grey bars). Furthermore, when these particles were 
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treated with DDT (100 mM) to trigger siRNA release, allowing the concentration of 
loaded 3PS-siLUC to be determined (light grey bars). The results showed only minor 
concentrations of loaded 3PS-siRNA, confirming the results from the indirect 
quantification. The loading efficiency calculated for 3PSsiNP.P2-T1, -T2 and 
3PSsiNP-T3 and -T4 was < 10 %, indicating that 3PS-siRNA was not successfully 
loaded to AuNPs (Figure 3.21). For 3PSsiNP-T5, the concentration of unloaded 3PS-
siLUC resulted in a loading efficiency of 29 %. Moreover, a similar loading efficiency 
was determined when the direct quantification was performed (concentration of loaded 
3PS-siLUC) (Figure 3.21).  
 
 
Figure 3.21: Loading efficiency of 3PS.siLUC onto AuNPs. Dark red bars represent the initial 
concentration added to AuNPs. Dark grey bars show the amount of unloaded 3PS-siLUC and light 
grey bars show the amount of loaded 3PS-siLUC, as determined after treatment with DDT (100 mM). 
The loading efficiency was calculate considering the initial amount of siRNA added as 100 % and is 
presented above the quantification bars. 
 
Although the loading efficiency determined for 3PSsiNP-T5 was low, the results 
suggest that dehybridised siRNA (in single strand form) is able to adsorb to AuNPs. 
The double strand of hybridised siRNAs holds hydrogen bonds between the adjacent 
bases of the sense and the antisense strand. However, when dehybridised, the single 
strand presents the ring nitrogens accessible, allowing the bases to participate on 
adsorption to Au. In addition, particles prepared with dehybridised siRNA without NaCl 
(3PSsiNP-T4) did not show the same loading efficiency, confirming that the salt aging 
method is necessary for loading nucleic acids to citrate stabilised AuNPs. 
The results suggest that PS-siRNA did not conjugate to AuNPs. The modification 
with three phosphorothioate moieties on the siRNA (3PS-siRNA) did not improve its 
loading efficiency when compared to siRNA featuring one phosphorothioate 
modification (PS-siRNA). Nevertheless, when phosphorothioate modified single 
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strand oligonucleotide (PS-ssODN) was loaded to AuNPs via the salt aging method, 
a high loading efficiency was determined (PSssNPs). PSssNP.P1 and PSssNP.P2 
were able to load 50 % of PS-ssODN (Figure 3.12). In addition, the prepared particles 
did not release PS-ssODN in extracellular conditions, however, when in an 
environment rich in GSH the release of PS-ssODN was observed (Figure 3.13). The 
significant loading efficiency of PSssNPs was initially attributed to the 
phosphorothioate modification. However, the findings of AuNPs prepared with PS-
siRNA suggest that the phosphorothioate modification is not the key factor to 
contribute to the functionalisation of AuNPs. To further investigate the loading 
efficiency of PS-ssODN, AuNPs were incubated with P2 and single strand ODN using 
the same salt aging method described in section 3.2.3. PSssNP.P2 was prepared 
using PS-ssODN. Particles comprising non-modified ssODN (ssNP.P2) were also 
prepared to evaluate the effect, if any, of the phosphorothioate modification in 
adsorbing to Au surfaces (Figure 3.22).  
 
 
Figure 3.22: Schematic representation of PSssNP.P2 and ssNP.P2. (A) AuNPs were coated with 
P2 and PS-ssODN. (B) AuNPs were coated with P2 and non-modified ssODN. (C) Phosphorothioate 
modified ssODN (PS-ssODN) and (D) non-modified ssODN (ssODN) sequences.  
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Particles were characterised and their loading efficiencies evaluated. DLS 
measurements (Figure 3.23 A) showed an increase in particle size, consisting with the 
previous findings shown in Figure 3.11 A. The UV-Vis spectrum showed no 
aggregation bands, with a slight shift in the SPR band (Figure 3.23 B), suggesting the 
successful coating of AuNPs by P2 and PS-ssODN (PSssNP.P2 – light blue line) or 
ssODN (ssNP.P2 – orange line).  
 
 
Figure 3.23: Characterisation of nanoparticles prepared with ssODN and PS-ssODN. Particles were 
prepared with P2 and characterize by DLS to determine the size and PdI (A) and by UV-Vis (B).  
 
Figure 3.24 shows the amount of unloaded (black bars) and loaded (grey bars) 
ssODN, allowing an indirect and direct quantification of the loading efficiencies of 
PSssNP.P2 and ssNP.P2. Particles PSssNP.P2 showed ~ 50 % of loading efficiency 
for PS-ssODN, which is in accordance with the previous results shown in Figure 3.11. 
This result indicates that PSssNPs prepared by the salt aging method are 
reproducible. Moreover, Figure 3.24 shows that there was no significant difference in 
the loading efficiency of ssNP.P2 when comparing to PSssNP.P2. These results 
suggest that the phosphorothioate modification in the sense strand of a ssODN plays 
little role, if any, in conjugation onto AuNPs. The possible explanation could be that 
the attachment to AuNPs is occurring through the exposed nitrogens of the bases. 
Kimura-Suda et al.34 demonstrated the chemisorption of single stranded DNA bases 
onto Au. By FTIR studies, they concluded that the adsorption affinity of each base to 
Au is A > C ³ G > T. Thus, it is possible to conclude that the significant loading 
efficiency showed by PSssNPs is related to the chemisorption of the exposed bases 
on a single strand oligonucleotide.  
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Figure 3.24: Quantification of non-modified ssODN and PS-ssODN in AuNPs coated with pPEGMA. 
Black bars show the unloaded ssODN and grey bars show the amount of ssODN loaded to AuNPs. 
Red line represents the ssODN concentration added to the formulations. The initial concentration 
was set to 100 % and the loading efficiency (%) calculated. The percentages above the quantification 
bars represent the calculated loading efficiency.  
 
Although the results reported in this chapter suggest that the phosphorothioate 
modification was not the key anchor for conjugation onto 20 nm AuNPs, it has been 
used in the literature for functionalisation of Au surfaces. The phosphorothioate 
modification has been studied for the direct assembly of DNA oligonucleotides to gold 
surfaces. Through the phosphorothioate modification is possible to control the 
alignment of AuNPs to form one, two or three-dimensional structures. Jiang et al.35 
showed the functionalisation of 13 nm gold nanoparticles with two non-complementary 
DNA strands (sequence A and B). A third DNA sequence was then added (sequence 
C), this sequence was complementary to a portion of the grafted sequences, allowing 
the post-hybridisation of the DNA. By controlling the phosphorothioate modification 
position and length of sequences A and B, it was possible to control the alignment of 
AuNPs, forming different architectures that were confirmed by TEM.  
Zhou et al.9 showed the functionalisation of 13 nm AuNPs with tandem 
phosphorothioate modified DNA sequences. The sequences presented a polyA tail 
where the multiple phosphorothioate modification was introduced. The stability in salt 
of the conjugates prepared with 1, 2, 4, 6 or 8 phosphorothioate modifications was 
evaluated. The conjugates that featured 8 PS-modifications showed the higher 
stability in salt, indicating that the increase in PS-modifications resulted in stronger 
attachment onto the gold surface. In addition, they also showed the DNA direct 
assembly of the conjugates. Conjugates were prepared with two different non-
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complementary sequences. After addition of the linker sequence, DNA was 
hybridised, resulting in particle aggregation. The particle aggregation was reversible 
by heating the conjugates at 75 °C.  
These findings show the successful binding of phosphorothioate modified single 
strand oligonucleotides to AuNPs. It could be possible to improve the conjugation of 
PS-siRNA onto AuNPs by introducing a polyA tail modified with multiple 
phosphorothioates in one of the strands of the siRNA. In the RNAi mechanism the 
guide strand (antisense strand) of the siRNA contains two overhang nucleotides at the 
3’-terminus, which is essential for the recognition and binding into the PAZ domain of 
the AGO2 protein.36,37 In addition, the 5’-phosphorylated end of the guide sense is also 
important for the recognition between the MID and PIWI domains onto the AGO2.38 
Therefore, modifications on the guide strand (antisense) of the siRNA might interfere 
in the RNAi mechanism. The addition of a polyA tail on the passenger strand (sense) 
of the siRNA could only be possible at the 3’-end, since modifications on the 5’-end 
would bind to the overhang oligonucleotides on the 3’-end of the guide strand, and 
interfere in the recognition site by the PAZ domain. A polyA tail modified with 
phosphorothioate on the 3’-end of the passenger strand could be a promising strategy 
to improve the loading of siRNA onto AuNPs. However, siRNAs longer than 30 bp are 
associated with immunological response via the protein kinase R (PKR) pathway, 









In this chapter pPEGMA featuring different chain lengths was successfully 
obtained by RAFT polymerisation. The polymerisation using RAFT chain transfer 
agent resulted in polymers bearing a dithioester end group that served as an anchor 
for chemisorption of pPEGMA onto AuNPs. The use of the RAFT chain transfer agent 
did not require the prior transformation to thiol moieties, as the successful polymer 
grafting of citrate-stabilised 20 nm AuNPs was achieved by simply incubating AuNPs 
with pPEGMA aqueous solutions.  
Phosphorothioate modified ssODN was successfully loaded to AuNPs, resulting 
in 50 % of loading efficiency. In addition, particles prepared with PS-ssODN and 
pPEGMA presented high stability in extracellular in vitro conditions. However, when 
GSH was added to mimic the intracellular environment, the complete displacement 
and release of PS-ssODN was observed, showing the controlled GSH-response of the 
nanocarriers. 
The phosphorothioate-modified siRNA sequences were not loaded onto AuNPs. 
The increase in the number of phosphorothioate modifications did not improve the 
loading efficiency, as the increase in salt concentration or siRNA molar ratios. 
Nevertheless, PS-ssODN was successfully loaded to AuNPs. When the loading of 
non-modified ssODN was evaluated, the particles also presented high loading 
efficiency (~ 50 %), confirming that non-modified ssODN are able to adsorb onto Au 
surfaces. It was clear that the successful loading of single stranded oligonucleotides 
is not dependent of the phosphorothioate modification, but mainly, it occurs through 
the exposed DNA bases that can be adsorbed onto Au. The lack of loading efficiency 
for PS-siRNA is because in double stranded sequences the bases are forming 
hydrogen bonds between the complimentary bases and thus, are not exposed for 
chemisorption onto Au. These observations discourage the use of phosphorothioate 
modification as anchors for siRNA conjugation onto AuNPs for siRNA delivery 
platforms.  
A possible strategy to load siRNA onto AuNPs is the addition of a polyA tail 
modified with phosphorothioates on the 3’-end of the passenger strand. However, the 
addition of a polyA tail could interfere in the recognition of the 5’-end of the guide 
strand by the AGO2 protein during the RNAi mechanism. Moreover, long strand 
siRNAs are associated with cytotoxicity mediated by activation of the PKR pathway. 
Therefore, it would be important to evaluate the RNAi efficiency and cytotoxicity of 
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The development of an optimal siRNA delivery platform is essential for the in vivo 
success of RNAi therapy. The ideal nanocarrier must be able to successfully load 
siRNA, present long blood circulation time without associated toxicity, be able to 
effectively cross through biological barriers and show controlled and fast release of 
siRNA.1 In particular, once the nanocarriers have reached the target cells/tissues and 
become internalised by cellular uptake, the fast release and endosomal escape of the 
siRNA into the cytoplasm is necessary to prevent its degradation in the late 
endosome/lysosome.2  
There are several approaches to promote fast endosomal escape and siRNA 
release, including the use of stimuli-responsive nanocarriers, such as pH-responsive 
nanoparticles. Different approaches have been employed to develop pH-responsive 
nanocarriers, with one being the incorporation of acid-labile features between the 
siRNA and the nanocarrier.3 Acid-labile bonds, for example, can be tuned to display 
stability at physiological pH yet fast dissociation in the acidic environment of the 
endosome.4  
Hydrazones and imines are examples of covalent bonds that can in principal be 
used for biomedical applications. These bonds can be easily obtained through the 
reaction of aldehydes with hydrazides or amines, resulting in an equilibrium between 
the starting materials and their respective products.5 The equilibrium can be shifted 
towards the products or in favour of the starting materials by e.g. adding water or 
changing the pH of the medium (Scheme 4.1). It is also, in principle, possible to control 
the pH at which hydrolysis occurs by tuning the electronics of the reaction partners.6 
 
 






















Hydrazones are compounds with the general formula R1R2C=NNHR3. They are 
usually more stable than imines in aqueous conditions because of the mesomeric 
effect which decreases the electrophilicity of the C=N bond (Scheme 4.2).7 However, 
they can undergo hydrolysis in the presence of an acid catalyst, and therefore, is a 




Scheme 4.2: Formation and resonance of hydrazones. Delocalisation of electrons results in the 
decrease of electrophilicity of the carbon atom of the C=N bond. 
 
Hydrazones have been utilised in drug and siRNA delivery platforms.8–12 Bae et 
al.8 reported nanosised polymeric micelles featuring pH-sensitive hydrazone bonds for 
the intracellular release of doxorubicin, an anticancer drug (Figure 4.1). The micelles 
were formed by the self-assembly of the amphiphilic block copolymer poly(ethylene 
glycol)-poly(aspartate hydrazone doxorubicin) (PEG-p(AspHyd-DOX)), in which 
doxorubicin (hydrophobic feature) was appended onto a single block of the polymer 
through acid-labile hydrazone bonds. The micelles showed controlled pH-sensitivity, 
as it remained stable at pH 7.0 and released the drug at the intracellular pH (~ 5 – 6). 
The pH-response was time dependent as the concentration of doxorubicin in the buffer 
solution was shown to increase over time at acidic pH. The in vitro studies showed 
that micelles were able to cross the cellular membrane and internalise into the cytosol 
of tumour cells, releasing the loaded cargo. The in vivo experiments showed the 
prolonged blood circulation of the micelles and specific accumulation on the tumour 
sites. This study showed the potential of hydrazone bonds as pH-sensitive candidates 





















Figure 4.1: Micelles with pH-responsive linkers for the delivery of doxorubicin.8 Micelles were 
prepared by the self-assembly of the amphiphilic block copolymer (PEG-p(AspHyd-DOX)). 
 
The work from Bouillon et al.4 reported the synthesis of biocompatible acid-labile 
polymers for siRNA delivery. The group used modified positively charged aminoacids 
that were condensed with synthetic bisaldehydes (EG-Ald) (Figure 4.2). The resulting 
hydrazone polymer showed effective loading of long strand DNA and siRNA facilitated 
by the protonation of the nitrogens of the amino acid side chains. The complexes 
loaded with siRNA showed effective delivery into the cells, resulting in gene 
knockdown of the luciferase gene, indicating the successful application of this system 
in siRNA delivery.  
 
 
Figure 4.2: Synthesis of acid-labile polymers by condensation of modified amino-acids with synthetic 
bisaldehydes for siRNA delivery.4 
 
Imines have been widely used in chemistry and biological applications since their 
discovery by Hugo Schiff in 1864,13 presenting the general formula R1R2C=NR3. The 
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equilibrium of the condensation reaction (Figure 4.1 B) can be influenced by external 
factors, such as temperature, pH and concentration of the reaction partners (aldehyde 
and amines).5 Although much is known about imine bonds, it was surprisingly only 
very recently that work was done to better understand the pH-sensitivity of imine 
bonds. Godoy-Alcántar, et al.14 reported in their landmark study in 2005 the structure-
stability correlation of imines formed by 25 aldehydes and 13 amines in aqueous 
conditions. The group evaluated the equilibrium constants and correlated the 
differences in imine structure with their formation and stability in buffers at different 
pH. The understanding of the structure-stability correlation provides knowledge for 
chemical modifications on the reaction partners to form imine bonds with specific pH-
sensitivity and thus, the pH-sensitivity can be tuned according to the desired 
application. The group showed that the pH-sensitivity of the C=N bond depends mostly 
on the basicity of the amine reaction partner and the difference between the HOMO 
and LUMO levels of the amine and aldehyde, respectively. They evaluated the 
condensation of different amines with a single aldehyde and determined the 
equilibrium constants for each imine product. The experiment demonstrated that when 
more basic amines were used for condensation, higher values of the equilibrium 
constants were determined. In addition, they also determined the HOMO energy levels 
for each amine and discovered that higher HOMO energies resulted in higher 
constants. However, the correlation between the pKa and the HOMO energy level was 
rather poor as weakly basic amines usually presented high HOMO energy values. 
These results indicate that the correlation between imine formation is not exclusively 
dependent on a single factor, but that both pKa and the HOMO energy levels of amines 
contribute to imine formation. The group also evaluated the correlation between the 
LUMO energy levels of the aldehydes and the equilibrium constants. The 
condensation of 13 aldehydes was performed with one amine and the equilibrium 
constants were determined. The results showed that when aldehydes presenting 
lower LUMO energies were used for condensation, higher equilibrium constants were 
observed. The correlation between the equilibrium constants and the LUMO energy 
level showed a good level of confidence, and therefore indicated that the aldehyde 
reaction partner showed an important effect on the formation of imine bonds. In 
general, this study demonstrates that high values of HOMO energy for amines and 
low values of LUMO energy for aldehydes favour the covalent contribution to imine 
formation. Considering that the same factors will influence the pH range over which 
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imine hydrolysis occurs, this study provides insightful knowledge for modelling the pH-
sensitivity of imine bonds.  
In biological applications, Wang, et al.15 described the development of tooth-
brush type superamphiphiles (Figure 4.3). The superamphiphiles were formed by the 
condensation reaction of the hydrophilic block copolymer PEG-b-PLKC, which 
contains primary amine groups from the PLKC block, and DBA, a hydrophobic 
molecule displaying an alkyl chain and a benzaldehyde end group. The polymers 
assembled into spherical micelles of 70 nm in size at pH 7.4. The group loaded the 
hydrophobic molecule Nile Red and showed that the micelles disassembled at pH 6.5, 
a value that is near the extracellular pH of tumour cells, and released the cargo within 
20 min. Moreover, when the pH of the medium was again increased to 7.4, a sufficient 
amount of imine bonds was formed, increasing the amphiphilic property of the system 
that resulted in micelle formation. The work from Godoy-Alcántar, et al.14 shows that 
imines hydrolyse over a relatively broad pH range of ~ three units. The relatively sharp 
nature of the pH response of this system can be explained that although only a fraction 
of imines were hydrolysed at pH 6.5, there is an increase of the hydrophilicity of the 
block polymer, and thus, the system lost the required hydrophobicity to remain within 
the micellar design. This narrow pH-response demonstrates the reversibility of imine 
bonds and their application as potential candidates for drug delivery. 
 
 
Figure 4.3: Micelle assembly by condensation of hydrophobic aldehyde DBA and the hydrophilic 
block copolymer PEG-b-PLKC. The resulting amphiphilic block copolymer is able to self-assemble 
into micelles.15 
 
Marin, et al.16 reported the design and characterisation of dendritic dynameric 
frameworks (Figure 4.4). These systems are composed of reversible covalent bonds 
used to link a hydrophilic and cationic head with a hydrophobic network building block, 
forming hydrophobic/hydrophilic dendritic architectures. The hydrophobic aldehyde 
JD is cross-linked via imine bonds with an amine-terminated PEG (PEG-NH2) and 
branched-PEI. Complexation with DNA by the dynameric frameworks showed 
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particles with a hydrodynamic diameter of 100 nm and high DNA loading capability. 
The group also evaluated the capability of the frameworks in loading DNA at pH 7.4 
by changing the ratios of PEG-NH2 and PEI. On account of the increased positive 
charges density, frameworks prepared in the absence of PEG-NH2 resulted in higher 
loading of DNA. The successful loading of DNA at pH 7.4 confirms the presence of 
cationic charges, and therefore, indicated that the condensation of PEI with JD to form 
an imine bond was achieved at pH 7.4. Moreover, the frameworks showed low toxicity 
and superior transfection efficiency in HEK 293T cells when compared to commercial 
transfection vectors.  
 
 
Figure 4.4: Dynameric framework formation by condensation of the hydrophobic aldehyde JD, NH2-
PEG and branched PEI. DNA loading was facilitated by electrostatic interactions of the positive 
charges of the amino groups of the PEI block with the negative charges of the phosphate groups of 
the DNA.16 
 
The examples described here demonstrate the potential of acid-labile C=N 
bonds as components within “smart” delivery platforms for the successful development 
of gene and RNAi therapy. However, the successful in vivo delivery of siRNA requires 
a platform that is capable of performing multiple functions, each at the appropriate 
step during the delivery process. In this regard, the use of block-copolymers presents 
a great advantage as components of the delivery platform. By using synthetic block-
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copolymers, it is possible to introduce different structures into the nanocarriers, each 
one being capable to perform a specific function.  
In this chapter, the use of a diblock copolymer featuring acid-labile C=N bonds 
as a new siRNA delivery platform is explored. The ideal delivery platform should 
present long blood-circulating time after systemic administration, but once internalised 
into the endosome vesicle, the fast dissociation of the platform and release of siRNA 
should occur. Therefore, the optimal acid-labile bond should present high stability at 
pH 7.4 and fast cleavage of the bond at pH ~ 5.0 (pH of the endosome environment). 
To obtain the appropriate pH-response, different hydrazones and imines were 
synthesised and their pH hydrolysis was evaluated. The acid-labile bonds presenting 
appropriate pH-sensitivity for siRNA delivery (stable at pH 7.0 and labile at pH 5.0) 
were appended on a diblock copolymer. The diblock copolymer is composed of a block 
of pPEGMA and a cationic block featuring the pH-sensitive bond (imine or hydrazone) 
(Figure 4.5).  
 
 
Figure 4.5: Schematic representation of diblock-copolymers for siRNA delivery. The copolymers are 
composed of a cationic block featuring the acid-labile bonds imine or hydrazones and an 
ethyleneglycol block.  
 
The pPEGMA block provides colloidal stability and long circulation time in blood 
vessels. Moreover, pPEGMA can decrease RES uptake due to its hydrophilicity and 
steric repulsion effects that reduce phagocyte interactions and complement 
activation.17 Through the positive charges of the cationic block, siRNA can be loaded 
via ionic interactions with the negative charges of the phosphate groups in the siRNA 
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sequence. In addition, the cationic moieties are appended onto the polymer through 
the condensation of an aldehyde-functionalised scaffold with an amine or hydrazide, 
resulting in a polymer block featuring acid-labile bonds (Figure 4.5). In this way, the 
block copolymers can effectively load siRNA and show pH-responsiveness through 
the imine/hydrazone bonds. Once in the acidic environment of the endosome, the 
imines or hydrazones would hydrolyse, resulting in endosomal escape and siRNA 
release. Inspired by the work of Wang, et al.,15 only a fraction of the C=N bonds need 
to hydrolyse to promote siRNA release. As the hydrolysis occurs, the cationic density 
of the block copolymer becomes too low for effective complexation of siRNA. Thus, it 
might be expected that siRNA release can be triggered when not all of the C=N bond 
are hydrolysed, i.e. a value close to pH ~ 6, avoiding any degradation of siRNA in the 
late endosome. To obtain a more robust delivery platform, the acid-labile copolymer 
can be functionalised onto AuNPs through the sulfur-Au chemistry as previously 
described in Chapter 3. The new multifunctional delivery platform presents a range of 
properties that results in long blood circulation time, stability at physiological pH, high 
loading of siRNA and effective endosomal escape and siRNA release (Figure 4.6). 
 
 
Figure 4.6: pH-response of the nanocarriers constituted of AuNPs and pH-responsive copolymer. 
The copolymers present a pPEGMA block and a cationic block. The cationic block features 
hydrazone or imine bonds, that once in acidic conditions is hydrolysed, resulting in the release of 




4.2 Results and Discussion 
In this section, the formation of model hydrazone and imine bonds and their 
stabilities at different pHs were explored. Aldehyde A1 (Scheme 4.3 A and B) was 
synthesised and its condensation with different hydrazides and amines was evaluated. 
Commercially available aldehydes (Scheme 4.3 C, 4.4. B and C) were also tested. 
The hydrolysis of each hydrazone/imine was evaluated by 1H NMR spectroscopy and 
equilibrium positions determined. Considering the biological applications of this work, 
three molecules were then selected to be appended onto diblock copolymer scaffolds. 
The copolymer synthesis was conducted by RAFT polymerisation and the polymers 
were characterised by 1H NMR spectroscopy and GPC. The polymers were then 
functionalised onto AuNPs and the loading efficiency of siRNA and pH response were 
evaluated. 
 
4.2.1 Attempts to modify the pH-sensitivity of hydrazone bonds 
As outlined in section 4.1, hydrazones are a class of compounds that present 
higher stability in water compared to imines. Thus, for the purposes of this work, the 
destabilisation of the hydrazone bond is necessary to obtain appropriate pH-sensitive 
bonds for siRNA delivery. Three different hydrazones were synthesised (Scheme 4.3) 
and their stability at different pHs evaluated. Hydrazones H1 and H2 (Scheme 4.3 A 
and B) were prepared from aldehyde A1 and different hydrazides to explore the effect 
of different substituents on the hydrazide compounds. Both hydrazones feature 
positively charged moieties that are essential for eventual complexation with siRNA. 
Aldehyde A1 was synthesised by a three-step reaction (Chapter 2 – section 2.5.1) and 
purified by precipitation as its hexafluorophosphate salt to obtain a white powder. 
Characterisation by 1H and 13C NMR spectroscopy confirmed that A1 was successfully 
obtained (Appendix B). To destabilize the hydrazone bonds, a commercially available 
aldehyde displaying an electron donating group (EDG) (-OCH2) was condensed with 
HZ1 to form hydrazone H3 (Scheme 4.3 C). EDGs in proximity to the carbonyl group 
are anticipated to result in an increase of the aldehyde LUMO level, and therefore 
reduced strength of the C=N bond.  
All hydrazones were synthesised by dissolving the reaction partners (aldehyde 
and respective hydrazides) in D2O in a 1:1 molar ratio (20 mM of each compound). 
The pH was increased to pH = 12.0 with small aliquots of NaOH(aq) (1 M) to favour the 
formation of hydrazones H1, H2 and H3 (Scheme 4.3). Then, the pH was slowly 
decreased by titrating H3PO4(aq) (1 M) and aliquots were taken to evaluate the position 
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of the equilibrium by 1H NMR spectroscopy. The yield of hydrazone was determined 
by the integration of the CH signal of the hydrazone bond at d ~ 8.3 ppm and compared 
to the aldehyde signal at d ~ 10.0 ppm.  
 
 
Scheme 4.3: Hydrazone formation by the reaction of aldehyde A1 with (A) HZ1 to form hydrazones 
H1, (B) with HZ2 to form hydrazone H2, and (B) aldehyde A2 to form hydrazone H3. The reactions 
are equilibrium processes and are pH-dependent. 
 
Figure 4.7 shows an example of the 1H NMR spectra of hydrazone H1 at different 
pHs. At pH 11, the complete formation of hydrazone was achieved (Figure 4.7 A). At 
pH 7 and below, the appearance of a second upfield signal at d ~ 8.1 ppm was 
observed that is associated with the isomerisation of the C-N bond. At pH 4.0 (Figure 
4.7 D) a small signal associated with the aldehyde was observed that became more 
significant at pH 1.0 (Figure 4.7 E), indicating partial hydrolysis of H1. However, even 
in acidic pH the hydrolysis did not reach completion as the hydrazone signals were 









































































Figure 4.7: Partial 1H NMR spectra (300 MHz, D2O) of hydrazone H1 at pH 1.0 – 12.0. H1 was formed by 
condensation of aldehyde A1 with hydrazide HZ1 at pH 12.0.  
 
The hydrazone yield at different pHs for all hydrazones is shown in Figure 4.8. 
More than 90 % of hydrazones H1, H2 and H3 were still present in solution even at 
pH 1.0, indicating that the EDG modification on the structure of the hydrazone did not 
make the hydrazone bond more labile at low pH.  
 
 
Figure 4.8: Hydrolysis of hydrazones H1 (red), H2 (grey) and H3 (green). Aldehydes were mixed 
with their respective hydrazide and the pH increased to pH = 12.0. After titration with H3PO4(aq) (1M), 
1H NMR spectra were analysed to determine the yield of hydrazone at different pH values. 
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It is worthwhile comparing this observation with a literature example. He and co-
workers12 (Figure 4.9) reported the condensation of a hydrophilic polymer (PEG-
NHNH2) with a aldehyde modified styrene polymer (PS-CHO) to form an amphiphilic 
hydrazone copolymer (Figure 4.9 A). The copolymer self-assembled into spherical 
nanoparticles of ~ 385 nm in size. The authors claimed that the electron-rich nature of 
the aromatic aldehyde of PS-CHO destabilised the hydrazone bond, allowing its 
hydrolysis at pH 4.0. This results in disassociation of the hydrophilic corona and 
decrease of the particle size (Figure 4.9 B). After the pH was again increased to 7.0, 
the particles were reformed, presenting size and morphology similar to the initial 
particles. The pH-responsive copolymer reported by He and co-workers contain the 
same EDG presented in hydrazone H3. However, the addition of an EDG on H3 did 
not result in destabilisation of the hydrazone bond. The pH-sensitivity demonstrated 
by He and co-workers could not be reproduced in this work. A possibility explanation 
could be amphiphilic nature of the polymers synthesized. The pH-sensitivity of the 
system could be attribute to a partial hydrolysis of the hydrazones, decreasing the 
hydrophilicity of the system to maintain the micellar form, and therefore, the dissemble 
of the particles occurred. After the pH is increased, the hydrazone are formed and the 
system regain its hydrophobicity/hydrophilicity to form spherical micelles. 
 
 
Figure 4.9: Spherical nanoparticles by conjugation of electron-rich aldehyde with hydrophilic 
modified PEG. The pH-sensitivity was confirmed by the disassemble of the nanoparticles in different 
pHs by TEM imaging.12 
 
The lack of pH-sensitivity of hydrazones H1, H2 and H3 can be associated with 
the aromatic structure of the aldehydes. Nguyen, et al.6 evaluated hydrazone 
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formation and equilibrium constants from an aliphatic and an aromatic aldehyde. They 
further evaluated the reversibility of these bonds by measuring hydrolysis at pH 6.0. 
The equilibrium constants determined for aromatic hydrazones were significantly 
higher when compared to the aliphatic hydrazones, and therefore, aromatic 
hydrazones showed higher stability at pH 6.0. The electron density of the aromatic 
ring raises the stability of hydrazones by conjugation with the C=N bond, decreasing 
its eletrophilicity. The hydrazone bond must present appropriate pH-sensitivity for 
endosomal release to be considered as a potential candidate for siRNA delivery 
platforms. Aliphatic hydrazones can be considered as potential candidates for 
endosomal release, however, on account of its lack of reactivity it is harder to modify 
its chemical structure. Therefore, it is more challenging to tune the pH-sensitivity of 
aliphatic hydrazones. Hydrazones H1, H2 and H3 did not show the desired pH 
response, and therefore, the evaluation of imine bonds as potential pH-sensitive 
candidates was assessed.  
 
4.2.2 Attempts to modify the pH-sensitivity of imine  
The low stability of imine bonds in water, especially in acidic pH, make this class 
of covalent bond unfeasible for delivery applications. Thus, enhancing the stability of 
imine bonds is required to improve its pH-sensitivity, especially towards the acidic 
environment of the endosome. Godoy-Alcatar and co-workers14 demonstrated that the 
pH-sensitivity of imines can be correlated with the pKa and the HOMO energy levels 
of the amine reaction partners. Thus, the evaluation of imines formed by the 
condensation of aldehyde A1 with amines presenting different basicity was performed 
(Scheme 4.4 A). Imines I1-I4 were formed from amines AM1-AM4. These amines 
present different pKa values and also, after protonation at neutral pH, are able to 
potentially complex with siRNA due to electrostatic interactions with the negative 
charges of the siRNA sequence. Amine AM5 is an arginine-modified compound and 
was chosen on account of reports describing high complexation and transfection 
efficiency of siRNA by arginine conjugates.18,19 Lastly, AM6 was selected because its 
methacrylate group presents the possibility to facilitate polymer synthesis by RAFT 
polymerisation, offering a straightforward route to a pH-sensitive polymer block. The 
pH-sensitivity of imine bonds can also be tuned by decreasing the LUMO energy levels 
on the aldehyde reaction partner.14 The LUMO energy can be decreased by addition 
of electron withdrawing groups (EWGs) and thus, the effect of different EWGs on the 
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aldehyde (Scheme 4.4 B and C) was also evaluated using the commercially available 
A3 and A4. 
Imines I1-I8 were prepared (Scheme 4.4) by the condensation of aldehydes (A1, 
A3 or A4) with amines (AM1-AM6) and their stabilities were evaluated at different pH 
values by 1H NMR spectroscopy. The imines were formed by mixing 1:10 molar 
equivalence of aldehyde (20 mM in D2O) and amine (200 mM in D2O). The pH was 
then increased to 12.0 by adding small aliquots of NaOH(aq) (1 M) and the 1H NMR 
spectra evaluated to confirm the complete formation of the imine product (I1 – I8). 
Then, the pH was slowly decreased by titrating H3PO4(aq) (1 M) and aliquots were 
collected for evaluation of their imine yields. Tetramethylsilane was used as an internal 
standard and the diagnostic CH signals from the imine and the aldehyde were used to 
calculate the imine yield. To illustrate, the 1H NMR spectra obtained for the hydrolysis 
of imine I1 are shown in Figure 4.10. 
 
 
Scheme 4.4: Imine formation by the reaction of (A) aldehyde A1 to form imines I1-I6, (B) aldehyde 
















































































































































Figure 4.10: Partial 1H NMR spectra (300 MHz, D2O) of imine I1 at different pHs. In A to E is shown 
the hydrolysis of I1 according to the pH of the medium. (A) Complete formation of I1 and (F) Complete 
hydrolysis of I1. 
 
The 1H NMR spectrum showed the complete formation of imine I1 at pH 12 (Figure 
4.10 A). Once the pH was £ 8.0 the CH signal from the aldehyde A1 appeared at d ~ 
10.0 ppm, indicating the hydrolysis of I1. However, the hydrolysis was only significant 
bellow pH < 7.0 (Figure 4.10 C). At pH 4.0, no traces of imine I1 were observed (Figure 
4.10 F), confirming 100 % hydrolysis of I1 in acidic pH. 
The pH-sensitivity of all imines (Figure 4.11) was observed by plotting the % 
imine yield obtained from the 1H NMR spectra against pH value. The “S”-shaped 
curves obtained demonstrated the expected behaviour of imine hydrolysis, where the 
position of the equilibrium can be shifted from almost complete imine to reaction 
partners over about three pH units. The pH value at which significant hydrolysis occurs 




Figure 4.11: Aldehydes were mixed with their respective amines in the molar ratios of 1:10 and the 
pH increased to pH = 12.0. After titration with H3PO4(aq) (1M), 1H NMR spectra were analysed to 
determine the yield of imines in different pHs. The error bars were determined by considering 5 % of 
error for the integral values. 
 
The pH sensitivity of imines I1-I4 is shown in Figure 4.11 A and can be observed 
that the order of stability is I1 > I2 > I3 > I4. Imine I1 thus showed the higher hydrolytic 
stability at lower pH values when compared to I2-I4 (Figure 4.11 A). When analysing 
the structure-stability relationship of imines I1-I4, the only structural difference is the 
amine reaction partners. Imine I1 presents an ammonium group (AM1) which bears a 
fixed positive charge. When analysing the difference in the structure of the other amine 
reaction partners, the order of the pKa decreased for I2-I3 (pKaAM2 > pKaAM3)(Scheme 
4.4 A).20 Although the stability of the imine bonds does not fully correlates with the 
basicity of the amine reaction partners,14 Figure 4.11 A showed a correlation between 
the stability of the C=N bond and the basicity of the amine, where amines presenting 
higher pKa showed higher stability in acidic pH. Imine I4 showed lower stability when 
compared to imine I3. The difference in the structure of these compounds is the 
distance of the morpholine ring from the imine bond. The morpholine ring in imine I4 
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is further from the C=N bond when compared to imine I3, and therefore, presents 
lesser effect over the stabilisation of the C=N bond. The same effect was observed 
with imine I5 (Figure 4.11 B), where the arginine functional group is far too distant from 
the C=N bond. 
Imines I7 and I8 showed good stability at pH 7.0 (³ 50 % imine). I7 features an 
electron withdrawing fluoro-substitution on the aromatic ring of the aldehyde that 
decreases the energy level of the LUMO.14 The lower LUMO energies contribute 
towards the strength of the covalent imine bond, resulting in higher stability. Although 
I8 showed suitable pH sensitivity for endosomal release (pH 7 > 50 % of imine bonds 
and pH 5 < 20 % imine bonds) (Figure 4.11 B), the fixed positive charge in the 
aldehyde is not ideal. When appended onto amine-functionalised polymers and 
subsequent hydrolysis occurs, the positively charged small molecule will be released 
from the polymer system. Consequently, the amine functions appended onto the 
polymer will protonate at low pH, leading to complexation with siRNA and interfere in 
the siRNA release from the nanocarriers. The same would likely occur with I6. In 
addition, I6 presented the lowest stability for all imines tested, disregarding its use as 
pH-sensitive components with a siRNA delivery platform. The screening of pH-
sensitivity for different imines identified the imine bonds that can potentially be used 
as candidates for siRNA delivery applications, and imines I1 and I7 were selected as 
potential candidates and further studies were performed as they display the highest 
stability at neutral pH.  
The pH-sensitivity of C=N bonds is also dependent on the stoichiometry of the 
reaction partners. In the previous experiments, the hydrolysis was evaluated using 1 
equivalent of aldehyde and 10 equivalents of amine. I1 and I7 showed ideal pH-
sensitivity (stable at pH 7 and hydrolysed at pH 5) in these conditions for siRNA 
delivery applications. However, when a high excess of one of the reaction partners is 
used, the position of the equilibrium shifts towards the imine formation. Therefore, the 
effect of the stoichiometry of the reaction partners in the pH-sensitive hydrolysis was 
evaluated. I1 and I7 were prepared using equimolar equivalents of aldehyde and 
amine (20 mM). The pH-dependence on the imine yield was calculated and compared 




Figure 4.12: Hydrolysis of I1 (red line) and I7 (blue line). Aldehydes were mixed with their respective 
amines in the molar ratios of 1:10 (filled lines) and 1:1 (dashed lines). The pH was increased to pH 
= 12.0 with NaOH(aq) (1 M) and after titration with H3PO4(aq) (1 M), 1H NMR spectra were analysed to 
determine the yield of imines in different pHs. 
 
With equal stoichiometries of the reaction partners, as anticipated the pH-
sensitivity decreased for both I1 and I7 (Figure 4.12 – dashed lines). However, even 
with equimolar ratios of the reaction partners, I7 showed advantageous pH-sensitivity 
as at pH 7.0, the imine yield was > 40 %, while at pH < 5.0 was completely hydrolysed 
(Figure 4.12). These observations demonstrate the ideal pH-sensitivity for systemic 
administration of siRNA (stable at pH 7.0) and enhanced endosomal release ( pH < 
6.0). 
The pH-sensitivity of model imines was evaluated and the results showed that 
when an EWG is incorporated to the aldehyde, the resulted imine (I7) showed 
appropriate pH-sensitivity for siRNA delivery applications. Considering that the goal of 
this project is to append the ideal pH-sensitive imine bond onto copolymer scaffolds, 
the polymer system might present different pH-sensitivity to the model imine 
compounds. Thus, the pH-sensitivity of a copolymer scaffold bearing I1 as an acid-
labile bond was evaluated. I1 was chosen to be appended onto a copolymer scaffold 
due to the simple and low-cost synthesis, and the aldehyde random copolymer P3 
(Mn: 8 kDa) (Scheme 4.5) was provided by Patrick Higgs who completed its synthesis 
within a separate project. Copolymer P3 featured ~ 9 units of aldehyde polymer and ~ 
42 units of poly(ethylene glycol) acrylate (PEGA). The copolymer was condensed 
using equimolar equivalents of aldehyde functions with AM1 in D2O to obtain 
copolymer P4 (Scheme 4.5). Its pH-sensitivity was then assessed by slowly titrating 
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H3PO4(aq) (1 M) and aliquots were collected to allow the evaluation of the imine yield 
by 1H NMR spectroscopy.  
 
 
Scheme 4.5:Condensation of aldehyde random copolymer P3 with AM1 to obtain imine random 
copolymer P3. 
 
The pH-sensitivity was compared with the model imine I1, showing that in a 
polymer system the imine yield was higher at pH 7.0 (physiological pH) (~ 30 %) than 
in the model I1 (< 10%) (Figure 4.13). This result indicates that in a polymer system 
the acid-labile bonds might be more stable, and therefore, if I1 and I7 are appended 
onto polymer scaffolds, the resulted copolymer would present excellent pH-sensitivity 
for siRNA delivery applications, showing high stability at pH 7.0 and hydrolysis at pH 
5.0. The higher stability for copolymers could be explained due to the higher density 
of acid-labile bonds in the system. Moreover, the condensation of the amine AM1 with 
the aldehyde copolymer resulted in a lower imine yield when compared to the model 
compound at basic pH (~ 40 % for P3 and ~ 80 % for I1) (Figure 4.13). The random 
copolymer features ~ 42 units of PEGA, and only ~ 9 units of the aldehyde polymer. 
Thus, the hydrophilicity and steric hindrance of PEGA might result in steric impediment 
of the aldehyde, obstructing AM1 to attack the carbonyl of the aldehyde. Hence, the 
synthesis of a copolymer featuring a different architecture of the blocks is necessary 
to enhance acid-labile bonds formation. In a diblock copolymer architecture it is 
possible to concentrate the positive charges within one of the blocks. The high density 
of positive charges allows stronger electrostatic interaction with the multiple negative 
charges of the siRNA, resulting in higher loading efficiency. For that reason, to obtain 
polymers able to successfully load siRNA and present acid-labile moieties, the 





























Figure 4.13: pH-sensitivity of I1 (red line) and random copolymer P4 (green line) in molar ratios of 
aldehyde:imine 1:1. Aldehyde copolymer P3 was mixed with AM1 (20 mM) and the pH was increased 
to pH = 12.0 with NaOH(aq) (1 M). The pH was slowly decreased by titration with H3PO4(aq) (1 M) and 
1H NMR spectra were analysed to determine the yield of imines in different pHs. 
 
4.2.3 Synthesis and characterisation of pH-responsive block copolymers by 
RAFT polymerisation 
Polyethylene glycol (PEG) is a highly hydrophilic polymer with very low toxicity 
that provides colloidal stability and biocompatibility to nanocarriers.21 PEG chains are 
often used to prolong the blood circulation of nanocarriers, improving their 
pharmacokinetics and accumulation into the target tissue. Hence, the use of PEG 
polymers in this project was deemed essential for the successful delivery of siRNA. 
The poly(ethylene glycol) methyl ether methacrylate monomer M2 (PEGMA500 Mn: 500 
g.mol-1) was used for the synthesis of the pH-responsive copolymers (Scheme 4.6). 
To prepare the pH-responsive diblock, pPEGMA macroCTA P5 was synthesised by 
RAFT polymerisation of M2 using CTPA as chain transfer agent and AIBN as initiator 
(Scheme 4.6). Then, P5 was purified by dialysis in MeOH and evaporated to dryness 
to obtain a pink oil.  
Chain extension of macroCTA P5 (Scheme 4.6) with 2-hydroxyethyl 
methacrylate monomer M3 (HEMA Mw: 130.14 g.mol-1) was performed in 1,4-dioxane 
using AIBN as initiator. The polymer pHEMA-b-pPEGMA P6 was dialysed in water 
and freeze-dried to obtain a pink oil. Block copolymer P6 was then decorated with 
aldehydes upon its pHEMA block by its reaction with excess of the acid chloride 1 and 
then purified by dialysis in MeOH. The decorated copolymer was evaporated to 
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dryness to obtain P7 as a pale pink oil. All polymers were characterised by 1H NMR 
spectroscopy and GPC (Table 4.1).  
 
 
Scheme 4.6: Synthesis of pHEMA(45)-b-pPEGMA(44) (P6) and its post-functionalisation to obtain an 
aldehyde copolymer P7. PEGMA500 monomer M2 was polymerised to obtain the macroCTA P5 
featuring 44 units of PEGMA. The macroCTA P5 was extended by reaction with M3 and the result 
copolymer P6 features 44 units of PEGMA and 45 units of HEMA. Reaction with 1 afforded P6 
featuring 17 units of aldehyde.  
 
Table 4.1: Characterisation of P5, P6 and P7. a As determined by 1H NMR spectroscopy (300 Hz, 
CDCl3). b As determined by GPC in DMF (0.6 mL min-1 with 1g/L LiBr) calibrated against methyl 
methacrylate standards of very low polydispersity (PDI <1.08). 
Polymer Mn (g/mol)a Mn (g/mol)b Mw (g/mol)b DP PDIb 
P5 22,300 8,800 10,600 44 1.21 
P6 28,200 13,300 16,500 45 1.24 
P7 30,400 - -  - 
 
The 1H NMR spectra for P5 (Figure 4.14 A) showed broadened signals, 
confirming the successful polymerisation of M2. The distinctive well-defined signal of 
the terminal methoxy groups (-OCH3) of PEGMA side chains was assigned at d = 3.37 
– 3.44 ppm. The signals at d = 4.05 – 4.30 and at d = 3.56 – 3.88 correspond to the 
first methylene protons (-OCH2) and the remaining methylene (-OCH2CH2) of the 
ethylene glycol side chains, respectively. The signals at d = 0.69 – 1.21 and d = 1.64 
– 2.15 correspond to the polymer backbone. The signals at d = 7.52 – 7.85 and d = 
7.91 – 8.08 ppm correspond to the aromatic protons of the polymer end group. These 
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integrals to those of the signals of the terminal methoxy groups and the first methylene 
of the ethylene glycol chain. For P5, the estimated DP = 44 corresponds to Mn ~ 22 
kDa. The GPC analysis of P5 (Figure 4.15 – orange line) showed a monomodal 
molecular distribution (PDI = 1.21), confirming that pPEGMA can be obtained with 
good level of control by RAFT polymerisation. 
 
 
Figure 4.14: Characterisation of P5, P6 and P7. 1H NMR spectrum (300 Hz, D2O or CDCl3) of (A) 
P5, (B) P6 and (C) P7. Diagnostic proton signals are annotated. 
 
 
Figure 4.15: Normalised refractive index traces of P5 (orange line) and P6 (purple line) obtained by 
GPC analysis in DMF containing 1g/L of LiBr at 0.6 mL/min. Near monodisperse poly(methyl 
methacrylate) standards were used for calibration and the average molecular weight (Mn) determined 
as 8,800 Da for P5 and 13,300 Da for P6. 
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The 1H NMR spectrum of P6 (Figure 4.14 B) showed the diagnostic signals 
previously described for P5. The broadening of the signal assigned as f, i at d = 4.02 
– 4.42 correspond to the overlapped signals of the first methylene within the glycol 
side chains of M2 and M3 (-OCH2). This signal was used to determine the DP of M3 
by comparing its integral to that of the signal of the terminal methoxy groups of M2. 
The diblock copolymer P6 presented Mn ~ 28 kDa, featuring an estimated 45 units of 
HEMA and 44 units of PEGMA. The GPC analysis of P6 (Figure 4.15 – purple line) 
showed a shorter retention time when compared to P5, confirming an increase in 
molecular weight. Moreover, P6 showed monomodal molecular weight distribution, 
resulting in a very similar PDI when compared to P5 (PDI = 1.21 and 1.24 for P5 and 
P6, respectively), indicating the successful and outstanding control of the chain 
extension of P5 by RAFT polymerisation. 
The 1H NMR spectrum of P7 (Figure 4.14 C) showed the well-defined signals of 
the pPEGMA block. The signals of the pHEMA block (i and j) shifted downfield in the 
spectrum and were assigned at d = 3.93 – 4.17 and d = 4.39 – 4.66. The successful 
conjugation of aldehyde moieties to the copolymer was confirmed by the broadened 
signals at d = 7.81 – 8.35 and d = 9.82 – 10.28, corresponding to the diagnostic protons 
of the aromatic ring and the CH proton of the aldehyde, respectively. The aldehyde 
copolymer P7 featured an estimated ~ 17 units of aldehyde and final Mn ~ 30 kDa. It 
was estimated that 38 % of the hydroxyl groups pf P6 reacted with acid chloride 1 to 
afford the aldehyde appendages. These results showed the successful synthesis of a 
diblock copolymer by RAFT polymerisation with an excellent level of control. In 
addition, the post-functionalisation of pHEMA was possible through one step reaction 
by a fast and efficient method to obtain diblock copolymers where one of the blocks 
features aldehyde moieties. 
The condensation of P7 with HZ1 to obtain a cationic block featuring hydrazone 
moieties was attempted, however the reaction yield was very low (data not shown). 
The long side chains of pPEGMA may have sterically shielded the aldehyde groups, 
impeding their reaction with HZ1. Furthermore, short side chains of ethylene glycol 
such as HEMA display lower critical solution temperatures (LCST).22 HEMA Polymers 
presented LCST < 25 °C,23 resulting in their transition from hydrophilic to hydrophobic 
with concomitant precipitation when working in temperatures above the LCST. This 
thermo-response is well-known24,25 in short chain ethylene glycol based-polymers. 
Longer polymer side chains of ethylene glycol present much higher LCSTs (e.g > 65 
°C)26 and are thus better suited for application within a delivery platform. Hence, the 
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synthesis of a diblock copolymer featuring similar lengths of the ethylene glycol side 
chains within each of the blocks is needed to overcome the LCST challenges and the 
possible steric hindrance of the aldehyde moieties. 
The methacrylate monomer PHEMA M4 (Mn: 500 g.mol-1) was chosen for chain 
extension of the macroCTA P5 (Figure 4.16). PHEMA displays a hydroxyl group at the 
end of a longer ethylene glycol chain (8-9 ethylene oxide units), and therefore, can 
evade the steric hindrance of the long PEGMA block. Moreover, PHEMA shows higher 
LCST (~ 90 °C) when compared to HEMA.26 To obtain pPHEMA-b-pPEGMA (Figure 
4.16), P5 was chain extend with M4 in 1,4-dioxane using AIBN as initiator (Figure 4.16 
A), resulting in 34 % of monomer conversion (Table 4.2). The diblock copolymer P8 
showed shorter retention time by GPC analysis when compared to the macroCTA P5 
(Figure 4.16 A). However, a bimodal molecular weight distribution was observed (PDI 
= 1.5), indicating a significant degree of uncontrolled polymerisation (optimal PDI for 
diblock copolymers < 1.2). To improve the molecular weight distribution of pPHEMA-
b-pPEGMA, the chain extension was performed whilst increasing the molar ratio of 
AIBN, maintaining 1,4-dioxane as polymerisation solvent to obtain P9 (Table 4.2). 
 
 
Figure 4.16: Optimisation of the RAFT polymerisation to afford pPHEMA-b-pPEGMA and respective 
normalised refractive index traces obtained by GPC analysis in DMF containing 1g/L of LiBr at 0.6 




Table 4.2: Conditions and characterisation of pPHEMA-b-pPEGMA block copolymers prepared by 
RAFT polymerisation. a As determined by 1H NMR spectroscopy (300 Hz, D2O). b As determined by 
GPC in DMF (0.6 mL min-1 with 1g/L LiBr) calibrated against methyl methacrylate standards of very low 
polydispersity (PDI <1.08). 




P8 44,100 100:1:0.3 1,4 - Dioxane 3 h 34 % 97,800 1.50 
P9 44,100 100:1:0.5 1,4 - Dioxane 3 h 52 % 110,000 1.74 
P10 41,300 100:1:0.5 Toluene 24 h 33 % 81,400 1.36 
P11 44,100 100:1:0.5 DMF 3 h 54 % 130,000 1.14 
 
The diblock copolymer P9 showed higher monomer conversion (52 %) when 
compared to P8 (Table 4.2). However, the GPC traces (Figure 4.16 B) revealed a 
bimodal distribution and increased PDI, showing that the increase in AIBN added did 
not improve the control of the polymerisation. Therefore, the chain extension was 
attempted using toluene as polymerisation solvent to obtain P10 (Figure 4.16 C). The 
resulting copolymer showed improved GPC traces and PDI when compared to P8 and 
P9 (Table 4.2), however, the monomer conversion was very low (33 %) even after 24h 
of polymerisation. Thus, the chain extension was performed in DMF, a common 
solvent for RAFT polymerisation. P11 (Figure 4.16 D) was obtained after 3 h, resulting 
in 54 % of monomer conversion and improved PDI = 1.14 (Table 4.2). The GPC traces 
(Figure 4.16 D) display a small shoulder after chain extension. However, considering 
the low PDI obtained (< 1.2), it is possible to conclude that the chain extension of the 
macroCTA P5 with M4 in DMF occurred with a reasonable level of control, resulting in 
a relatively monodisperse diblock copolymer (P11) that its adequate for use in the 
target application.  
Copolymer P11 was characterised by 1H NMR spectroscopy to determine the Mn 
and DP by integrating the signals of the ethylene glycol side chain of PHEMA and the 
signal of the terminal methoxy group of PEGMA. The macroCTA P5 presented Mn ~ 
47 kDa, featuring ~ 90 units of PEGMA. The diblock copolymer P11 presented Mn ~ 
72 kDa, suggesting the addition of ~ 50 units of PHEMA. 
Copolymer P11 was then functionalised by its reaction with aldehyde 2 (Scheme 
4.7) to obtain the aldehyde copolymer P12. The conversion to an aldehyde-




Scheme 4.7: Post-functionalisation of P11 to obtain pH responsive polymer P13. P11 was reacted 
with the acid chloride 2 to obtain P12 featuring 30 units of aldehyde. Hydrazide HZ1 was appended 
onto the copolymer by condensation to obtain the cationic diblock copolymer P13. 
 
The signals at d = 7.51 – 7.87 and d = 7.93 – 8.30 (corresponding to the three protons 
of the aromatic ring) and d = 9.91 – 10.19 (corresponding to the aldehyde) (Figure 
4.17 A) were broadened, suggesting that the aromatic aldehyde was successfully 
appended onto the copolymer. It was estimated that P12 presented ~ 30 units of 
aldehyde, resulting in Mn ~ 76 kDa (Table 4.3).  
 
 
Figure 4.17: 1H NMR spectrum (300 Hz, CDCl3 or D2O) of (A) P11 and (B) P12. Protons signals are 
annotated corresponding to diagnostic protons on the polymer. Normalised refractive index traces of 
(B) P4 and (D) P5 obtained b 
 
P13 was then obtained (Scheme 4.7) after condensation of P12 with HZ1 in 
MeOH. The 1H NMR spectrum pf P13 (Figure 4.17 B) showed the complete 
disappearance of the aldehyde signals. The broadening of the signals at the aromatic 
region arise on account of the overlapping of the CH and the NH signals of the 
hydrazone bond with the aromatic protons of the aldehyde. The appearance of a signal 
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at d = 4.43 – 4.61, corresponding to the -CH2 protons of the hydrazone (labelled as “p” 
in Figure 4.17 B) was also observed. Together, these results indicate that P13 was 
obtained successfully by a two-step synthesis on pre-formed diblock polymers 
scaffolds synthesised by RAFT polymerisation. 
 
Table 4.3: Characterisation of macroCTA P5 and diblock copolymer P11 and its post-functionalisation 
to obtain aldehyde functionalised copolymers P12 and P14 cationic copolymers P13 and P15. a As 
determined by 1H NMR spectroscopy (300 Hz, D2O or CDCl3). b As determined by GPC in DMF (0.6 
mL min-1 with 1g/L LiBr) calibrated against methyl methacrylate standards of very low polydispersity 
(PDI <1.08). 
Polymer Mn (g/mol)a Mn (g/mol)b Mw (g/mol)b PDIb 
P5 46,800 44,100 49,200 1.12 
P11 71,900 130,000 147,600 1.14 
P12 76,400 - - - 
P13 79,800 - - - 
P14 74,000 - - - 




Scheme 4.8:Post-funtionalisation of P14 and P15. P11 was post-functionalised by its reaction with 
excess of acid chloride 1 to obtain polymer P13 featuring ~ 16 aldehyde units. Hydrazide HZ1 was then 
appended onto P13 the polymer to obtain the polycation P15. 
 
The same post-functionalisation approach was repeated to obtain copolymers 
P14 and P15 (Scheme 4.8). The aldehyde function in these polymers does not feature 
the F-substitution on the aromatic ring to allow the evaluation of the effect of the F-
substituent on the pH-responsiveness of these polymers. The copolymers were 
characterised as described previously. The analysis of the 1H NMR spectrum of P14 
(Appendix B) indicates a copolymer featuring an estimated 16 aldehyde units and Mn 
~ 74 kDa (Table 4.3). The aldehyde units were fully then functionalised through 
reaction with HZ1 to obtain the hydrazone cationic polymer P15 (Table 4.3). The 
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cationic copolymers P13 and P15 were then used for complexation with siRNA to 
evaluate the capability of these polymers as delivery platforms. 
 
4.2.4 Preparation and characterisation of polyplexes: Complexation of siRNA 
with cationic copolymers 
Polyplexes between P13/P15 and siRNA were formed based on the electrostatic 
interactions between two polyelectrolytes of opposite charge (Figure 4.18). The ratio 
of positive charge (ammonium groups within the polymer) to the negative charge 
(phosphate groups within siRNA), the so called N/P ratio, determines the loading and 
stability of the polyplexes formed, and is highly dependent on the composition and the 
molecular weight of the polymers.27 In a typical example, a 10 µM solution of siRNA in 
RNase-free water was mixed with a previously prepared solution of P13 or P15 to form 
P13siPP (Figure 4.18 A) and P15siPP (Figure 4.18 B). 
 
 
Figure 4.18: Preparation of polyplexes loading siRNA. Polymers (A) P13 and (B) P15 were mixed 
with siRNA at different N/P ratios to obtain polyplexes P13siPP and P15siPP. 
 
The concentration of the cationic polymers was varied to form polyplexes with N/P 
ratios of 0.5 to 20. The solutions were allowed to equilibrate at room temperature to 
promote the self-assembly of the polyplexes. Because of the electrostatic interactions 
between the positive charges of the cationic polymers and the negative charges of the 
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siRNA, the loading capacity of the polyplexes can be evaluated by a gel retardation 
assay. In this assay, agarose gel electrophoresis of the polyplexes was performed to 
evaluate the migration rate of nucleic acids in the presence of polycations P13/P15. 
Naked siRNA is used as a control and its migration rate on the gel is compared with 
the migration rate of the polyplexes. Polyplexes presenting high loading of siRNA show 
lesser mobility in the gel on account of the neutralisation of the negative charge and 
the larger size, and therefore, display retarded migration rates when compared with 
naked siRNA.28 Polyplex P13siPP showed loading of siRNA at N/P ratios above 2 
(Figure 4.19 A). At N/P ratio = 2 unloaded siRNA was still observed, however, when 
higher N/P ratios were used, the complete loading of siRNA was achieved (N/P ratios: 
5, 10 and 20. Figure 4.19 A). P15siPP did not achieved loading of siRNA at any N/P 
ratios tested (Figure 4.19 B). Polymer P15 displays only 16 units of the positive charge 
from its ammonium functional groups, whilst polymer P13 displays 30 units of the 
positive charges of its ammonium functional groups. These observations suggest that 
at low densities of cations, siRNA complexation is not possible. 
 
 
Figure 4.19: Gel retardation assay of (A) P13siPP and (B) P15siPP. Polyplexes were prepared by 
simply mixing aqueous solutions of P13 or P15 and siRNA. Agarose gel 3 % was prepared in TBE 
buffer 0.5 X and the samples were loaded onto the gel using DNA loading buffer. The electrophoresis 
was perfomer in TBE buffer 0.5 X at 80 V for 1 h. 
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Polyplexes using P13 were characterised by DLS to determine the hydrodynamic 
diameters of the particles formed (Figure 4.20). All particles presented size ~ 30 nm 
with PdI > 0.5. The high polydispersity of the particles indicates that the complexation 
with siRNA, although successful, resulted in particles of a wide range of sizes, a 
feature that is not desirable for siRNA delivery.  
 
 
Figure 4.20: DLS Measurements of P13siPP (hydrodynamic diameter and PdI). The polyplexes 
were prepared by the self-assembly of P13 and siRNA at N/P ratios of 5 (pink line), 10 (yellow line) 
and 20 (green line).  
 
Polyplex formation is driven by two main factors: the electrostatic interactions 
between the positive charges of the cationic polymer and negative charges of the 
nucleic acids, and the entropy of the system.29,30 The mode of addition of the 
components to spontaneously form polyplexes might influence the physicochemical 
properties of the formed particles. Subtle changes on the order of mixing (e.g. siRNA 
to polymer solution or polymer to siRNA solution)29 or on the mode of addition (e.g. 
pipetting, vortex or dropwise addition)31 may change particle size and improve 
polydisperse distribution. However, the process of polyplexes formation is not well 
understood29,32 and further investigation is needed to elucidate the effect of the mode 
of adding the reagents on the physicochemical properties of polyplexes. 
 
4.2.5 Conjugation of cationic/hydrazone polymers P3/P15 onto AuNPs and 
subsequent complexation with siRNA 
Hydrazone polymers P13 and P15 were incubated with AuNPs of 20 nm size 
(Figure 4.21) to obtain P13NPs and P15NPs, respectively. The molar ratio of polymer 
to AuNPs was varied to determine the concentration of polymer needed to effectively 
shield the Au core. Salt-induced aggregation of AuNP-polymer conjugates was 
evaluated by addition of NaCl(aq) (1 M) followed by analysis of the UV-Vis spectrum. 
The aggregation factor was calculated by the ratio of the absorbance for aggregate 
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particles to the absorbance of bare 20 nm AuNPs (l615/l524). Thus, high values of 




Figure 4.21: Preparation of AuNPs coated with hydrazone polymers P13/P15. Nanoparticles were 
first incubated with (A) P13 or (B) P15 and the concentration of polymer needed to successfully coat 
20 nm AuNPs was determined (P13NPs and P15NPs).  
 
Uncoated AuNPs were tested as a control, showing high aggregation factor 
values consistent with the expected salt-induced aggregation of citrate-stabilised 
AuNPs (Figure 4.22). For conjugates P13NPs (Figure 4.22 A) and P15NPs (Figure 
4.22 B) molar ratios above 50 fold-excess showed lower values of aggregation factors 
after addition of NaCl(aq) (final conc. 100 mM), suggesting sufficient polymer coating 
of the Au nanoparticle core. The similar aggregation behaviour for particles coated 
with P13 and P15 was expected as both polymers presented similar molecular weights 
( Mn ~ 80 kDa). AuNP-polymer conjugates prepared using the molar ratios 1:100, 
1:500 and 1:1,000 (AuNP:polymer) were selected for further characterisation by DLS 
(Figure 4.23). P13NPs showed an increase in the hydrodynamic diameter relative to 
uncoated AuNPs, with particle size ~ 50 nm for particles coated with 1:100 and 1:500 
molar ratios and particle size ~ 70 nm for particles prepared at 1:1,000 molar ratio. 
Moreover, the nanocarriers presented narrow size distribution and low polydispersity 
(PdI = 0.2) (Figure 4.23 A). A similar behaviour was observed for P15NPs, where for 
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all molar ratios used, the particles resulted in average size ~ 70 nm and PdI = 0.3 
(Figure 4.23 B). 
 
 
Figure 4.22: Stability of AuNPs coated with (A) P13 and (B) P15 at different polymer molar ratios in 
NaCl(aq) (1 M). Dark red bars show the aggregation factors obtained from UV-Vis experiments of 
AuNP-polymer conjugates in H2O. (A) Green and (B) yellow bars represent the aggregation factors 
after addition of NaCl(aq) (1 M).  
 
 
Figure 4.23: Characterisation by DLS of AuNPs coated with (A) P13 and (B) P15 at different molar 
ratios. Particles were prepared by incubation of AuNPs with hydrazone polymer at 1:100, 1:500 and 
1:1,000 molar ratios. 
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4.2.6 Complexation of nanocarriers with siRNA 
Polymer-coated AuNP P13NPs and P15NPs were purified by centrifugation and 
then incubated with siRNA to obtain P13siNPs or P15siNPs at different N/P ratios 




Figure 4.24: Preparation of nanoparticles loaded with siRNA. P13NPs and P15NPs were incubated 
with siRNA at different N/P ratios to obtain the nanocarriers P13siNPs and P15siNPS. 
 
 
Figure 4.25: Nanoparticle nomenclature. AuNPs were coated with P13 or P15 in different molar 
ratios. After purification, the particles were incubated with siRNA at different N/P ratios to evaluate 
the loading efficiency of the nanocarriers. 
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The particles were isolated by centrifugation and the supernatant was collected for 
quantification of the amount of unloaded siRNA. This method allows an indirect 
quantification of the amount of siRNA loaded to the particles, and thus, it is possible 
to calculate the loading efficiency of the nanocarriers. P13100si2NP and P13500si5NP 
did not show loading of siRNA (Figure 4.26 A). The final N/P ratios for these particles 
were 2 and 5 respectively. However, when more polymer was added to AuNPs 
(P131,000si20NPs), the N/P ratio increased to 20, and 60 % of siRNA loading was 
achieved (Figure 4.26 A). For P15siNPs, the particles did not load siRNA for any of 
the N/P ratios tested (Figure 4.26 B). These results correlate with the gel retardation 
assay showed in Figure 4.19, where for polyplexes P13siPP, high loading of siRNA 
was observed for N/P ratio > 5 (Figure 4.19 A) and no siRNA loading was observed 
for polyplexes P15siPP (Figure 4.19 B).  
 
 
Figure 4.26: Quantification of unloaded siRNA in the supernatants of (A) P13siNPs and (B) 
P15siNPs. Unloaded siRNA was determined using a Qubit miRNA assay kit. The red line represents 
the initial concentration of siRNA added to the formulation. 
 
To evaluate the pH-response of the nanocarriers, P131,000si20NP were purified 
by centrifugation and washed three times with Hepes buffer at pH 7.4. The particles 
were then incubated in phosphate buffer 10 mM at pH 7.0 and pH 5.0. After 24 h, the 
particles were isolated by centrifugation and the supernatant collected for 
quantification of siRNA released from the nanocarriers. Figure 4.27 shows the 
quantification of siRNA after incubation in buffer at pH 7.0 (blue bar) and at pH 5.0 
(pink bar). This data indicates that P131,000si20NP did not alter the siRNA release at 
any pH, suggesting that the hydrazone polymer is not pH-responsive and that it is 
likely no C=N bonds hydrolysed, even at pH 5.0. This result is in agreement with the 
pH-sensitivity screening of hydrazones presented in Figure 4.8, where the hydrazones 
tested did not hydrolyse when the pH was lowered, even at pH 1.0. Although in the 
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experiment using P131,000si20NP much lower concentrations of hydrazone were used 
(µM concentrations was used for the pH-responsiveness of nanoparticles, whilst mM 
concentrations were used for the pH-sensitivity of model hydrazones) the hydrazones 
bonds remained stable at pH 5.0.  
 
 
Figure 4.27: Quantification of siRNA released from P131,000si20NPs at pH 7.0 (blue bar) and at pH 
5.0 (pink bar). The samples were isolated by centrifugation and the supernatant collected to 
determine the amount of siRNA released. The siRNA was quantified using the QuBit miRNA assay 
kit and the fluorescence readings were obtained at the green emission. 
 
The lack of pH-sensitivity of P131,000si20NP at pH 5.0 discourages the use of 
hydrazones as pH-responsive bonds for endosomal release. These findings are in 
contradiction with the examples in the literature for hydrazones bonds used for siRNA 
delivery8,33–35 which claim successful release in acidic environment (tumour loci or 
endosome vesicle). The pH-sensitivity screening for hydrazones (Figure 4.8) and 
imines (Figure 4.11) provided a new insight on the design of acid-labile bonds for 
specific pH-response. The imine I7 appears to be a promising candidate as a 
component of a pH-sensitive nanocarrier for siRNA delivery. Therefore, the synthesis 
of a diblock copolymer featuring an electron withdrawing substituent on the aldehyde 
moieties is important to evaluate the pH-sensitivity of these bonds for siRNA 
applications. The imine polymer can be conjugated onto AuNPs to further 
complexation with siRNA. The pH-sensitivity test can be performed, followed by gene 
knockdown in vitro to determine the capability of the delivery platform to successfully 
release siRNA into the cytosol of the target cell, and it is hoped this idea will be the 





Work towards the development of a new pH-responsive nanocarrier was 
discussed. Molecules featuring acid-labile hydrazone or imine bonds were prepared 
and their stabilities at different pH values were evaluated. The hydrazones tested did 
not show the appropriate pH-sensitivity for endosomal release, even when a 
destabilizing EDG was introduced on the aldehyde reaction partner. In fact, the pH 
hydrolysis experiments showed that hydrazones formed from aromatic aldehydes did 
not hydrolyse even at pH 1.0, discouraging the use of these bonds for siRNA delivery 
platforms. These observations are contrary to some described previously in the 
literature.8–12 A possible explanation could be attributed to the lower concentration 
used in delivery platforms (µM and nM) when compared to organic molecules at mM 
concentrations. These pH-responsive bonds are sensitive to concentrations and 
usually more hydrolysis occur in diluted conditions. Moreover, several reports in the 
literature demonstrate the pH-response using amphiphilic polymers. On account of 
their amphiphilic nature it is possible to assume that only a fraction of the bonds are 
hydrolysed, decreasing the necessary hydrophobicity of the system to maintain the 
micelle form and thus, the micelle disassemble occurs releasing the cargo at a specific 
pH. 
The pH hydrolysis profile identified imines I1 and I7 as potential candidates as 
pH-sensitive moieties to be conjugated on nanocarriers. The pH hydrolysis profiles at 
equivalent molar ratios of the reaction partners showed that the equilibrium position is 
shifted towards the starting materials when compared with the pH hydrolysis profiles 
using 10-fold excess of the amine reaction partner. The EWG substituent on the 
aldehyde reaction partner of I7 increased the stability of the imine bond, suggesting I7 
is of potential use within a delivery platform due to its adequate pH-sensitivity (stable 
at pH 7.0 and hydrolysed at pH 5.0). Interestingly, the pH-sensitivity of model imine I1 
changed when it was incorporated within a polymer system, indicating that model 
studies must also be done within the polymer in addition to the small molecules. After 
evaluation of the pH hydrolysis profiles at equivalent molar ratios, model imine I1 
showed poor stability at neutral and acidic pH. However, its stability improved when 
the compound was appended onto the random copolymer P4. These observations 
suggested the polymers featuring imines I1 and I7 would be suitable candidates for 
incorporation into a siRNA delivery platform, since it displays good stability at 
physiological conditions and hydrolysis in acidic environments. Moreover, the 
difference of the pH-sensitivity of model compounds vs polymer systems was an 
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important finding, since polymeric architectures are generally components of delivery 
platforms.  
RAFT Polymerisation was performed to obtain diblock copolymer scaffolds with 
good level of control. The copolymer post-modifications to obtain a diblock featuring 
cations upon one of the block was successfully achieved by a two-step reaction. 
 
After its complexation with siRNA, the hydrazone copolymer (P13) featuring ~ 30 
positive charges showed efficient siRNA loading, whilst the copolymer P15 (~ 16 
positive charges) did not show complexation with siRNA. This observation 
demonstrates that siRNA complexation does not occur at low densities of cations. 
Moreover, the copolymers were successfully conjugated onto AuNPs resulting in 
particles presenting ~ 50 – 70 nm size (P13NP and P15NP). Particles loaded with 
siRNA (P1,000si20NP) did not release siRNA at pH 5.0. The stability at pH 7.0 and 5.0 
of the polymer-Au conjugates loaded with siRNA confirms the lack of pH-sensitivity of 
hydrazone bonds demonstrated by the pH-sensitivity screenings of the model 
hydrazone bonds.  
Taken together these studies showed the potential application of pH-sensitive 
imine bonds for siRNA delivery, as model imine I7 showed promising pH-response in 
acidic pH and stability at physiological pH. The synthesis of a diblock copolymer 
featuring I7 moieties presents as a potential component within the delivery platform, 
performing multiple functions to overcome the biological barriers (e.g. prolonged 
circulation and endosomal escape) associated with in vivo siRNA delivery, a feature 
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5. Summary and Future Work 
 The development of new nanocarriers for siRNA delivery is the tipping point to 
translate the therapeutic potential of RNAi into clinical applications. In this work the 
development of nanocarriers based on the loading of phosphorothioate-modified 
siRNA onto AuNPs was demonstrated. The addition of one or three phosphorothioate 
modifications did not improve the loading of siRNA onto AuNPs. Studies from the 
literature indicates that a long polyA tail containing multiple phosphorothioate 
modifications is able to successfully bind onto AuNPs. Therefore, the addition of a 
phosphorothioate modified polyA tail in the 3’-end of the sense strand of the siRNA 
could be a promising strategy to overcome the challenges of loading siRNA onto 
AuNPs. However, long modifications on the siRNA sequence could interfere in RNAi 
mechanism, impeding the AGO2 binding sites. Furthermore, long siRNA strands are 
associated with PKR activation and consequently, cytotoxicity. Thus, further studies 
needed to be conducted to assess the RNAi efficiency of siRNAs containing 
phosphorothioate modified polyA tail. The studies will be conducted as shown below: 
- Evaluation of RNAi efficiency of siRNAs containing a phosphorothioate modified 
polyA tail at the 3’-end of the sense strand; 
- If the sequences shown the required RNAi efficiency (> 50%), the evaluation of 
the length and number of phosphorothioate modifications needed to 
successfully conjugate onto AuNPs will be assessed; 
- If successful, the optimal formulation (stable nanocarriers with high loading of 
siRNA (> 50 %) will be tested in vitro and in vivo.  
The use of cationic copolymers featuring pH-responsive moieties presents a 
promising strategy to overcome the endosomal escape challenges. This work 
demonstrated that model imine bonds showed advantageous pH-sensitivity for 
triggered release in the acidic environment of the endosome. Therefore, further studies 
should be performed to better understand and optimise the pH-sensitivity of these 
bonds. The evaluation of the kinetic rates of hydrolysis at a range of pH values would 
bring further knowledge for the optimisation of the pH-sensitivity. In particular, the 
kinetic rates of hydrolysis at pH 7.4 and pH 5.5 would be interesting to estimate the 
stability of the acid-labile bonds for in vivo applications, and also estimate the rates of 
siRNA release. Furthermore, the post-functionalisation of polymer scaffolds to obtain 
imine moieties will be performed. The conjugation of these polymers onto AuNPs 
would facilitate the evaluation of this platform for siRNA delivery, and thus, studies of 
siRNA release at different pH values and evaluation of gene knockdown in vitro will be 
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developed to assess the efficacy of the delivery platforms for siRNA applications. 
Lastly, for the siRNA therapy to be successful for the treatment of acute myeloid 
leukaemia, the addition of functional targeting ligands in the delivery platform must be 
achieved for the selective accumulation of the particle into the target cells. The polymer 
chains will be functionalised with sialic acid residues targeting the over-expressed 
CD33 receptor found on leukemic cells. The active targeting of the delivery platform 
will be assessed in vitro and in vivo by cellular uptake and gene silencing assays. In 
summary, the main studies to be conducted are described below:  
- Kinetics evaluation of imines at pH 7.4 and 5.5; 
- Synthesis of polymers featuring imine bonds 
- Development of nanocarriers based on AuNPs and cationic copolymers; 
- Evaluation of the siRNA release rates of nanocarriers at pH 7.4 and 5.5; 
- Evaluation of the gene and protein silencing in vitro and in vivo; 
- Synthesis of cationic copolymers featuring sialic acid residues for the targeting 
of AML cells; 
- Evaluation of cellular uptake of target and non-target nanocarriers in vivo; 








6. Appendix A 
 
 
Figure A.1: Standard-curves of (A) Cy5-labelled PS-ssODN determined by fluorescence 
spectroscopy and (B) 3PS-siRNA targeting the luciferase gene (3PS-siLUC) determined using the 






7. Appendix B 
 
 
Figure B.1: 1H NMR spectrum (300 MHz, CDCl3) of compound a.  
 
 




Figure B.3: 1H NMR spectrum (300 MHz, CDCl3) of compound b. 
 
 




Figure B.5: 1H NMR spectrum (300 MHz, D2O) of aldehyde A1. 
 
 




Figure B.7: 1H NMR spectrum of (A) (300 MHz, CDCl3) aldehyde-functionalised copolymer P14 and 
(B) (300 MHz, D2O) hydrazone-functionalised copolymer P15.  
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